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I. INTRODUCTION 
Duchenne muscular dystrophy (DMD) is the most prevalent heriditary 
neuromuscular disease in newborn boys (1:3500) (Emery, 1991; Ryder et al., 2017). 
It is characterized by severe and progressive generalized muscle degeneration and 
wasting, manifesting at an average age of 2.5 years (Ciafaloni et al., 2009), and 
leading to a total loss of ambulation latest at the age of 12 years (Blake et al., 2002). 
Affected individuals die within their 2nd to 3rd decade of life due to cardiorespiratory 
failure (Eagle et al., 2007; Passamano et al., 2012). DMD is triggered by a great 
variety of mutations, located within the dystrophin (DMD) gene, the largest gene in 
the human genome, located on the X-chromosome (Koenig et al., 1987; Monaco et 
al., 1986; Roberts et al., 1993). Mutations cause a loss of function of the muscle 
structure protein dystrophin, which is anchored as part of the dystrophin 
glycoprotein complex (DGC) to the sarcolemma (Nowak and Davies, 2004; Straub 
et al., 1992). Some mutations, however, lead to a low presence of truncated but 
partially functional dystrophin, which results in a milder form of the disease, the 
Becker muscular dystrophy (BMD) (Blake et al., 2002). Up to date, the most 
important therapeutic measures concerning the treatment of DMD are 
multidisciplinary care and glucocorticoid medication, aiming to relieve the 
symptoms and to slow down disease progression (Bello et al., 2015a; reviewed in 
Birnkrant et al., 2018b). Besides, for few disease-causing mutations, promising 
mutation-specific therapies intending to restore dystrophin expression have been 
developed within the past few years or are currently under investigation (National 
Library of Medicine, 2019; Ryan, 2014; Van Ruiten et al., 2017). Some recent 
molecular therapy approaches aim to permanentely restore dystrophin expression 
by editing the genome, converting DMD into the milder BMD (Long et al., 2016; 
Xu et al., 2016). Especially in therapeutic trials, the reliable assessment of disease 
progression is of prior importance. However, the availability of noninvasive, easy 
to use, sensitive diagnostic tools is limited, especially for young pediatric DMD 
patients. One of the primary used outcome measures for the assessment of physical 
capacity and the validation of therapeutic interventions, is the 6-minute walking test 
(6-MWT) (Bushby et al., 2014; McDonald et al., 2017; McDonald et al., 2010; 
Mendell et al., 2016). The diagnostic validity of this muscle function test is highly 
limited by its dependance on an active cooperation, the individual performance of 
the day (Geiger et al., 2007; McDonald et al., 2010) and, in general, of the ability 
to walk. For the development and validation of new therapeutic and diagnostic 
approaches, animal models mirroring the clinical picture of DMD are of need. 
However, the existing mammalian animal models have different genotypic or 
phenotypic characteristics limiting their applicability in biomedical research 
(McGreevy et al., 2015; Willmann et al., 2009). In comparison to other animals, the 
pig as omnivore shares a high number of similarities with humans (Aigner et al., 
2010). Therefore, a genetically engineered DMD pig lacking DMD exon 52 
(DMDΔ52) has been generated using somatic cell nuclear transfer (SCNT) and 
characterized at our institute (Klymiuk et al., 2013). 
In this work, a female DMD carrier sow, generated by SCNT, was used to generate 
a stable DMD breeding herd. Different husbandry conditions to increase nursing 
efficiency were evaluated and DMD knockout pigs generated by breeding were 
characterized. A genome-wide combined linkage disequilibrium and linkage 
analysis (cLDLA), to identify potential genetic modifiers, which might influence 
phenotypic variations, was commenced. A new therapeutic approach, aiming at 
I. Introduction     2 
permanently converting DMD into the milder BMD by restoring the DMD reading 
frame using adeno-associated viral vectors (AAV) to introduce CRISPR/Cas9 and 
two gRNAs targeting exon 51 flanking sequences, was applied to DMDΔ52 pigs. 
The restoration of internally truncated but functional dystrophin expression was 
assessed and improvement of muscle function was validated. Furthermore, a study 
using multispectral optoacoustic tomography (MSOT) to detect collagen in muscles 
of DMD knockout pigs was performed and the method was validated as new 
diagnostic biomarker in DMD. 
Parts of this dissertation have been published: 
Moretti A, Fonteyne L, Giesert F, Hoppmann P, Meier AB, Bozoglu T, Baehr A, 
Schneider CM, Sinnecker D, Klett K, Fröhlich T, Rahman FA, Haufe T, Sun S, 
Jurisch V, Kessler B, Hinkel R, Dirschinger R, Martens E, Jilek C, Graf A, Krebs 
S, Santamaria G, Kurome M, Zakhartchenko V, Campbell B, Voelse K, Wolf A, 
Ziegler T, Reichert S, Lee S, Flenkenthaler F, Dorn T, Jeremias I, Blum H, 
Dendorfer A, Schnieke A, Krause S, Walter MC, Klymiuk N, Laugwitz KL, Wolf 
E, Wurst W, Kupatt C. Somatic gene editing ameliorates skeletal and cardiac 
muscle failure in pig and human models of Duchenne muscular dystrophy. Nature 
Medicine 2020; 26(2):207-214. 
Regensburger AP, Fonteyne LM, Jungert J, Wagner AL, Gerhalter T, Nagel AM, 
Heiss R, Flenkenthaler F, Qurashi M, Neurath MF, Klymiuk N, Kemter E, Frohlich 
T, Uder M, Woelfle J, Rascher W, Trollmann R, Wolf E, Waldner MJ, Knieling F. 
Detection of collagens by multispectral optoacoustic tomography as an imaging 
biomarker for Duchenne muscular dystrophy. Nature Medicine 2019; 25(12):1905-
1915. 
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II. REVIEW OF THE LITERATURE 
1. Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD) is the most prevalent hereditary 
neuromuscular disease in newborn boys (1:3500) (Emery, 1991). In newborn 
screening studies in the USA, the prevalence of DMD has been reported as 15.9 
cases per 100,000 and in the UK as 19.5 cases per 100,000 live male births 
(reviewed in Ryder et al., 2017). The disorder is inherited in a X-linked recessive 
manner, therefore primarily boys are affected, whereas female carriers of the 
disease rarely manifest clinical symptoms (Moser and Emery, 1974). 
DMD is caused by mutations in the DMD gene, which prevent the expression of the 
functional muscle structure protein dystrophin. Phenotypically, the lack of 
dystrophin results in progressive muscle damage and degeneration leading to 
muscle weakness and wasting. Following symptoms are a loss of ambulation (LoA), 
severe respiratory impairment and cardiomyopathy (Nigro et al., 1990; Nigro et al., 
1995). 
Currently, for most patients only symptomatic therapies are available, which aim to 
slow down disease progression but are no cure. However, for few disease-causing 
mutations, promising new therapies aiming at the restoration of dystrophin 
expression, were developed within the past few years or are currently under 
investigation. Moreover, life expectancy of affected patients has been 
fundamentally improved in the past decades due to multidisciplinary care. 
Nevertheless, as a consequence of cardiorespiratory complications, DMD still leads 
to an early death between the ages of 20 and 30 (Eagle et al., 2002; Eagle et al., 
2007; Passamano et al., 2012). 
1.1. Clinical features 
DMD patients are clinically normal at birth, albeit serum creatine kinase (CK) 
levels, a blood serum marker for muscle damage, are already elevated (reviewed in 
Blake et al., 2002). The first clinical manifestations of DMD appear in early 
childhood at soonest one year of age (average at 2.5 years of age) (Ciafaloni et al., 
2009). Caregivers, e.g. family members or other educators, might notice initial 
signs, such as clumsiness and a developmental delay (e.g., children start walking 
later than usual). Nevertheless, symptoms usually are consciously recognized later, 
between two and five years of age, during toddler and preschool age (Ciafaloni et 
al., 2009), when children present a waddling gait and/or toe walking (reviewed in 
Birnkrant et al., 2018b; Verma et al., 2010). DMD patients at this stage also show 
a special manner to get up from a sitting in a standing posture, called Gowers’ sign, 
which is typical for neuromuscular disorders (Gowers, 1879). The Gowers’ sign 
description (Fig. 1) goes back on Dr. Gowers, who, in 1879, first published a 
definition of this special pattern of standing up (Gowers, 1879; Wallace and 
Newton, 1989). 
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Figure 1: Gowers’ sign. The Gowers’ sign is a medical sign describing the typical 
way of getting from a sitting into a standing posture by “walking up the legs” with 
the hands. This behavioral pattern indicates muscle weakness in the lower limbs, 
hips and pelvic girdle (Asadi, 2017). 
 
The first clinical stage is followed by a plateau phase, called the “honeymoon 
period” between the ages 5 and 8, where symptoms are often stabilized or even 
slightly improved (Brooke et al., 1983; Connolly et al., 2013). Subsequently, at the 
age of 7 to 8 years, a rapid clinical deterioration with a severe decline in functional 
ability and muscle strength starts (Brooke et al., 1983; Yiu and Kornberg, 2015). 
Patients show a severely labored gait and lose the ability to climb stairs, chairs or 
even toilet seats. In this stage, individuals with DMD may not be able to walk more 
than ten steps and are already dependent on physical assistance (Deutsche 
Duchenne Stiftung, 2017). 
Calf pseudohypertrophy, Achilles heel contractures and tightening iliotibial bands 
on the one hand and an abnormal body posture on the other hand are most likely 
mutually dependent (Brooke et al., 1983). The chronic static positioning together 
with the inability to move the joints to their full extent, the muscle imbalances 
around the joints and the fibrotic changes cause joint contractures and a decreased 
muscle extensibility. These pathological changes exacerbate the symptoms and lead 
to severe deformity such as lordosis or scoliosis. Until the age of 12 years, most 
DMD patients already lose the ability to walk and become wheelchair bound. 
Limited upper-limb function follows at a later disease stage (reviewed in Birnkrant 
et al., 2018b; Verma et al., 2010). 
Respiratory muscles (i.e. intercostal muscles and diaphragm) undergo similar 
pathological changes as other skeletal muscles. As a consequence of immobilization 
and muscle contractures, individuals with DMD develop a declined chest wall 
function leading to a reduced respiratory function and restricted breathing. 
Restricted breathing results in hypoventilation, first requiring assisted cough and 
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nocturnal ventilation and a full-time ventilation at later stages (reviewed in 
Birnkrant et al., 2018b; Verma et al., 2010). 
The heart muscle, as a subtype of striated muscle, is likewise affected by the loss 
of dystrophin, causing myocardial fibrosis, dilated cardiomyopathy and arrhythmia 
(Nigro et al., 1990; Nigro et al., 1995; Silva et al., 2017). Even though an early 
involvement of the heart has been reported, cardiomyopathy in DMD patients is 
often asymptomatic, even at late stages. However, the development of a clinically 
apparent heart failure in DMD patients is latest present until the age of 18 (Nigro et 
al., 1990). In former times, the respiratory failure was the major reason for mortality 
in DMD. Nowadays, the cardiomyopathy is the main cause of death. This is due to 
the fact, that all other clinical features of the disease can be improved or cured by 
surgical or therapeutical means (Cheeran et al., 2017). Recognizing heart failure 
remains a challenge and requires a regular assessment of cardiac function (reviewed 
in Birnkrant et al., 2018b; Nigro et al., 1990; Van Ruiten et al., 2017). 
Regarding mental capabilities, DMD patients might show a mild cognitive 
impairment, which indicates that the brain function is also abnormal in some 
individuals with DMD (reviewed in Blake and Kroger, 2000; Hinton et al., 2007; 
Prior and Bridgeman, 2005). 
The gastrointestinal motor function also is shown to be markedly disturbed in 
several individuals with DMD (Lo Cascio et al., 2016). According to Kraus et al., 
in a cross-sectional prospective study, nearly 50% of patients are diagnosed with a 
functional obstipation (Kraus et al., 2016). However, there are only few case reports 
including histological examinations of the intestine, one showing smooth muscle 
fibrosis in the entire gastrointestinal tract (Leon et al., 1986). Another study 
hypothesizes a prolonged gastrointestinal transit time, but contrarily proves a 
normal gut transit (Kraus et al., 2018). Other nutritional complications are loss or 
gain of weight, low bone density, mandibular contracture, and swallowing 
dysfunction. These symptoms are partly attributed to long-term glucocorticoid 
treatment or calcium supplementation (reviewed in Birnkrant et al., 2018b; Kraus 
et al., 2016). However, the clinical context of gastrointestinal symptoms has not yet 
been fully elucidated. 
Even though the awareness of DMD as important neuromuscular disease increased 
over the past years, these days there is still an average delay of 1 year, before boys 
are brought to a healthcare provider to evaluate the symptoms (Ciafaloni et al., 
2009). 
As women have two X-chromosomes, female carriers of DMD have one functional 
and one dysfunctional copy of the DMD gene. Therefore, they present a mosaic 
expression of dystrophin (Arahata et al., 1989), meaning that there is no total lack 
but a partial availability of dystrophin, compensating the loss. Nevertheless, there 
are some manifesting carriers showing symptoms, based on non-random X-
chromosome inactivation (XCI) (Kamdar and Garry, 2016). Thus, clinical signs 
may vary from mild muscle weakness and cramps to DMD like severity (Moser and 
Emery, 1974; Soltanzadeh et al., 2010). However, affected female carriers do not 
mainly present with severe paralysis as seen in affected males, but primarily with 
symptoms of a cardiomyopathy, such as dilated cardiomyopathy, often seen as left-
ventricle dilatation (Bushby et al., 1993; Hoogerwaard et al., 1999). 
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1.2. Becker muscular dystrophy 
Becker muscular dystrophy (BMD) is a milder form of the neuromuscular disorder. 
The clinical course is similar to DMD but has a later onset of clinical manifestation 
and a much longer survival. BMD, equally to DMD, is caused by mutations in the 
DMD gene. The great majority of mutations on this gene locus result in a total loss 
of dystrophin leading to the manifestation of the severe disease type, DMD. 
However, mutations can also lead to a low presence of truncated but partially 
functional dystrophin, which results in the milder BMD disorder (reviewed in Blake 
et al., 2002). 
In the past few years, new molecular therapy approaches took a major step in the 
direction of curing DMD by aiming to partially restore dystrophin, thus converting 
DMD into the milder BMD. 
1.3. Structure of the DMD gene  
The DMD gene is located on chromosome Xp21.2-p21.1 (OMIM#300377) 
(McKusick, 2002). With 2.5 million base pairs, it is the largest known gene in the 
human genome. Composed of 79 exons, it is transcribed into a full-length 14-kb 
mRNA (Roberts et al., 1993). The gene encodes dystrophin, a 427-kDa cytoskeletal 
protein. Dystrophin is predominantly expressed in skeletal and cardiac muscle and, 
with smaller amounts, in the brain. 
Three independently regulated promoters are responsible for ensuring the 
expression of the full-length dystrophin: The B promoter (brain), the M promoter 
(muscle) and the P promoter (Purkinje cells), designated after the regions of their 
predominant activity. These promoters control the transcription of three different 
mRNAs, which share 78 same exons but contain unique first exons. The three 
resulting isoforms are designated Dp427 (B), Dp427 (M) and Dp427 (P) (Figure 2; 
reviewed in Blake et al., 2002). 
Besides the promoters for these three long isoforms, there are four internal 
promoters, controlling the expression of truncated COOH-terminal dystrophin 
transcripts. To express their tissue-specificity, they are called R (retinal), (B3) 
brain-3, (S) Schwann cell and (G) general promoter. These promoters, which are 
distally located, use a unique first exon, splicing into exons 30, 45, 56 and 63, 
respectively. The generated protein products are referred to as Dp260 (R), Dp140 
(B3), Dp116 (S) and Dp71 (G). These smaller proteins are ubiquitously expressed 
(reviewed in Blake et al., 2002; Muntoni et al., 2003). Dp71 (71kDa) is the most 
abundant transcript of the DMD gene in non-muscle tissue. It is expressed in several 
tissues such as brain, liver, kidney, lung and cardiac muscle, and ubiquitously 
expressed in most other tissues except for skeletal muscle (Austin et al., 1995; 
reviewed in Blake et al., 2002; Lederfein et al., 1992; Muntoni et al., 2003; Sarig et 
al., 1999). The other truncated isoforms are mainly expressed in the central and 
peripheral nervous system (reviewed in Blake et al., 2002). All in all, there are 
numerous isoforms and splice variants of mRNAs transcribed from the DMD gene 
in various tissues throughout the whole body (Austin et al., 1995; Feener et al., 
1989).
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Figure 2: Schematic representation of the human DMD gene and the 
localization of the different promoter regions within the gene (adapted from 
Blake et al., 2002). 
 
1.4. Dystrophin 
Dystrophin, the product of the DMD gene, is a rod-shaped cytoplasmic muscle 
structure protein of about 150 nm length. It shares several features with the 
cytoskeletal protein spectrin and α-actinin (Koenig et al., 1988). Strongly anchored 
to the sarcolemma (the plasma membrane of cardiac and skeletal muscle), 
dystrophin connects the dystrophin glycoprotein complex (DGC) with the 
extracellular matrix (ECM) and the intracellular contractile apparatus (Campbell 
and Kahl, 1989; Rybakova et al., 2000; Straub et al., 1992). Figure 3 shows the 
DGC, an assembly of integral membrane proteins, and its localization in the 
sarcolemma. 
 
Figure 3: Schematic representation of the dystrophin glycoprotein complex 
(DGC). Dystrophin, localized to the periphery of striated muscles, is the membrane 
linker between the actin filaments and the external scaffold (adapted from Nowak 
and Davies, 2004). 
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Dystrophin can be separated into four domains. The 240 amino acid NH2-terminal 
domain (N-terminus) is identified as actin-binding site. A following rod-shaped 
domain is formed by a sequence of 25 triple-helical segments, which are similar to 
the repeat domains of spectrin. This rod domain and the N-terminus are part of the 
subsarcolemmal cytoskeleton. A third domain is a cysteine-rich segment. It is 
similar in part to the complete COOH domain of α-actinin in Dictyostelium. The 
last segment is a 420 amino acid COOH-terminal domain (C-terminus). It is located 
within or at the plasma membrane and links dystrophin to the integral membrane 
proteins (Koenig et al., 1988; Straub et al., 1992). 
As shown in Figure 3, the main function of dystrophin is to be a transmembrane 
linker between actin and laminin in striated muscle cells (Campbell and Kahl, 1989; 
Ervasti and Campbell, 1993). Muscle fibers are protected from long-term 
contraction-induced damage and necrosis by the DGC stabilizing the sarcolemma 
(Rando, 2001; Straub and Campbell, 1997).  
1.5. Mutations in the DMD gene 
DMD, as well as BMD, can be the result of a spontaneous or an inherited mutation 
of the DMD gene. There is a great amount of independent mutations, varying in 
type, size and localization. Intragenic single- or multi-exon deletions build the 
majority of mutations. The frequency varies between 72%, according to Leiden 
DMD mutation database (Aartsma‐Rus et al., 2006) and 60-65%, often mentioned 
in literature (Koenig et al., 1989; reviewed in Muntoni et al., 2003). Duplications 
of one or more exons are found in 5-15% of patients, depending on the sensitivity 
of the technique used. The remaining portion contains smaller deletions and 
insertions, or point mutations (reviewed in Aartsma‐Rus et al., 2006; Abbs and 
Bobrow, 1992; Prior and Bridgeman, 2005). 
Deletions in the DMD gene are found to be apparently nonrandom. There are two 
hotspot regions within the gene, where deletions are primarily located (Koenig et 
al., 1987). The first hotspot region is located towards the central portion of the gene. 
It includes exons 45-55. The endpoint where the mutation actually occurs, called 
genomic breakpoint, lies within intron 44. The second hotspot region lies within the 
5´ portion of the DMD gene, including exons 2-19. The genomic breakpoints are 
most frequently found in the introns 2 and 7 but also expand towards the 
downstream introns (Beggs et al., 1990; Koenig et al., 1989; Muntoni et al., 2003; 
Prior and Bridgeman, 2005). The hotspot regions for deletions make the detection 
of these larger mutations comparatively straightforward (Prior and Bridgeman, 
2005). Using a single multiplex polymerase chain reaction (PCR) technique, about 
98% of deletions can be identified by the use of two multiplex reactions only (Beggs 
et al., 1990). 
Point mutations are found evenly distributed among the DMD gene. They can cause 
frameshifts or affect splice sites, but they can also create missense codons or 
premature stop codons (reviewed in Roberts et al., 1994). 
Generally, most mutations result in nonsense codons or frameshifts. A schematic 
explanation for an out-of-frame mutation is shown in Figure 4. A frameshift 
mutation is caused by the deletion or duplication of a number of nucleotides not 
divisible by three, which disrupts the open reading frame (ORF) (Monaco et al., 
1988). 
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Figure 4: Schematic description of an out-of-frame mutation and its 
consequence on dystrophin expression. a) An intact exon intron sequence, 
resulting in a stable mRNA product after splicing. The mature mRNA is translated 
into functional dystrophin. b) Intragenic deletions lead to a disrupted ORF, thus to 
a frameshift. The result is either an unstable mRNA resulting in nonsense mediated 
mRNA decay, or a truncated nonfunctional dystrophin protein. 
 
According to Monaco et al. (1988), the phenotypic difference between BMD and 
DMD can be explained by the type of mutation. The authors stated that deletion 
events in the genome, which maintain an ORF, result in the production of a 
truncated but semi functional dystrophin protein, leading to BMD. These kinds of 
mutations are called in-frame mutations. In contrast, an out-of-frame mutation is an 
intragenic deletion that cannot maintain the ORF and frameshifts after splicing of 
intron sequences. The translation either leads to an unstable mRNA product, 
causing mRNA degradation due to nonsense mediated mRNA decay, or the 
generation of a truncated nonfunctional dystrophin protein, with both translation 
pathways resulting in DMD. 
In general, the milder BMD most commonly results from deletions or duplications 
that do not disrupt the ORF (Beggs et al., 1990). However, few deletions or 
duplications (9%) do not follow the reading-frame rule, stated by Monaco et al. In-
frame mutations are also found in some DMD patients (Beggs et al., 1991; Koenig 
et al., 1989), whereas out-of-frame mutations are present in few BMD individuals 
(Aartsma‐Rus et al., 2006). 
Additionally, the phenotype, to some extent, is also determined by the size and 
location of the deletion (Arikawa-Hirasawa et al., 1995; Beggs et al., 1991; Fanin 
et al., 1996). Regarding the size, very large deletions, especially in particular 
regions, may result in a more severe phenotype (Beggs et al., 1991). Concerning 
the location of in-frame mutations the severity of the phenotype can be anticipated: 
It has been reported, that mutations in the N-terminal domain result in low levels of 
dystrophin and thus are classified as severe BMD or intermediate. An additional 
deletion of parts of, or of the whole central rod domain, give rise to DMD. Patients 
with deletions or duplications only in the proximal rod domain show primarily 
severe cramps and myalgia. Mutations in the central rod domain usually are 
associated with milder phenotypes, such as mild BMD, except if the deleted region 
becomes too large. Some BMD patients show deletions in the syntrophin binding 
domain, whereas mutations concerning the cysteine-rich domain result in DMD. 
Mutations in exon 74 or higher are found in BMD as well as in DMD patients 
(reviewed in Aartsma‐Rus et al., 2006; Beggs et al., 1991). An intact C-terminal 
domain seems to be essential for the stability of dystrophin (Koenig et al., 1989). 
Nevertheless, individuals with similar mutations show different phenotypes, 
suggesting epigenetic or environmental influence on the clinical expression. Thus, 
the severity of the phenotype cannot be certainly predicted by the size or type of 
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mutation (Beggs et al., 1991). 
1.6. Pathomechanism  
Dystrophin is a structural key component in muscle fibers. The main function of 
the DGC is to stabilize the plasma membrane. The loss of dystrophin in DMD 
patients results in delocalization of the dystrophin-associated proteins from the 
membrane (reviewed in Deconinck and Dan, 2007). This impairs the structural 
integrity of the muscle membrane resulting in fragile membranes. Mild exercise-
induced muscle fiber damage is normal to occur even in healthy musculature (Petrof 
et al., 1993). However, in DMD patients the damage is greater. Regenerative 
processes aim to replace or repair lost or damaged muscle fibers, but repetitive 
greater damage exceeds the regenerative capacity of the muscles, due to limited 
number and ability of satellite cells. Therefore, normal mechanical stress in the 
musculature already leads to micro-lesions, followed by membrane leakage and 
muscle fiber damage (reviewed in Deconinck and Dan, 2007; Klingler et al., 2012; 
Petrof et al., 1993). The micro-lesions and resulting hyperosmotic stress lead to an 
increased sodium and calcium permeability. 
The intracellularly increased sodium leads to depletion of ATP supply, as Na+/K+ 
pumps, normally regulating the electrolyte balance, cannot compensate the 
increased influx. Sodium, accompanied by water molecules, leads to cellular edema 
and necrosis (Klingler et al., 2012). Calcium, as a second messenger, is able to 
activate a cascade of inflammatory processes. With the disturbance of Ca2+-
homeostasis, various Ca2+-dependent proteases, such as calpain, are activated, 
resulting in cell and membrane proteolysis and therefore cell death (Bodensteiner 
and Engel, 1978; reviewed in Deconinck and Dan, 2007; Klingler et al., 2012; 
Yeung et al., 2005). Calcium overload also results in oxidative stress (due to the 
production of reactive oxygen species), leading to an accumulation of acidic 
metabolites, such as lactic acid, mainly dissociated into La- and H+ at physiological 
pH. La- increases the activity of collagen promoters. Procollagen mRNA production 
increases, leading finally to collagen synthesis. However, until now comparatively 
little attention has been paid to the actual role of fibrosis in DMD. As fibrosis in 
general is described as the exchange of normal tissue against scar tissue, indicating 
that fibrous connective tissue results from a reparative or reactive process, it is a 
general belief, that the increase of connective tissue in DMD is a secondary 
phenomenon. Fibrosis in DMD is generally seen as a compensatory replacement of 
the lost muscle tissue. Nevertheless, an endomysial tissue increase can already be 
observed long before any muscle fiber degradation appears, indicating that the 
fibrotic remodeling itself plays a major role in DMD. A co-determining role in the 
myofascial pathology is discussed, for example due to a possible negative effect of 
fibrosis on the nutrition of enclosed muscle cells (Klingler et al., 2012). 
In histological examinations, muscle fibers are in process of regeneration, 
degeneration or are already necrotic. Degeneration and necrosis are followed by 
phagocytosis, with the presence of inflammatory cells (reviewed in Blake et al., 
2002). Regenerating muscle cells histologically show larger and centrally placed 
myonuclei. The cytoplasm is RNA-rich, hence basophilic. The muscle fiber 
diameter decreases, leading to an increased variation of muscle fiber diameters 
(Bell and Conen, 1968; Bradley et al., 1972; Schmalbruch, 1984). Necrotic fibers 
are often seen in clusters, so called grouped necrosis. Necrotic tissue is gradually 
replaced by fatty and connective tissue (fibrosis), with the functional consequence 
of a decrease in the quantity of contractile tissue. These structural changes give rise 
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to the then clinically apparent pseudohypertrophy and contractures (reviewed in 
Blake et al., 2002; Wokke et al., 2014). 
1.7. Modifier genes in DMD 
Factors, independent from the pathogenic mutation, can influence the expressivity 
of Mendelian diseases (Bello et al., 2016). These factors are called modifier genes 
and are defined as genetic loci, which are able to positively or negatively influence 
the phenotype of a primary disease-causing mutation. As shown above, in DMD 
not a single, but several different causative mutations are present. As a result, it is 
hard to distinguish between the primary mutation, which is causative for the 
disease, and a secondary modifying locus (reviewed in Vo and McNally, 2015). 
Besides the genetic heterogeneity in DMD, the identification of modifier genes is 
complicated by the above-mentioned varying onset of clinical symptoms and 
different disease progression. Nonetheless, common symptoms can be observed and 
taken into account in regards to modifying gene loci. To identify these bases of 
variability in DMD is important for patient consultation, prognosis and an 
appropriate therapeutic approach (reviewed in Bello and Pegoraro, 2019). To date, 
several loci have been identified to be associated with variable DMD sub-
phenotypes. In general, their influence may be reflected by the age of onset, the 
muscle groups which are affected, the severity or the progression of the disease 
(reviewed in Vo and McNally, 2015). Yet, the most commonly observed 
phenotypic variation in DMD patients, whose DMD mutations all prevent 
dystrophin expression, is the age at loss of ambulation (LoA) (Bello et al., 2016). 
In this context a single nucleotide polymorphism (SNP) in the gene promoter of 
secreted phosphoprotein 1 (SPP1 or Osteopontin, encoded by the SPP1 gene) has 
been described as potential genetic modifier in DMD patients (Bello et al., 2015b). 
Pegoraro et al. (2011) described this polymorphism, rs28357094, as significantly 
associated with disease progression (disease severity was defined by the age at 
LoA). The less common G allele (GT/GG genotype) was related to an earlier 
ambulatory loss of about one year. Thereby, the effect of the TT genotype is similar 
in magnitude to the therapeutic use of steroids (delaying LoA for about one year). 
At the age of 14, 20% of DMD patients with the TT genotype where shown to be 
still ambulatory, whereas none of the individuals with the GT/GG genotype were 
able to walk. The cause is, that the G allele variant decreases the promoter strength 
and consequently leads to a lower SPP1 mRNA production. Many studies were 
done to explain the function of SPP1. Osteopontin, amongst others, plays a role in 
bone-remodeling, muscle repair, the maintenance or reconfiguration of tissue 
integrity during inflammation and immune function (Giacopelli et al., 2004; 
reviewed in Vo and McNally, 2015). Furthermore, SPP1 is activated by 
transforming growth factor beta (TGFB) family members. There exist more than 30 
TGFB family members, located in the ECM, which, for example, coordinate cell 
growth during development, regulate injury response, or are important for muscle 
health (Lamar et al., 2016; Taipale et al., 1994). Studies in double mutant mice, 
lacking both dystrophin and SPP1, revealed significant reduction in TGFB, fibrosis 
and inflammatory cell infiltration. Yet, due to its broad expression pattern, it is 
complicated to understand the means by which SPP1 exactly modifies DMD 
(Vetrone et al., 2009; reviewed in Vo and McNally, 2015). Moreover, the working 
group of van den Bergen et al. (2015) in their study disproved the significant 
association between SPP1 rs28357094 SNP and LoA as they were unable to 
replicate the results in 336 genotyped patients. 
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Another important potential genetic modifier, also associated with the age at LoA 
in DMD patients, is latent TGFB binding protein 4 (LTBP4). Its function is to 
regulate, together with other latent TGFB binding proteins (LTBPs), the 
extracellular availability of latent TGFB (Lamar et al., 2016). Latent TGFB gets 
secreted as precursor and gets activated before the interaction with TGFB receptors 
on the cell surface (reviewed in Vo and McNally, 2015). LTBPs bind to inactivate 
TGFB in the ECM (Ceco et al., 2014). The importance of the regulating role of 
LTBP4, especially during development, is underlined by findings describing a 
multi-organ syndrome in humans with an recessive LTBP4 loss (Urban et al., 2009). 
LTBP4 is primarily expressed in skeletal muscle, smooth muscle, heart and at a 
lower level in other tissues. In patients with DMD, four non-synonymous SNPs 
(nsSNPs) in LTBP4 are associated with a prolonged ambulation (Giltay et al., 1997; 
Lamar et al., 2016). The four nsSNPs (rs2303729, rs1131620, rs10880 and 
rs1051303) form two major amino acid haplotypes: IAAM and VTTT (the names 
derive from the amino acids specified by these nsSNPs). From these two, a 
homozygous IAAM haplotype shows a significant association with a later LoA in 
several studies. Patients heterozygous or homozygous for VTTT showed an earlier 
ambulatory loss (Bello et al., 2015b; Flanigan et al., 2013; van den Bergen et al., 
2015). LTBP4 containing the ameliorative haplotype IAAM, is able to alter TGFB 
binding or release. Consequently, TGFB signalling is reduced leading to decreased 
muscle fibrosis and benefiting muscle regeneration capacity (Flanigan et al., 2013). 
In line with these findings, Ltbp4 was also identified to modify muscular dystrophy 
in mice. By differently targeting the Ltbp4 gene, the outcomes in muscular 
dystrophy could be modified in both directions, a decreased fibrosis and improved 
muscle pathology, or increased proteolysis and fibrosis (Heydemann et al., 2009). 
To explore the function of LTBP4 in detail in skeletal muscle and, in particular, in 
muscular dystrophy, Lamar et al. (2016) generated mice, which overexpress the 
murine Ltbp4 gene. The elevated levels of LTBP4 here led to increased muscle 
strength and, proportional to it, an increased muscle mass. Therefore, targeting 
LTBP4 is discussed as a therapeutic approach. 
The two named genetic modifiers, SPP1 and LTBP4, are the most researched 
polymorphic loci in DMD. They are both involved in molecular pathways, which 
regulate inflammation response to muscle injury, regeneration, and fibrosis 
(reviewed in Bello and Pegoraro, 2019). Several further, less investigated, possible 
genetic modifiers of the clinical phenotype in DMD have been discussed. Recently, 
in 2017, a common null polymorphism (R577X, rs1815739) in human ACTN3 
(encoding α-actinin-3) was shown to be significantly correlated to reduced muscle 
strength and a longer time in 10 m walking test in ambulatory patients with DMD. 
α-Actinin-3, an isoform of sarcomeric α-actinins, is only expressed in fast, 
glycolytic muscle fibers. In patients homozygous for the null polymorphism 
R577X, α-actinin-3 is completely absent (Hogarth et al., 2017). ACTN3 is known 
as “the gene for speed”: an α-actinin-3 deficiency was already previously shown to 
be detrimental in elite athletes as well as in general population, reducing muscle 
power and sprint performance (reviewed in Bello and Pegoraro, 2019; Clarkson et 
al., 2005; Eynon et al., 2013; Moran et al., 2007). Bello et al. (2016) prioritized 
rs1883832 SNP in the untranslated region of CD40. CD40, also known as tumor 
necrosis factor receptor superfamily member 5 (TNFRSF5), is a co-stimulatory 
molecule for T cell polarization. The minor allele at rs1883832 reduces the 
expression of CD40. In the study of Bello et al., this was shown to be associated 
with an earlier LoA in a total of 660 DMD patients. Nevertheless, the precise role 
of CD40 in muscular dystrophy is still poorly understood (reviewed in Bello and 
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Pegoraro, 2019). Another modifier locus, THBS1, was detected by Weiss et al. 
(2018). THBS1 gene encodes thrombospondin-1 (THBS1), which activates TGFB 
signaling by directly interacting with LTBP4 in the ECM. Thus, it controls the 
bioavailability of TGFB. Furthermore it acts as inhibitor of pro-angiogenic nitric 
oxide signaling. Weiss et al. discussed a protective effect of the THBS1 distal 
regulatory SNPs. Together with regulatory variants resulting in reduced expression 
of LTBP4, it was found to prolongate ambulation in patients with DMD. The 
working group of Davis et al. (2000) discussed myoferlin (MYOF) as possible 
modifier of muscular dystrophies after they found out, that a mouse model of DMD 
(mdx mouse) showed an upregulation of MYOF at the membrane of skeletal 
muscle. C2 domains, which are part of all ferlin family members, play a role in 
calcium-mediated membrane fusion events. Vieira et al. (2017) suggested 
phosphatidylinositol transfer protein α (PITPNA) as possible DMD modifier, 
referring to findings in two atypical DMD-dogs which demonstrated a strikingly 
mild dystrophic phenotype. This finding was pursued by knockdown of PITPNA 
gene in dystrophin-deficient sapje zebrafish and human DMD myogenic cells. 
Decreased expression of PITPNA led to increased expression of phosphorylated 
Akt (pAkt) and decreased phosphatase and tensin homolog (PTEN) levels. The 
muscle structure was ameliorated and survival was increased. 
Although several genetic modifiers have been identified in DMD, the overall 
knowledge in this field is still initial. However, a detailed knowledge about modifier 
genes in DMD is important, since individual differences in disease progression 
complicate the interpretation of results of clinical trials (reviewed in Aartsma-Rus 
and Spitali, 2015). Most studies rely on hypothesis only, discovering candidate 
genes which are pre-specified genes of interest to find putative modifiers. Hence, 
most identified modifiers were already known to play a role in muscle health, with 
their pathways beeing already well established. Genome-wide association studies 
(GWAS) of polymorphisms influencing the muscle phenotype, however, scan the 
entire genome for common genetic variants. As hypothesis-free, unbiased approach 
GWAS would be necessary to identify also unexpected associations in DMD 
(reviewed in Bello and Pegoraro, 2019). To further increase the mapping precision 
of quantitative trait loci (QTL) a genome-wide combined linkage disequilibrium 
and linkage analysis (cLDLA) as fine mapping method can be conducted (Farnir et 
al., 2002). This method is based on the informative recombinations within 
gentoyped pedigrees as well as on informations given from historical 
recombinations of earlier, not genotyped generations (Meuwissen et al., 2002). For 
example, Muller et al. (2017) demonstrated that the haplotype-based genome-wide 
cLDLA can allow more precise mapping of QTL than the more commonly used 
SNP-based GWAS. 
2. Animal models for DMD 
There is a wide range of natural and engineered mammalian animal models 
reflecting the clinical aspects of DMD, including mouse, rat, rabbit, cat, monkey, 
dog and pig models. Tailored animal models are indespensable for the elucidation 
of DMD pathogenesis (reviewed in Nakamura and Takeda, 2011). The model 
organisms are of great importance for the development of new targeted therapies, 
aiming to prevent disease progression or to reverse pathological mechanisms 
(reviewed in Wells, 2018). Safety, as well as efficacy prediction of new therapeutic 
strategies requires reliable animal models mimicking the situation displayed in 
humans. Moreover, the discovery and validation of new biomarkers, indicating 
II. Review of the literature     14 
physiological processes, pathological changes and the response to therapeutic 
treatment, plays a major role (Aigner et al., 2010). 
2.1. Rodent models 
The X Chromosome-Linked Muscular Dystrophy (mdx) in mouse (Bulfield et al., 
1984) is the best known animal model for DMD. With more than 2800 published 
papers using the mdx mouse, it is the most widely utilized DMD model to date 
(reviewed in Wells, 2018). The model is a spontaneous mutant failing to produce 
dystrophin due to a mutation in exon 23 of the murine Dmd gene, which introduces 
a premature stop codon (Sicinski et al., 1989). This mouse model displays the 
biochemical processes and early stages of the disease, but yet it is not the best model 
organism in reflecting the clinical aspects of DMD. While exhibiting muscular 
dystrophy (Bulfield et al., 1984), the phenotype of mdx mice is much milder than 
in DMD patients. Obvious clinical signs of dystrophic musculature are completely 
missing (reviewed in Wells, 2018). Histological key features such as fibrosis and 
fatty deposits among muscle tissue, smaller number of myofibrils, insufficient 
regeneration process and severe degeneration in muscle fibers are only present in 
the diaphragm of mdx mice, but absent in every other muscle (Fukada et al., 2010). 
Last but not least, the life span of mdx mice is only slightly reduced (Chamberlain 
et al., 2007). A possible explanation for this milder phenotype might be that the 
mutation does not disturb the expression of four shorter isoforms, expressed from 
the Dmd gene through varying promoter usage (Araki et al., 1997). As the original 
B10-mdx mouse (C57BL/10 background) (Bulfield et al., 1984) is a weak model 
for DMD, it has been backcrossed onto several other genetic backgrounds. One 
resulting mouse line was the DBA/2J-mdx model, which is a backcross onto the 
DBA/2J mouse strain (reviewed in Wells, 2018). This model organism seems to 
worsen the dystrophic phenotype as desired and even reflects a cardiomyopathy. 
Unfortunately, the control DBA/2J mice show a similar myocardial pathology. 
Hence, the DBA/2J-mdx mouse is also a poor model for DMD (Hakim et al., 2017). 
Another tailored mouse model has been generated by Araki et al. (1997), disrupting 
exon 52 of the Dmd gene. This mutation is known to result in clinical DMD in 
humans. Nevertheless, the mdx52 still shows limited, if at all, clinical signs of 
muscular dystrophy (reviewed in Wells, 2018). Perkins and Davies (2002) 
discussed, that throughout an increased expression of utrophin, an autosomal 
homologue of dystrophin, the loss of dystrophin in mdx mice could, at least in part, 
be compensated. Therefore, utrophin knockout (KO) mice were crossed with mdx 
mice (Deconinck et al., 1997). While these double-KO mice display a more severe 
dystrophic phenotype, they are obviously inappropriate as models for DMD, since 
DMD patients do not lack both, dystrophin and utrophin (reviewed in Wells, 2018). 
Altogether, there are several mouse models of DMD, but none of them 
appropriately mirrors the phenotype of DMD patients. A further disadvantage of 
the mouse as animal model can be seen in the small body size, imposing limitations 
on analysis, such as dose-finding in therapeutic trials of new treatments. 
Two different rat models of DMD have been generated, both published in the year 
2014. Larcher et al. (2014) engineered two lines of Dmd-mutant rats using 
transcription activator-like effector nucleases (TALENs) targeting exon 23 of the 
Dmd gene. The musculature of the Dmdmdx rat lacks dystrophin and displays severe 
necrosis and regeneration, at a later stage it shows fibrosis and fatty infiltration. 
Clinically, muscle strength and spontaneous motor activity are impaired. 
Furthermore, Dmdmdx rats show signs of dilated cardiomyopathy. Nakamura et al. 
II. Review of the literature     15 
(2014) generated Dmd-mutated rats using a clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas system, targeting exon 3 and 16 in the rat Dmd 
gene simultaneously. Phenotypically this rat model shows similiar alterations as the 
Dmdmdx rats, except for the heart, where a clear evidence of a functional 
cardiomyopathy is missing (reviewed in Wells, 2018). The two rat models of DMD 
seem to reflect the clinical aspects of DMD better that the mouse models. 
2.2. Rabbit model 
A novel animal model for DMD in the rabbit has been engineered and characterized 
by Sui et al. (2018). DMD knockout (KO) rabbits were generated by co-injection 
of Cas9 mRNA and sgRNA targeting exon 51 into zygotes of rabbits. This model 
exhibits a typical DMD phenotype, with impaired physical activity, muscle 
degeneration and fibrosis, and increased CK levels. Also functional alterations in 
the heart seem to be present in this model, indicating the development of 
cardiomyopathy. Nevertheless, this publication was the first introduction to this 
new animal model for DMD and it is not yet clear, if, for example, the reduction in 
activity, shown in this model, is sufficiently robust for accurate drug trials 
(reviewed in Wells, 2018). 
2.3. Feline model 
Progressive muscular dystrophy due to dystrophin-deficiency has been described to 
naturally occur in cats (Carpenter et al., 1989; Gaschen et al., 1999). The 
hypertrophic feline muscular dystrophy (HFMD) mainly results in muscle 
hypertrophy, predominantly observed in the tongue and diaphragm, leading to 
difficulties in eating and drinking. In histological examinations, degeneration and 
regeneration processes can be observed. Nevertheless, dystrophin in cats with 
HFMD is still faintly detectable in immunostaining of muscle fibers. About 10% of 
dystrophin, compared to normal dystrophin amounts, is detectible in Western blot 
analysis of skeletal muscle, showing that there is no total failure of dystrophin 
expression. Additionally, muscle fibers in HFMD cats do not show fibrotic 
alterations. Moreover, only a few cats suffer of cardiomyopathy. Histological 
changes in the heart are only present in some cases (Gaschen et al., 1999). All in 
all, dystrophin-deficient cats are not suitable as experimental models for human 
DMD (reviewed in Wells, 2018). 
2.4. Nonhuman primate model  
Chen et al. (2015) generated a dystrophin deficiency in rhesus monkeys. By using 
CRISPR/Cas9 for injection into fertilized oocytes, they targeted exon 4 and exon 
46 in the monkey DMD gene, causing a frame shift of the coding sequences and 
thereby a termination of the full-length expression of dystrophin. The mutation 
results in a partial depletion of dystrophin and muscle degeneration. However, the 
CRISPR/Cas9 technology causes mosaic mutations, targeting only up to 87% of the 
dystrophin alleles, resulting in genetic and phenotypic variability. This again 
doesn’t comply with the mutations found in human DMD patients, which result in 
a total loss of dystrophin. 
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2.5. Canine models 
The most famous homologue of DMD in dogs is the Golden Retriever Muscular 
Dystrophy (GRMD), also known as Canine X-linked Muscular Dystrophy 
(CXMD), which is the result of a spontaneous single base change in intron 6 leading 
to the skipping of exon 7 and therefore the termination of the dystrophin reading 
frame (Sharp et al., 1992). As well as DMD patients, GRMD dogs show myofiber 
degeneration with mineralization and fibrosis with fatty infiltration, altogether 
resulting in an atrophy of the musculature. Serum CK levels in affected dogs are 
elevated. The dog model also shows signs of cardiomyopathy (Sharp et al., 1992; 
Valentine et al., 1988). The mutation of the GRMD model has been introduced onto 
a Beagle background to enable a better handling due to a smaller body size. The 
phenotype of the resulting Beagle-based canine X-linked Muscular Dystrophy 
(CXMDJ) is roughly identical to the phenotype described in GRMD dogs (Shimatsu 
et al., 2005). Another canine model of DMD is the Cavalier King Charles Spaniel 
with dystrophin-deficient muscular dystrophy (CKCS-MD). It carries a missense 
mutation in the splice site of exon 50 in the canine dystrophin gene. The mutation 
gives rise to a single exon deletion (exon 50) in the mRNA, leading to a disrupted 
reading frame and the premature truncation of the gene product. While the 
phenotype of this dog model of DMD seems to resemble that of the two previously 
described dog models, GRMD and CXMDJ, the localization of the mutation is 
clinically more relevant. The region is also most commonly mutated in human 
DMD patients (Walmsley et al., 2010). There are many other dog breeds diagnosed 
with a muscular dystrophy due to a loss of dystrophin. Several of them have been 
used for the development of a dog model of DMD. Nevertheless, the big 
disadvantage of all these models is the high phenotypic dog-to-dog diversity 
described. These individual variations and the fact, that many DMD dogs die within 
the first 6 month of life, lead to difficulties in reaching the size of an experimental 
group and in showing clear statistically significant results (reviewed in Wells, 
2018). 
2.6. Pig models 
Last but not least, in 2013, a tailored pig model of DMD has been generated in our 
working group. Klymiuk et al. (2013) established the large animal model by gene 
targeting, deleting DMD exon 52 in male pig cells. The region corresponding to 
human DMD exon 52 was replaced by a neomycin resistance cassette. DMD pigs 
were then generated by nuclear transfer. The introduced mutation reflects a frequent 
mutation in human DMD patients (Muntoni et al., 2003). DMD pigs lack dystrophin 
and exhibit progressive muscle weakness, impaired mobility and disturbances in 
locomotion due to dystrophic changes of skeletal musculature. Histological 
examination of the DMD pig muscle tissue reflects the structural changes seen in 
DMD patients. These findings include excessive variation of muscle fiber 
diameters, internalized central nuclei indicating regeneration processes, cell 
infiltration, necrosis of muscle fibers and interstitial fibrosis. The DMD pig shows 
an accelerated strong muscle phenotype and disease progression, leading to muscle 
structure changes already in newborn piglets. Furthermore, serum CK levels are 
severely elevated. Most likely due to respiratory failure, the maximum life span of 
DMD pigs is around 3 month of age (Klymiuk et al., 2013). Therefore, male DMD 
pigs do not reach sexual maturity. To overcome this drawback, in cooperation with 
the working group of Matsunari we generated unique chimeric boars, comprising 
mutant cells which harbor the lethal DMD mutation and normal cells. These 
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chimeric boars, containing DMD XKOY germ cells, show a milder impairment of 
respiratory and motor function. The model indicates, that muscle dysfunction, at 
least partly, can be cured by normal cells. However, most importantly, the chimeric 
boars are able to reach adulthood. The design of such chimeric DMD XKOY boars 
as effective system to produce tailored DMD pigs, will have a great impact on the 
establishment of next-generation theraphies, such as gene editing and gene therapy, 
cell-transplantation therapy and medication aiming at exon-skipping (Matsunari et 
al., 2018). 
Summarizing the advantages and disadvantages of the different animal models for 
DMD it becomes apparent that, except for the pig, all models are far from humans 
with regard to genetics, anatomy and physiology. Most models of DMD are not able 
to reliably reflect the patients’ situation and therefore are not stable in predicting 
efficiency and safety of new therapies or devices. This is an obstacle to the 
extrapolation and interpretation of treatment effects from animal to human 
(reviewed in Aigner et al., 2010; Echigoya et al., 2016). Pigs, unlike the other 
named animals, are omnivores, as well as humans. They show a huge number of 
similarities in anatomy, physiology, pathology and metabolism (reviewed in Aigner 
et al., 2010). The cardiovascular and immune, as well as respiratory and skeletal 
muscle system of pigs and humans closely resemble each other. Therefore, 
generally one can say, that pigs as large animal model for DMD are supporting 
translational medicine by bridging the gap between proof-of-concept trials in mice 
and clinical studies in DMD patients (Klymiuk et al., 2016). 
3. Diagnostic approaches in DMD 
As already mentioned above, diagnosis of DMD is regularly delayed. The first 
clinical symptoms are noted at a mean age of 2.5 years with a first evaluation by a 
care provider at a mean age of 3.6 years. In many cases the initial consultation of a 
pediatrician doesn’t result in diagnostic testing, but in referral to occupational, 
physical or speech therapy or programs for development stimulation (Ciafaloni et 
al., 2009). Immediate referral to a specialist for neuromuscular problems, who 
requests genetic analysis of the DMD gene, would avoid the diagnostic delay 
(reviewed in Birnkrant et al., 2018b). To date, definite diagnosis of DMD disease 
is made at a mean age of 4.9 years (Ciafaloni et al., 2009). Early diagnosis of the 
disease and sensitive monitoring of disease progression are necessary for most of 
the current therapeutic approaches, such as corticosteroid treatment, which aim to 
intervene before severe and irreparable muscle damage have taken place (reviewed 
in Ciafaloni et al., 2009). 
Family history in many cases gives a first hint for the diagnosis of DMD, as 
approximately 1 in 3 DMD cases (about 30%) stem from spontaneous de novo 
mutations in the DMD gene (reviewed in Aartsma-Rus et al., 2016; reviewed in 
Ciafaloni et al., 2009). Therefore it is carefully analyzed before further diagnosis in 
patients presenting any suspicion of abnormal muscular function (reviewed in 
Birnkrant et al., 2018b). 
3.1. Genetic testing  
DMD diagnosis is verified by genetic testing. A correct diagnosis is important for 
providing proper care and support to patients and for further family planning. 
Moreover, mutation-specific therapy approaches require clear and exact 
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localization of the underlying mutation (reviewed in Aartsma-Rus et al., 2016). 
Dystrophin gene deletion or duplication analysis is the initial confirmatory DNA 
analysis done in individuals with suspected DMD. It is the most labor- and cost-
efficient way, since approximately 65% of the DMD causing mutations are single- 
or multi-exon deletions or duplications in the dystrophin gene, as shown above 
(reviewed in Aartsma-Rus et al., 2016; reviewed in Birnkrant et al., 2018b). 
Chamberlain et al. (1988) established a multiplex PCR kit, containing primers for 
9 exons to detect 80% of deletions in the DMD gene. Two years later, Beggs et al. 
(1990) presented primers for 9 additional exons. In conjunction the Chamberlain 
and Beggs multiplex PCR kit is able to detect 97% of all deletions. However, 
multiplex PCR is no longer recommended for the genetic diagnosis of DMD, but is 
still used in many laboratories, since the method is cheap. Aartsma-Rus et al. (2016) 
even recommends re-analysis of historic cases identified with multiplex PCR. The 
detection of duplications is more technically and laborious demanding. Although 
causing DMD in 5-8% of patients, these mutations were not routinely screened, 
until a multiplex ligation-dependent probe amplification (MLPA) assay had been 
designed. To date MLPA is the most reliable and suitable method, simultaneously 
screening all 79 exons of the DMD gene for both, deletions and duplications 
(reviewed in Aartsma-Rus et al., 2016; reviewed in Birnkrant et al., 2018b). It is a 
cheap and simple assay offering a high ease of use (Lalic et al., 2005). Although 
MLPA is proposed as the screening method of choice for detecting rearrangements 
in the DMD gene, ambiguous MLPA amplification products can occur. These 
uncertain products should absolutely be verified by other methods, as they might 
result from small mutations which partially disturb MLPA amplification (Okizuka 
et al., 2009; Sansovic et al., 2013). Alternatively to MLPA, comparative genomic 
hybridisation array (array CGH) can be used to detect relative abundance of each 
exon of the DMD gene (reviewed in Aartsma-Rus et al., 2016). MLPA and array 
CGH are both able to identify the boundaries of a deletion or duplication and hence 
might indicate, whether the mutation results in a disruption of the reading frame or 
not. As explained before, this is important to predict disease progression (reviewed 
in Aartsma-Rus et al., 2016). 
If the screening for deletions or duplications is negative, whole dystrophin gene 
analysis is the next step to analyse for the remaining mutation types able to cause 
DMD (reviewed in Birnkrant et al., 2018b). These mutations, as stated above, 
include point mutations and smaller deletions, duplications or insertions. Therefore, 
Sanger sequencing can be used to identify individual exons. Sanger sequencing is 
more expensive and labor-intensive than MLPA or array CGH. A better alternative 
to this method, however, are next-generation sequencing (NGS) techniques, which 
in the future might even be able to replace MLPA, array CGH and Sanger 
sequencing. NGS has a high sensitivity and specificity and is able to identify various 
types of mutations, including novel mutations not identified before, such es novel 
partial deletions (Okubo et al., 2016; Wang et al., 2014; Wei et al., 2014). However, 
NGS until now is cost- and labor-intensive. In some cases, genetic testing does not 
confirm the clinical diagnosis. The reason for this can be mutations located within 
an intronic region, which are harder to detect. This is the case in about 0.5% of 
reported mutations. Even if such mutations are identified by NGS, it is still 
questionable whether they cause an alteration on the RNA level. Hence, subsequent 
RNA analysis need to be done (reviewed in Aartsma-Rus et al., 2016). 
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3.2. Examination of muscle biopsies 
Finally, if a clear identification of the DMD causing mutation by genetic analysis 
is not possible at all, the presence of dystrophin protein in skeletal muscle can be 
tested. This is done by staining cross-sections of a muscle biopsy with 
immunohistochemical (IHC) techniques or by analysing muscle protein extract by 
western blot (immunoblotting) (reviewed in Birnkrant et al., 2018b; Magrath et al., 
2018). Hereby it can be tested, if any dystrophin is produced or not (reviewed in 
Muntoni et al., 2003). Furthermore, histological examinations in individuals with 
DMD can give a clear picture of the degree of severity of the dystrophic process. 
Therefore, cross-sections of muscle tissue are stained with haematoxylin and eosin 
(HE). In the preclinical stage typical alterations in muscle tissue are active necrosis, 
phagocytosis and regenerative activity. With increasing age, the degree of variation 
in fiber size diameter increases, as well as phagocytosis, whereas regeneration 
processes decline (Bradley et al., 1972). Special staining methods, such as Masson 
Trichrome (MT) and Sirius Red (SR), allow the detection of fibrosis, which is 
discussed to be a significant co-determining factor for myofascial pathology. An 
increase of collagenous connective tissue might have a negative effect on the 
nutrition of the enclosed muscle cells (Klingler et al., 2012). 
Muscle biopsies are not only of use with regard to histological examinations and 
gel-based quantitative proteomics. Although two-dimensional polyacrylamide gel 
electrophoresis (2-DE) up to date remains the method of choice and is widely 
applied (Abdallah et al., 2012), gene expression profiles from muscle biopsies can 
also be generated by other methods. Expression microarrays for example, can 
identify components with possible important control functions or unexpected 
involvement in regulatory or pathological pathways in muscle (Bakay et al., 2002; 
Haslett et al., 2003). Even more effective, however, are holistic proteome analyses 
by mass spectrometry (MS). MS as a gel-free quantitative technique enables 
profiling of proteins with a high throughput rate, thus providing high precision in 
quantification of proteins (Abdallah et al., 2012). Several MS-based gene 
expression studies in animal models for DMD emphasize the increasing importance 
of these holistic proteome studies. 
A 2-DE and MS of hindlimb muscles of mdx compared to WT mice identified 
differently abundant proteins (Ge et al., 2003). Investigation of mdx mice at 
different ages revealed age-dependent changes of the muscle proteome (Ge et al., 
2004). Several subsequent proteome studies in the mdx mouse investigated age-
related changes in other muscles, such as the tibialis anterior muscle or diaphragm 
and proteome differences between different muscle groups (Carberry et al., 2013; 
Carberry et al., 2012a, b). In the GRMD dog model a quantitative proteomic study, 
using isotope-coded affinity tag (ICAT) profiling analyzed by MS, indicated that a 
central hallmark of muscular dystrophy in dogs is a defective energy metabolism, 
providing new insights into molecular pathology of DMD (Guevel et al., 2011). In 
the tailored pig model of DMD generated by our institute (Klymiuk et al., 2013), a 
proteome analysis revealed the extent of proteome changes in DMD muscle 
compared to WT. Analysis of 2-day-old versus 3-month-old DMD and WT pigs 
showed that proteome changes increase markedly with age. This reflects the 
progression of early pathological changes in this model (Frohlich et al., 2016). Carr 
et al. (2017) incorporated the different existing MS-based proteomic datasets of 
dystrophin-deficient tissue. The authors used proteome datasets of the mdx mouse, 
the GRMD dog and the dystrophin-deficient pig. Since in DMD patients proteome 
studies of skeletal muscle are still missing, they performed the intersection of data 
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of studies using blood and urine of DMD patients. The muscle proteome differs 
between species, individuals and muscles. However, the absence of dystrophin has 
a profound impact on the muscle proteome. The identification of differentially 
expressed proteins in DMD might unveil the molecular pathophysiology, leading 
to novel therapeutic targets or possible biomarkers to monitor disease progression. 
Biopsy procedure, however, involves an invasive surgical intervention. It requires 
general anesthesia with special precautions in DMD boys in comparison to healthy 
individuals. Risks are mainly perioperative cardiac and respiratory complications 
due to anesthesia, but also rhabdomyolysis. Up to date, little is known about the 
short- and long-term consequences of muscle biopsy excision (Hayes et al., 2008; 
Verhaart et al., 2019). Therefore, this method indeed is a last necessary step for a 
reliable diagnosis, but an inappropriate tool concerning clinical trials. 
3.3. Muscular function tests 
Since up to now primary outcome measures are based on quantitative and manual 
muscle examinations and timed function tests, it is of current interest to develop 
classification systems and simplified scales to assess the functional abilities of 
DMD patients (Kim et al., 2018). Multidisciplinary rehabilitation assessment 
includes muscular function tests for the evaluation of mobility and disease 
progression. 
In most early studies in children with neuromuscular diseases (NMD) in general, 
the muscle strength was measured and assessed. One example of this is the Brooke 
Scale (Brooke et al., 1981; Stuberg and Metcalf, 1988). Already in 1982, a scale 
especially devised for boys with DMD, called the Hammersmith Motor Ability 
Scale (HMAS) was developed (Scott et al., 1982). Used within a clinical setting, 
this test is satisfactory. However, validity and reliability have never been 
determined. Moreover, the test has been developed before the broad application of 
corticosteroids, thus excludes the detection of an improvement following treatment 
(Scott et al., 2012). 
The more recent studies focus on functional scales. There are several general scales 
which can be utilized for the assessment of different NMD, such as the Gross Motor 
Function Measure (GMFM) and the Motor Function Measure (MFM) (Berard et 
al., 2005; Mazzone et al., 2010; Russell et al., 1989). Other scales are specifically 
designed to evaluate aspects of function in certain cohorts. The Hammersmith 
Functional Motor Scale (HFMS) for spinal muscular atrophy (SMA) types 2 and 3 
in children, for example monitors the clinical progress and tests the motoric abilities 
in children with limited mobility (Main et al., 2003). An expanded version of this 
test evaluates the ambulatory patients in this certain cohort (O'Hagen et al., 2007). 
The test was further expanded to assess children with non-ambulant SMA using the 
Modified Hammersmith Functional Motor Scale (MHFMS) (Krosschell et al., 
2006). This test especially is useful in young children (younger than 30 months) 
and thus may also be beneficial in young DMD boys (Connolly et al., 2013; 
Krosschell et al., 2011). As young DMD patients are an especially challenging 
population, another test, the Bayley III infant motor scale, which normally is used 
to test motor delay in the first years of life, has been validated and demonstrated as 
useful in very young DMD boys. The Bayley III test allows to study motor function 
in children less than 6 months old (Connolly et al., 2013). Another currently 
relevant functional scale, particularly designed for the evaluation of disease 
progression in ambulant DMD boys, is the North Star Ambulatory Assessment 
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(NSAA). This test of Scott et al. (2012) is an adaption of the HMAS for DMD boys 
developed in 1982. The NSAA contains important disease milestones, already 
previously used in DMD boys, such as getting from sitting to standing, timed rising 
from the floor or the 10 m timed walk/run test. Furthermore, it includes new items 
that allow the detection of possible improvement due to treatment, such as running 
and hopping – aspects of function which usually are not observed in untreated DMD 
boys. NSAA performance takes only approximately 10 minutes to complete, has a 
high test-retest ability and a good intra- and inter-rater reliability. Last but not least, 
it is practical, requiring only minimal equipment for standardization. The NSAA is 
designated as reliable test and actual gold standard to score DMD motor ability 
(Cacchiarelli et al., 2011; De Sanctis et al., 2015). 
A simple but regularly applied global assessment of the endurance and ability to 
walk, as well as of the evaluation of functional mobility in DMD patients is the 6- 
minute walking test (6-MWT) (Pane et al., 2014). It describes the distance walked 
over a period of 6 minutes. The 6-MWT is used to assess functional capacity in 
several different diseases (McDonald et al., 2010). For the measurement of walking 
skills at baseline, functional capacity and assessment of disease progression it is 
useful in DMD patients. Furthermore, it is regularly used as additional evaluation 
method for muscle function in clinical trials of DMD therapies (Goemans et al., 
2011; Pane et al., 2014). The 6-MWT is simple to apply, accurate, well-tolerated 
and reproducible (Anonymous 2002). Pane et al. (2014) refers to the 6-MWT as the 
primary outcome measure in most of clinical trials of DMD. However, since DMD 
patients fall frequently, safety, feasibility and accuracy of this test might be 
compromised (McDonald et al., 2010). 
The NSAA and timed functional tests have a high reliability and validity. They are 
foundational clinical assessments of muscle function in the ambulatory period of 
DMD patients and thus should be done every 6 months (reviewed in Birnkrant et 
al., 2018b). 
A new Comprehensive Functional Scale for DMD (CFSD) and accompanying 
Ambulatory Functional Classification System for DMD (AFCSD) have been 
developed based on other previously published classification systems. The CFSD 
only, already consists of 21 items and 78 sub-items (Kim et al., 2018). This new 
functional assessment was established in 2018. It appears as rather complex 
evaluation scale, and might thus be not practical in use. To date only preliminary 
evaluation of CFSD and AFCSD exist. 
There are several functional tests to assess muscular function in DMD patients. First 
of all, the great number of different functional scales might complicate the 
comparison of the results of different clinical trials. Moreover, lack of 
understanding and motivation, especially in young children, may affect the 
performance outcome (Geiger et al., 2007). Cognitive impairment and behavioral 
challenges in some individuals with DMD can additionally exacerbate the potential 
problems of functional tests (Hinton et al., 2007). Last but not least, muscular 
function tests are only feasible in ambulant DMD patients, excluding the evaluation 
of disease progression in non-ambulatory individuals with DMD. However, non-
ambulant patients make up the majority of the patients, since the average age at loss 
of ambulation is about 10.5 years and the median survival of the patients is 30 years 
(Straub et al., 2016). 
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3.4. Biomarkers in DMD 
A biomarker is defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic response to therapeutic intervention” by the Biomarkers Definitions 
Working Group of the National Institutes of Health (NIH) (Anonymous 2001). This 
definition includes prognostic, as well as diagnostic biomarkers, and biomarkers, 
that indicate the response to a therapeutic agent (reviewed in Aartsma-Rus and 
Spitali, 2015). In DMD there are several different kinds of biomarkers which aim 
to quantify disease pathology and progression. Biofluid markers, found in serum, 
urine and saliva, occur due to passive protein leakage or an active release of proteins 
in the circulatory system. Primary tissue markers are compounds of the dystrophin 
glycoprotein complex. Secondary muscle tissue markers are for example cellular 
stress proteins, metabolite transporters and mitochondrial enzymes. Last but not 
least, there are several noninvasive imaging biomarkers (reviewed in Dowling et 
al., 2019).  
3.4.1. Biomarkers in body fluids 
3.4.1.1. CK, AST, ALT, LDH in blood serum 
An elevation of blood serum creatine kinase (CK) level counts as important 
indicator for DMD. CK plays a major role in tissues with fluctuating energy 
demands, like brain and muscle (Schlattner et al., 2006). It catalyzes the reversible 
reaction of creatine and adenosine triphosphate (ATP) forming phosphocreatine and 
adenosine diphosphate (ADP) (reviewed in Wallimann et al., 1992). There exist 
mitochondrial and cytosolic CK isoenzymes. The elevation of circulating cytosolic 
CK isoforms in serum is tissue-specific. The circulating isoform CK-BB rises after 
brain damage, CK-MB after acute myocardial infarction. The myofibrillar CK-MM 
is present in skeletal muscle, its elevation in serum indicates muscle damage 
(Ebashi et al., 1959; Koch et al., 2014; Schlattner et al., 2006). In the case of muscle 
injury, cell membrane permeability increases, allowing CK-MM to leak into 
interstitial fluids. This results in elevated circulating CK-MM in blood serum. The 
quantification of serum CK levels is low in cost and an easy to apply measurement 
method (Ciafaloni et al., 2009; Koch et al., 2014). CK-MM hence is routinely 
measured and proposed as best biomarker for skeletal muscle damage in general 
(reviewed in Koch et al., 2014; McLeish and Kenyon, 2005). 
CK in newborn infants with DMD is already severely increased. As a result, the 
routine measurement is discussed as potential newborn screening method for DMD 
(Zellweger and Antonik, 1975). However, it has to be noted, that there are several 
other causes for a CK elevation, such as other hereditary forms of muscular 
dystrophy, injuries or traumas, recent bacterial or viral infections, hypothyroidism 
or drugs. Even though CK under the named differential diagnoses rarely approaches 
the levels found in DMD patients, false positive diagnosis need to be seriously taken 
into account and should be avoided (reviewed in Verma et al., 2010). A single-tier 
newborn screening, only based on increased CK levels at birth, as it was introduced 
in many countries, therefore strictly requires a re-testing at around 6-8 weeks of age 
(reviewed in Mendell and Lloyd‐Puryear, 2013). A lasting CK elevation is an 
indicator but still no prove for the disease. Diagnosis of DMD needs to be confirmed 
by further methods, such as genetic testing (reviewed in Birnkrant et al., 2018b). 
Last but not least, since only limited data on the impact of an early diagnosis and 
an early initiation of therapy in DMD exist, so far there are restrictions of regular 
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screenings for DMD in newborns (Kemper and Wake, 2007). 
Not only newborn screening benefits from CK as diagnostic marker in DMD. Using 
CK as indicative measurement in children displaying early clinical symptoms of 
DMD is recommended but yet underutilized (Ciafaloni et al., 2009). Typically, in 
patients with DMD, CK levels are severely elevated, ranging between 5000 and 150 
000 IU/L (normal <200 IU/L) (reviewed in Verma et al., 2010). Regular 
measurements show a CK peak between 1 and 6 years of age and a decrease with 
age due to the replacement of muscle tissue by connective and fatty tissue (Zatz et 
al., 1991). Elevated CK levels consequently indicate a floride, i.e. active, state of 
the disease. Thus, as CK elevation is directly associated with muscle damage, the 
parameter can also be utilized as biomarker in therapeutic trials. However, it is 
discussed to be of little use here, as a decline of CK can stand for both, the reduction 
of CK-leakage due to the success of a therapeutic approach or a further decrease of 
muscle quality (reviewed in Aartsma-Rus and Spitali, 2015; Jensen et al., 2017). 
Interestingly, in 1972 observations of an individual with DMD already showed, that 
CK levels may vary between different measurement timepoints, sometimes being 
only mildly increased and years after being elevated severely (Bradley et al., 1972). 
A reason for varying CK levels could be hemolysis due to the procedure of blood 
collection. Perovic and Dolcic (2019) in their study examined the influence of 
hemolysis on clinical chemistry parameters, and described a hemolysis interference 
for CK. For CK-MB even clinically significant differences were detected (Koch et 
al., 2014). Other reasons for varying serum CK levels are, for example, seasonal 
and an intra- and interindividual variation (Nicholson et al., 1985; Percy et al., 
1982). Summarizing, CK evaluation as indicator for DMD, as informative 
biomarker about the clinical course of the disease, or as diagnostic biomarker in 
therapeutic trials is reasonable. Nevertheless, for a reliable clinical assessment CK 
has always to be considered together with several other clinical parameters. 
Serum analysis of DMD patients will not only reveal the presence of elevated CK. 
Persistently elevated serum activities of transaminases, i.e., aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT), together with a 
negative diagnostic workup for a hepatic dysfunction (e.g. gamma GT is not 
elevated), can also be indicative for DMD and should be considered, although the 
reason for this is so far unexplained (reviewed in Aartsma-Rus et al., 2016; 
Birnkrant et al., 2018b; Verma et al., 2010). Less commonly, DMD is considered 
due to increased serum enzyme concentration of lactate dehydrogenase (LDH) 
(reviewed in Birnkrant et al., 2018b). 
3.4.1.2. Emerging DMD biomarkers in blood 
There is an entire list of emerging biomarkers in body fluids, which are found to be 
altered in DMD patients and animal models for DMD compared to healthy controls 
(HC). 
Concerning the coagulation cascade, in serum a peptide of coagulation factor XIIIa 
was for example identified as discriminator between dystrophin-deficient mdx mice 
and wild-type (WT) controls (Alagaratnam et al., 2008). Several more up- and 
down-regulated factors in plasma samples of mdx compared with WT mice were 
identified. Among these is fibrinogen, another important factor in the coagulation 
cascade. It was shown to be increased in abundance in dystrophic mice (Colussi et 
al., 2010) as well as in DMD patients (Hathout et al., 2014; Nadarajah et al., 2012). 
Moreover, fibrinogen was shown to be accumulated in dystrophic muscles of DMD 
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patients and mdx mice, and it was speculated to promote inflammation and to be 
linked to the formation of fibrotic tissue (Vidal et al., 2008). 
Concerning serum lipids, significantly higher triglycerides, phospholipids, free 
cholesterol, cholesterol esters and total cholesterol concentrations were measured 
in DMD patients compared to healthy controls (HC) (Srivastava et al., 2010). 
Another discussed serum biomarker for DMD is fibronectin, a glycoprotein. 
Fibronectin is a major component of the ECM. Significantly increased levels in 
DMD patients compared to age-matched healthy subjects are found (Cynthia 
Martin et al., 2014). 
Matrix metalloproteinase-9 (MMP-9) is another potential serum biomarker in 
individuals with DMD. Longitudinal studies in DMD patients on corticosteroid 
treatment showed that MMP-9 levels were significantly elevated in older, non-
ambulatory patients. Moreover, MMP-9 was shown to increase significantly with 
age. It is therefore discussed as biomarker for the assessment of disease progression 
(Hathout et al., 2014; Nadarajah et al., 2011). However, studies in patients on 
corticosteroid treatment did not allow the discrimination of effects derived from 
aging or the influence of the therapy on MMP-9 (Zocevic et al., 2015). 
In a new proteome profiling study of individuals with DMD not yet treated with 
glucocorticoids, compared to HC, 107 elevated and 70 decreased proteins were 
identified in serum. Elevated proteins mainly were of muscle origin and cell 
adhesion proteins, but also ECM and pro-inflammatory proteins. Proteins that were 
found to be decreased, are mainly involved in cell adhesion processes, cell 
differentiation or have to do with growth factors. Interestingly, subsequent 
treatment of the same cohort with glucocorticoids allowed to examine the impact 
of therapy on the detected serum biomarkers. 17 proteins, associated with DMD, 
were shown to normalize under treatment. 80 proteins, not associated with DMD, 
were shown to be up- or downregulated after treatment, illustrating a broader effect 
of glucocorticoids (Hathout et al., 2019). These results are important, since most 
current therapies and therapy trials in DMD patients contain glucocorticoid 
treatment (reviewed in Aartsma-Rus and Spitali, 2015). 
Several other elevated proteins, mainly of muscle origin, were identified in serum 
of DMD patients. Among these were for example myofibrillar proteins, such as titin 
(connectin) and myosin, glycolytic enzymes, such as aldolase, transport proteins, 
as for example fatty acid binding protein and myoglobin and others, like CK-MM 
(Hathout et al., 2014). 
Another important group of potential biomarkers for the diagnosis of DMD in early 
stages, and the analyses of progression and treatment, are microRNAs (miRNAs). 
miRNAs are small non-coding RNAs, which function in the post-transcriptional 
regulation of gene-expression in a sequence specific manner by inducing mRNA 
degradation or translational repression. In the control of skeletal muscle and cardiac 
development, several essential miRNA families were identified. miRNAs are 
known to control in part regenerative myogenesis, and the differentiation, 
maintenance and repair of muscle (reviewed in Hrach and Mangone, 2019). Due to 
muscle cell damage specific muscle-miRNAs (dystromiRs) leak into the 
bloodstream. Thus, dystromiRs are extracellular dystrophy-associated miRNAs, 
whose levels correlate with the severity of the disease. Up to now, several miRNAs 
were found to be up- or downregulated in DMD patients or animal models for DMD 
compared to healthy controls (Becker et al., 2016; Cacchiarelli et al., 2011; 
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Catapano et al., 2018; Llano-Diez et al., 2017; Mitchell et al., 2008; Zaharieva et 
al., 2013). 
3.4.1.3. Emerging DMD biomarkers in urine 
Since taking blood samples still is minimally invasive, some recent studies focused 
on potential urine-accessible metabolites as biomarkers associated with DMD. 
Urine can be collected easily, on multiple time-points and noninvasively (reviewed 
in Dowling et al., 2019; Thangarajh et al., 2019). Titin, which is already named 
above as a serum biomarker, was also detectable in urine of DMD patients (Matsuo 
et al., 2019; Rouillon et al., 2014). Equally, the L-arginine/nitric oxide pathway (L-
Arg/NO), which regulates endothelial function and was found to be impaired in 
DMD patients, was reported to be affected in urine (and plasma) of individuals with 
DMD (Horster et al., 2015). A major PGD2 metabolite, tetranor-PGDM, was 
observed to be elevated in urine of DMD patients. Even longitudinal changes were 
detectable, as the metabolite was found to increase further with age. This supported 
the hypothesis, that prostaglandin D2 (PGD2)-mediated inflammation is involved in 
the DMD pathology (reviewed in Aartsma-Rus and Spitali, 2015; Nakagawa et al., 
2013; Takeshita et al., 2018). Several further studies of candidate biomarkers in 
urine of DMD patients exist (Catapano et al., 2018; Rouillon et al., 2018). However, 
until now none of these urine biomarkers reached practical implementation. 
3.4.2. Noninvasive imaging biomarker in DMD 
Until now, clinical trials generally rely on measures of muscle function and strength 
(Zaidman et al., 2017). However, noninvasive imaging modalities are valuable 
clinical and research tools for monitoring disease progression in DMD. Imaging 
biomarkers can be used for cardiac and respiratory assessment, but also for 
monitoring progressive alterations in muscle over time. 
3.4.2.1. Echocardiography and Holter monitoring 
Echocardiography (ECG) allows the monitoring of cardiac dysfunction in DMD 
patients (reviewed in Birnkrant et al., 2018b; Cheeran et al., 2017; Silva et al., 
2007). As noninvasive imaging method for cardiac assessment it is recommended 
for young patients (before the age of 6-7 years) as it is well tolerated and does not 
require anesthesia. By ECG, the ejection fraction (EF) and cavity dimensions can 
be noted, thus enabling the detection of left ventricular dysfunction or dilated 
cardiomyopathy (Barison et al., 2009; reviewed in Birnkrant et al., 2018a). In the 
late non-ambulatory stage of DMD patients, it is recommended to include periodic 
24 h Holter monitoring in surveillance (reviewed in Birnkrant et al., 2018a). 
3.4.2.2. Quantitative ultrasound assessment 
Fatty infiltration as well as increased interstitial fibrous tissue among dystrophic 
skeletal muscle of DMD boys results in an increased echo intensity in standard 
ultrasound B-mode imaging (Pillen et al., 2009; Reimers et al., 1993). The echo 
intensity, also known as the grey value of the image, is determined by the amount 
of returning echoes per square area. The changes in echo intensity can be quantified 
by two different methods: by quantitative backscatter analysis (QBA) the 
amplitudes of the sound-waves, which are scattered back from the tissue, are 
directly measured during imaging procedure; the backscattered amplitudes can also 
be analyzed after the imaging process, after compression into greyscale levels 
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(GSL) received from the images. Both methods are shown to perform similarly 
(Rutkove et al., 2014; Shklyar et al., 2015; Zaidman et al., 2017). Skeletal muscle 
echogenicity can visually be graded, for example by the Heckmatt scale, ranging 
from normal (grade I) to very strong muscle echo and complete loss of bone echo 
(grade IV) (Heckmatt et al., 1982). 
Quantitative ultrasound (QUS) was shown to identify differences earlier than 
simple functional measures, such as the 6-MWT and supine-to-stand test (Rutkove 
et al., 2014; Zaidman et al., 2017). A near-significant association between QUS and 
the NSAA functional scale was demonstrated (Rutkove et al., 2014). Moreover, 
QUS was stated to detect disease progression in DMD (Zaidman et al., 2017). QUS 
is a noninvasive and painless imaging modality, demanding low effort. As it does 
not require anesthesia, it is especially useful in the assessment of skeletal muscle in 
young children with DMD. 
3.4.2.3. Magnetic resonance imaging and spectroscopy 
One of the preferred approaches to noninvasively diagnose disease pathology and 
progression in individuals with DMD is magnetic resonance imaging (MRI). MRI 
benefits of a high soft tissue contrast with exquisite detail and provides volumetric 
information. It avoids harmful ionizing radiation, unlike for example computed 
tomography (CT) or x-ray and is therefore generally applicable to pediatric patients 
(Magrath et al., 2018). 
With regard to cardiac assessment in individuals with DMD, cardiovascular 
magnetic resonance imaging (CMR) is the noninvasive imaging method of choice 
for assessing cardiac dysfunction and evaluating the degree of cardiomyopathy 
(reviewed in Birnkrant et al., 2018a; Cheeran et al., 2017; Magrath et al., 2018). 
CMR provides higher sensitivity compared to ECG and is recommended already at 
early ages (Buddhe et al., 2016). It enables to detect the earliest signs of 
cardiomyopathy, long before the onset of clinical symptoms (Magrath et al., 2018). 
A typical cardiac MRI protocol, to assess cardiac function and morphologic 
changes in DMD patients, incorporates several different techniques: black-blood 
imaging for the evaluation of thoracic and cardiovascular anatomy, dynamic (cine) 
white-blood imaging (balanced steady-state free precession) for the assessment of 
global and regional cardiac function, contrast enhanced perfusion imaging and late 
gadolinium enhancement (LGE) for the assessment of myocardial fibrosis (Silva et 
al., 2007). As a result, CMR allows to note early heart failure symptoms, such as 
tissue degeneration and myocardial structural changes (e.g. myocardial fibrosis and 
fibrofatty involvement), just as myocardial function and regional wall motion 
abnormalities (normal/ mild or severe hypokinesia/ akinesia, dyskinesia). Cardiac 
mass, left ventricular (LV) remodeling and wall thickening as well as abnormal 
chamber dimensions can be assessed. End systolic and end diastolic time frames 
can be identified, allowing for example to detect depressed LV ejection fraction 
(LVEF) (Barison et al., 2009; reviewed in Birnkrant et al., 2018a; Magrath et al., 
2018; Silva et al., 2007). There are several alternative MRI methods to assess 
cardiovascular function in DMD. Pre- (native) and postcontrast parametric "spin-
lattice" relaxation time (T1-weighted mapping) (Bell and Jones) techniques, for 
example, are emerging cardiac biomarkers for early myocardial microstructural 
remodeling (such as diffuse fibrosis), enabling to estimate extracellular volume 
fraction. However, these methods assist ancillary to the named standard biomarkers, 
but are not widely used (Magrath et al., 2018). One reason for this is, that for 
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implementing T1 mapping in clinical routine, the characteristic range of normal T1 
values at a particular magnetic field strength must be established to identify 
deviations from the normal range (Bottomley et al., 1984). Apart from magnetic 
field strength, a plethora of factors influence T1 time values, such as protocol 
parameters, motion, sequence design and scanner adjustments. Altogether, these 
factors highly reduce comparability between different sites over time. A further 
limitation in the comparability of T1 times between different study sites is, that 
analysis of parametric T1 maps often uses relatively restricted in-house developed 
tools, early-stage commercial packages, or manufacturer prototypes. Therefore, 
highly adaptable and robust tools for standardized T1 quantification and map 
presentation are desirable. Furthermore, analysis is not standardized and often 
based on expert knowledge (reviewed in Messroghli et al., 2017). 
Since current clinical trials mostly rely on ambulatory endpoints (e.g. muscular 
function tests), thereby excluding non-ambulatory patients, MRI and magnetic 
resonance spectroscopy (MRS) are emerging techniques providing promising 
biomarkers for muscle quality or primary outcome measures for all DMD patients. 
MRS is capable to measure the concentrations of different chemical components 
within tissues and is based on the same physical principles as MRI. As DMD 
muscles show compositional and structural changes, these approaches can be used 
to assess the following: alterations of the maximal muscle cross-sectional area 
(mCSA), muscle damage, inflammation and edema and, at a later stage of the 
disease, fat infiltration and fibro-fatty replacement (Forbes et al., 2013; Mathur et 
al., 2010). The visualisation of these pathologic changes depends on different 
specialized imaging protocols, which provide quantitative outcome measures 
(Straub et al., 2016). mCSA, for example, can be measured using longitudinal 
relaxation time (T1) weighted MRI (Mathur et al., 2010). High sensitivity for 
detecting DMD disease pathology and progression was shown for two quantitative 
MR measures: transverse relaxation time (T2) weighted magnetic resonance 
measures (MRI-T2) and intramuscular fat fraction (FF) (Willcocks et al., 2016). 
Both methods are most commonly used in (multicenter) clinical trials to assess 
disease severity, activity and progression by MRI (Barnard et al., 2018; Forbes et 
al., 2013; Forbes et al., 2014; Willcocks et al., 2016). FF can for example be 
measured by 3-point chemical shift-encoded (Dixon) MRI or proton MRS (1H-
MRS). With 1H-MRS the separation of water and lipid signal is possible. For a more 
targeted evaluation of inflammation and damage in muscle tissue, 1H20 T2 can be 
used. FF is not only shown to correlate with disease progression but also with the 
outcome of functional tests (Willcocks et al., 2016). However, there are several 
limitations to these methods indicating, that other MRI variables need to be 
established. As 1H20 T2 primarily detects inflammation and damage, it is not 
suitable for tracking disease progression in terms of fibrosis. Consistent with its 
sensitivity to inflammation, 1H20 T2 is highly responsive to corticosteroid therapy 
and might thus be more appropriate for clinical trials with anti-inflammatory 
therapeutics (Arpan et al., 2014). In MRI-T2, water T2 changes are nonspecific due 
to the sensitivity to edema, inflammation, necrosis and fibrosis on the one hand, and 
lipid on the other hand (Straub et al., 2016). Moreover, MRI-T2 is influenced by 
treatment with corticosteroids. In addition, the measurement of FF has poor 
prognostic value, since there is a high inter- and intrasubject variability (Gerhalter 
et al., 2019). Furthermore, adipose infiltration of muscles tissue has a very 
heterogeneous distribution in DMD patients (Chrzanowski et al., 2017; Hooijmans 
et al., 2017). 
A relatively new emerging MRI protocol is 23Na MRI, to calculate total sodium 
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concentration (TSC) and intracellular-weighted 23Na signal (ICwS) in muscle 
tissue. As intracellular sodium concentration is shown to increase severely due to 
loss of dystrophin and resulting muscle cell damage, 23Na MRI is a more promising 
tool for informations about early pathological changes (Gerhalter et al., 2019; 
Glemser et al., 2017), but its capability is highly restricted to a limited number of 
specialized ultra high-field MRI sites worldwide and it is not established in the 
clinical routine. 
Even if MRI exams may become shorter and simpler and the acceptance for 
younger patients improves (reviewed in Magrath et al., 2018), very young children 
are usually not able to cooperate for MRI procedure, such as breath holding for 
periods of 5 to 20 seconds for cardiac MRI. Thus, MRI in patients younger than 6-
7 years requires anesthesia, harboring specific risk for DMD patients. Hence, these 
procedures are typically avoided in early live periods, when they are not tolerated 
(Birnkrant et al., 2018a). 
3.4.2.4. Other noninvasive imaging modalities 
When DMD patients, at a later stage of the disease, complain about cardiac rhythm 
disturbances, event monitors, recording for a longer period of time, can additionally 
be indicated for cardiac surveillance (reviewed in Birnkrant et al., 2018a). 
Another noninvasive imaging tool to assess muscle condition in DMD patients is 
electrical impedance myography (EIM). The method is based on applied low-
electric alternating current, dissipating as it travels through a substance (here: 
muscle), and thereby producing a measurable voltage (reviewed in Rutkove, 2009). 
Localized impedance changes indicate underlying muscle structure alterations. EIM 
is painless and requires low effort (Rutkove et al., 2014). However, there are only 
few studies about EIM in DMD and many questions to the mechanism remain open. 
Thus EIM still needs to be refined (reviewed in Rutkove, 2009). 
An emerging tool to assess clinical anisotropy for monitoring muscle degeneration 
in DMD is Viscoelastic Response (VisR) ultrasound. The extent of anisotropy is 
given by the ratios of VisR relative viscosity (RV) or relative elasticity (RE). RE 
and RV are measured with parallel versus perpendicular to muscle fiber alignment 
oriented asymmetric radiation force. VisR ultrasound shows significantly higher 
RE and RV anisotropy ratios in rectus femoris muscle of DMD patients compared 
to HV. However, even if VisR ultrasound is stated to reflect changes in viscous and 
elastic anisotropy associated with muscle degeneration, investigations in other 
muscle groups do not exactly reflect these results. Furthermore, to date, only a pilot 
in vivo clinical feasibility study exists (Moore et al., 2018). 
Concerning the appearance of gastrointestinal symptoms, such as constipation and 
gastro-oesophageal reflux, a scintigraphic gastric emptying scan, to assess gastric 
emptying time, can be useful (Birnkrant et al., 2018b). 
4. Multidisciplinary treatment and emerging therapies for DMD 
DMD disease requires exhaustive clinical multidisciplinary management. Up to 
date, despite corticosteroid treatment, there exists no effective therapy for DMD. 
However, several genetic approaches have been made in the last few years 
(reviewed in Guiraud and Davies, 2017). 
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4.1. Multidisciplinary treatment for DMD  
A main aspect of multidisciplinary care in DMD patients is the treatment with 
glucocorticoids. Glucocorticoids, as anti-inflammatory and immunosuppressant 
drugs, slow down muscle deterioration. This causes prolongation of ambulation 
(estimated 3-year median delay of LoA), prevention of scoliosis surgery and 
maintained respiratory and upper limb function (reviewed in Bello et al., 2015a; 
Birnkrant et al., 2018b). Prednisone and prednisolone, typical representatives for 
synthetic glucocorticoids, however, show significant adverse effects in long-term 
treatment. Side effects include, in order of frequency, weight gain, adrenal 
suppression and insulin resistance (cushingoid appearance), growth retardation, 
behavioral changes, bone morbidity, cataracts, and skin abnormalities (Bello et al., 
2015a; Hoffman et al., 2019). These effects are in particular problematic in very 
young and elderly patients (Hoffman et al., 2019). However, glucocorticoid 
initiation in younger children with DMD, not yet affected from significant physical 
decline, was shown to be especially beneficial (Merlini et al., 2012). Deflazacort, a 
synthetic corticosteroid with labelled indication especially for DMD, showed a 
greater effect on extending the preservation of independent ambulation than 
prednisone/prednisolone treatment. However, the same adverse effects as for 
prednisone or prednisolone were observed for deflazacort, with the sole difference 
of less weight gain (Bello et al., 2015a). A novel synthetic steroid for treatment of 
DMD is vamorolone. Vamorolone seems to optimize the anti-inflammatory effect, 
traditional for steroids. Of importance, suspectibility to bone morbidity, adrenal 
suppression and insulin resistance appeared to be less pronounced for vamorolone 
relative to other published trials of glucocorticoid treatment (Hoffman et al., 2019). 
Another important aspect in the multidisciplinary care for DMD patients at all ages 
is physiotherapy to prevent contractures and deformity. Postural correction, as well 
as orthotic intervention and splinting, are necessary at later stages of the disease. 
To further improve quality of life and to extend the overall lifespan, physical aids, 
such as wheelchairs and medical devices for assisted respiration are used. Rarely, 
orthopaedic surgery, such as posterior spinal fusion, is required (reviewed in 
Birnkrant et al., 2018b; Hrach and Mangone, 2019). 
As soon as any signs of heart failure are detectable, or latest at the age of 10 years, 
specific treatment should be initiated for patients with DMD (reviewed in Birnkrant 
et al., 2018b). Cardiovascular medication regimes vary in individuals with DMD 
and show different efficiency at treating the DMD associated cardiomyopathy 
(Cheeran et al., 2017). As first-line therapy, patients in young adulthood receive 
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor 
blockers (ARBs) (reviewed in Birnkrant et al., 2018a; Cheeran et al., 2017). Only 
about a third of DMD patients receive β-blockers. Few DMD patients are on other 
guideline-directed medications for heart failure, such as diuretic therapy and 
mineralocorticoid receptor antagonists. Additionally, steroid therapy is suggested 
to delay the progression of cardiomyopathy and therefore, to improve the overall 
survival (reviewed in Cheeran et al., 2017; Verma et al., 2010). 
Gastrointestinal and nutritional management is indispensable for DMD patients 
with complications, such as weight loss or gain, swallowing dysfunction, 
mandibular contracture, constipation or low bone density. The management 
includes general nutrition plans, nutrient supplementation (e.g. 25-hydroxy-vitamin 
D, multivitamin or mineral supplement), as well as daily intake of osmotic laxatives 
(e.g. polyethylene glycol, or lactulose) (Birnkrant et al., 2018b). 
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4.2. Emerging treatments for DMD 
Considerable progress, concerning the treatment of DMD, has been made in the 
past years in genetic approaches. There is a full list of treatment trials for DMD, 
which changes continually. An update on the ongoing trials is available at the WHO 
International Clinical Trials Registry Platform or at ClinicalTrials.gov (reviewed in 
Birnkrant et al., 2018b). 
4.2.1. Cell therapy 
Muscle precursor cells of one genotype are able to fuse with host muscle fibers of 
another genotype and then to express the donor genes (Partridge et al., 1989). Based 
on this, the transplantation of myoblasts of healthy donors into skeletal muscle of 
DMD patients, with the main goal to create a pool of dystrophin competent satellite 
cells, is one therapeutic approach studied for treatment of DMD (Bajek et al., 2015; 
Sun et al., 2019). Partridge et al. (1989) showed, that transplantation of normal 
muscle precursor cells in skeletal muscle of dystrophic mdx mice induces 
dystrophin expression. In a DMD patient, intramuscular cell transplantation of 
normal muscle precursor cells even showed long-term expression of donor derived 
dystrophin (Skuk et al., 2007). However, several other studies in DMD patients 
state that there is either no or only low expression of donor derived dystrophin 
(Karpati, 1991; Mendell et al., 1995) and that there are no functional improvements, 
except for one study (Huard et al., 1992). Compared to myoblasts, muscle stem 
cells, with their regenerative ability and their capacity to renew themselves, have a 
strong therapeutic advantage (Sun et al., 2019). Stem cell transplantation, using 
muscle satellite cells transduced with micro-dystrophin, was shown to regenerate 
mdx dystrophic muscles (Ikemoto et al., 2007). The transplantation of a single 
mouse muscle fiber, containing only few or even a single satellite cell, in mouse 
likewise showed better engraftment than myoblast transplantation (Collins et al., 
2005; Sacco et al., 2008). In addition, experiments of transplanting human satellite 
cells into immunocompromised mdx mice led to a stable engraftment (Garcia et al., 
2018). Equally, stem cell transplantation using bone marrow stromal cells showed 
potential as therapeutic agent (Dezawa et al., 2005). A recent study analyzed the 
effect of intracoronary allogeneic cardiosphere-derived cells (CAP-1002) 
administered by global intracoronary infusion in hearts of DMD patients with 
substantial myocardial fibrosis. Cell therapy here showed signals of efficacy on 
cardiac as well as on upper limb function (Taylor et al., 2019). 
Up to date, several subsequent studies focus on stem cell-based therapies for DMD. 
However, there are many safety concerns and practical limitations (such as for 
example the small number of satellite cells that can be isolated from a muscle 
biopsy), which so far prevent the clinical application of human satellite cells. 
Another disadvantage of cell therapy is the low dissemination rate of satellite cells 
and the high rate of death among satellite cells after transplantation. Furthermore, 
systemic administration with the goal to reach all skeletal muscles including, for 
example, diaphragm, leads to the aggregation of satellite cells as microthrombi in 
small vessels, instead of the colonization of muscle tissue (Sun et al., 2019). The 
transplantation of allogeneic cells also requires posttransplantational 
immunosuppression to prevent rejection of the cells (Bajek et al., 2015). 
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4.2.2. Ribosomal read-through of premature termination codons 
In 11% of individuals with DMD, a nonsense point mutation generates a premature 
termination codon (PTC) within the protein coding region of the mRNA. The PTC 
stalls translation, leading to an unstable and nonfunctional truncated dystrophin 
protein product (Bladen et al., 2015). By altering the RNA confirmation and hence 
reducing the codon-anticodon accuracy, aminoglycoside antibiotics, such as 
gentamicin, enable the read-through of PTCs by promoting the insertion of 
alternative amino acids at the position of the mutated codon. Thereby, dystrophin 
synthesis increases. However, aminoglycosides also have severe adverse effects 
when used long-term or at high dosage, such as renal and otic toxicity (reviewed in 
Guiraud and Davies, 2017; Linde and Kerem, 2008). PTC124, a new small organic 
molecule without antibiotic characteristics, was shown to read through disease-
causing PTCs without displaying the severe side effects observed for 
aminoglycosides. It furthermore does not affect intended termination due to the stop 
codon localized at the end of the coding sequence (Linde and Kerem, 2008). Due 
to these properties, PTC124 is a promising genetic treat for DMD patients with the 
causal mutation being a nonsense mutation leading to premature termination of 
translation (Bushby et al., 2014; McDonald et al., 2017). PTC124 with the trade 
name translarna, in 2014, under its former name ataluren, gained approval by the 
European Commission for use in the European Union, as the first mutation-specific 
therapy in DMD (Ryan, 2014). 
4.2.3. Utrophin modulators 
Another therapeutic approach in DMD is the upregulation of the expression of the 
protein utrophin. Utrophin, a member of the spectrin superfamiliy, shares 80% 
homology with dystrophin, thus is an autosomal homologue of the protein. It is 
normally highly expressed during embryogenesis and is later progressively 
substituted at the sarcolemma by dystrophin. In adult muscle, utrophin can be found 
at neuromuscular and myotendinous junctions. The great structural and functional 
similarities between the two proteins allow for using utrophin as surrogate for 
dystrophin (reviewed in Guiraud and Davies, 2017; reviewed in Perkins and Davies, 
2002; Song et al., 2019). As already stated above, in dystrophin-deficient mdx mice, 
the upregulation of utrophin is discussed to prevent the expression of the severe 
DMD phenotype. This thesis is supported by the generation of the utrophin null-
mdx double knockout mice, which exhibit a severe dystrophic phenotype, lethal 
within several weeks after birth (reviewed in Perkins and Davies, 2002). Altogether, 
this gives rise to the approach of utrophin-derived therapies to treat dystrophin 
deficiency in DMD patients (Goyenvalle et al., 2011). In different animal models, 
such as the GRMD dog and the mdx mouse, a miniaturized utrophin encoding 
synthetic transgene was shown to be highly functional acting as surrogate to 
compensate the loss of dystrophin. Miniaturized utrophin was able to prevent most 
of the detrimental physiological and histological aspects, such as necrosis of muscle 
fibers and mononuclear cell infiltrates. Unfortunately, limitations to this method are 
set by the achievable adeno-associated viral (AAV) vector dose (Song et al., 2019). 
Ezutromid (SMT C1100), an utrophin modulator, was shown to reduce 
degeneration of musculature, leading to an improved muscle function in the mdx 
mouse (reviewed in Guiraud et al., 2015). Subsequently, first in pediatric clinical 
trials with SMT C1100 have been completed, reporting tolerability and safety for 
this agent (reviewed in Guiraud and Davies, 2017; Ricotti et al., 2016). There are 
other utrophin modulators, such as heregulin and resveratrol, aiming to upregulate 
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utrophin by modulating the utrophin promoter. However, these drugs were reported 
to be efficient in the mdx mouse, but clinical trials for DMD are still missing 
(Moorwood et al., 2011).  
4.2.4. Delivery of mini- or microdystrophin via AAV vectors 
Adeno-associated viruses (AAV) as vectors are not only capable to deliver 
miniaturized utrophin, but also used to deliver mini- and microdystrophin systems, 
thereby restoring dystrophin in DMD patients. In general, AAV vectors have clear 
benefits compared to other vector systems, e.g. they display non-pathogenicity and 
only minimal immunogenicity and they show an extensive tissue and cell tropism 
(e.g. muscle cells amongst others count as the most efficient targets), accompanied 
by site-specific integration and long-term persistence (reviewed in Athanasopoulos 
et al., 2000; Athanasopoulos et al., 2004). In mice, AAV vectors are shown to 
mediate high long-term transgene expression in muscle fibers (Fisher et al., 1997). 
However, a disadvantage is the size of the AAV genome (<5 kb), limiting the 
packaging volume and therefore the transgene capacity (reviewed in 
Athanasopoulos et al., 2004). To overcome this obstacle, dystrophin protein is 
reduced to its essential components. A rod-truncated micro-dystrophin is shown to 
ameliorate the dystrophic phenotype of mdx mice (Sakamoto et al., 2002; 
Yoshimura et al., 2004). As one approach, systemic in utero AAV delivery of 
micro-dystrophin in mdx mice to reach the dystrophin deficient fetuses, shows 
dystrophin-expressing muscle-fibers and a significant improvement of the 
dystrophic phenotype at 9 weeks after birth (Koppanati et al., 2010). In the GRMD 
dog, localized and systemic delivery of recombinant AAV vectors expressing a 
canine microdystrophin was shown to restore dystrophin expression, stabilizing the 
clinical symptoms (Le Guiner et al., 2017). Trials of AAV micro-dystrophin 
therapies in human DMD patients are partly completed or currently running 
(National Library of Medicine, 2019). So far, small adverse events were 
manageable and the treatment results in neuromuscular and respiratory function 
improvements (reviewed in Duan, 2018). However, a steep setback is a recently 
reported vector-dose-dependent severe immunotoxicity of AAV vectors in non-
human primates and piglets (Hinderer et al., 2018). Concerning this, careful clinical 
monitoring and early laboratory evaluations for signs of toxicity is indispensable 
(Hinderer et al., 2018). Moreover, further studies in large animal models to 
cautiously approach non-toxic levels are essential. 
4.2.5. Exon skipping by antisense oligonucleotides targeting RNA 
In DMD, most mutations disrupt the ORF, whereas mutations where the ORF 
remains intact, lead to the synthesis of truncated dystrophin, resulting in the milder 
BMD. This less severe form of the disease exemplifies, that an internally deleted 
dystrophin can be functional. The spectrin-like rod domain, for example, in which 
most of the DMD causing mutations occur, is largely dispensable. Thus, splicing 
around a here located mutation can lead to the production of a truncated but 
functional dystrophin (Lu et al., 2003). Antisense oligonucleotide (AON)-mediated 
exon skipping aims to correct the ORF, and hence to restore the synthesis of partly 
functional dystrophin (Sharp et al., 2011). It thus converts an out-of-frame mutation 
in an in-frame mutation, inducing a BMD phenotype (Aartsma‐Rus et al., 2009). 
AONs are synthetic single-strand DNAs or RNAs with a length of 20 to 25 bases. 
The sequences are designed in a way, that they recognize and bind to a 
complementary sequence in the target RNA and modulate premature mRNA 
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splicing (reviewed in Nakamura and Takeda, 2009) by hiding specific exons from 
the splicing process or from translation. This leads to skipping of the target exon 
and thereby restoration of the ORF (Aartsma‐Rus et al., 2009). The AONs 2′-O-
methyl phosphorothionate AO (2OMeAO) and phosphorodiamidate morpholino 
oligomer (PMO) are most frequently used. To enhance their pharmaceutical 
properties, they differ from each other in chemical modifications of the 
oligonucleotides (reviewed in Nakamura and Takeda, 2009). PMO is largely 
unmetabolized, charge-neutral, and not linked to hepatotoxicity, immune or platelet 
activation. It thus provides properties, necessary for safety and tolerability (Mendell 
et al., 2016). 
The approach is mutation specific. Nevertheless, as shown above, most deletions 
cluster in hotspot regions, allowing that AON-mediated skipping of a small number 
of exons is applicable to a relatively large number of patients. In theory, exon-
skipping mediated by AONs, amounts to 83% of all DMD mutations, including 
deletions, small mutations and duplications (Aartsma‐Rus et al., 2009). The 
therapeutic approach has been extensively tested in DMD mouse models, (Aoki et 
al., 2012; Sharp et al., 2011), in dog models of DMD (Mcclorey et al., 2006; Yokota 
et al., 2009), and has already been translated into clinical trials (Goemans et al., 
2011; Van Deutekom et al., 2007). Eteplirsen is a PMO, designed to skip exon 51 
in the DMD gene (Mendell et al., 2016). Exon 51 skipping restores the ORF of 13% 
of DMD patients. This is the largest targetable group of all individuals with DMD 
(Aartsma‐Rus et al., 2009). In 2016, eteplirsen, with the trade name Exondys 51 
(Sarepta Therapeutics), reached approval by the U.S. Food and Drug 
Administration (FDA) (Syed, 2016). Patients, treated with eteplirsen over a longer 
period of time, show no or only rare signs or symptoms of renal or hepatic toxicity, 
which is attributed to the chemistry of PMO (Mendell et al., 2016). Effects on 
cardiac muscle, however, have not been reported yet (reviewed in Guiraud and 
Davies, 2017). There are several ongoing or already completed trials of other exon 
skipping therapies, such as golodirsen (SRP-4053), amenable to exon 53 skipping, 
PRO045, designed to skip exon 45, or PRO044, designed for exon 33 skipping 
(National Library of Medicine, 2019; Van Ruiten et al., 2017). Nevertheless, as 
AONs target RNA, so far they are only able to cause very small, temporary 
increases of dystrophin. As a consequence, exon skipping drugs based on AONs 
require regular systemic application and it is not yet clear if the levels of restored 
dystrophin in patients are sufficient to affect the course of the disease (Muntoni and 
Wood, 2011). 
4.2.6. Somatic gene editing 
Better than exon-skipping on the level of RNA is a permanent gene correction. 
There are different genome editing tools, i.e. transcription activator-like effector 
nucleases (TALEN), zinc-finger nucleases (ZFN) or Cas9 endonuclease associated 
to clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) (Gaj et 
al., 2013). Among these, the emerging CRISPR/Cas9 technology, first published 
by Jinek et al. (2012), which originally provides bacteria and archaea immunity to 
viruses, represents the most promising, simple and versatile RNA-directed tool for 
introducing double-stranded (ds) breaks into the DNA. The CRISPR/Cas9 enzyme 
mechanism in bacteria and archaea operates as adaptive defense system using 
antisense RNAs of past viral invasions as memory signatures. Cas9, as a CRISPR-
associated endonuclease, uses a guiding sequence within a RNA duplex for the 
formation of base pairs with targeted DNA sequences. Thereby the endonuclease is 
able to introduce a site-specific DNA ds break (Doudna and Charpentier, 2014). In 
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January 2016, the emerging importance of CRISPR/Cas9 as preferred gene editing 
tool in DMD was stressed by two publications, published parallely. CRISPR-
mediated genome editing was shown to restore the dystrophin expression in 
dystrophin deficient mdx mice. An intact Dmd ORF was restored by skipping the 
mutant Dmd exon 23. The gene editing components were delivered by adeno-
associated viral vectors. Long et al. (2016) were able to show dystrophin expression 
in varying degrees not only in skeletal but also in cardiac muscle. In Xu et al. 
(2016), dystrophin expression in the transduced muscles was restored to about 50%. 
In 2018, the proof of concept was confirmed in a large animal model for DMD, a 
small group (n = 4) of deltaE50-dogs. The CRISPR/Cas9 system and the sgRNAs 
targeting a mutation specific region were delivered by adeno-associated virus 
serotype 9 (AAV9). Amoasii et al. (2018) were able to restore dystrophin 
expression levels ranging from 3 to 90% of normal. Cardiac muscle showed a 
dystrophin expression of up to 93% of normal. 
CRISPR/Cas9 to date is the most powerful and promising method to heal inherited 
or from de novo gene mutation deriving diseases, such as DMD, by correcting the 
mutations responsible for the disease (Long et al., 2016). 
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III. ANIMALS, MATERIAL AND METHODS 
1. Animals 
In this work animals were produced by breeding from a herd of heterozygous 
female DMD+/- pigs inseminated with sperm of wild-type boars. One single German 
Landrace and Swabian-Hall mix sow with a heterozygous DMD exon 52 deletion 
(DMDΔ52) was used to establish the breeding herd. Following Mendelian 
inheritance, litters comprised male and female wild-type piglets (WT), 
heterozygous DMDΔ52 carrier pigs (DMD+/-) and male DMDΔ52 knockout pigs 
(DMDY/-). As DMD is an X-chromosomal disease, the male offspring of a female 
carrier (DMD+/-), receiving the X-chromosome with the mutated DMD, still have a 
Y-chromosome not carrying a DMD allele. Therefore, in the following, DMD 
knockout pigs are referred to as DMDY/-. 
All animal experiments were carried out according either to the German Animal 
Welfare Act with permission by the Regierung von Oberbayern (55.2-1-54-2532-
163-2014 and 02-16-137). 
2. Material 
2.1. Devices 
Agarose gel elecrophoresis chamber   OWL Inc., USA 
Artificial wet nurse unit    HCP-Technology, Notrup 
AT-FS708 switch     Allied Telesis Inc., USA 
BE400 incubator     Memmert, Schwabach 
Benchtop 96 Tube working rack   Stratagene, USA 
Centrifuge 5424 R     Eppendorf, Hamburg 
Centrifuge 5430 R     Eppendorf, Hamburg 
Centrifuge Rotina 380 R Hettich Lab Technology, 
Tuttlingen 
Daewoo KOC-154K microwave   Daewoo, South Korea 
Excelsior AS A82310100  Thermo Scientific, USA 
FiveEasy pH meter F20    Mettler-Toledo, USA 
FreeStyle Freedom Lite blood glucose meter  Abbott Laboratories, USA 
Grant JB Nova water bath    Grant Instruments, UK 
Heating plate with magnetic stirrer RH basic IKA-Werke, Staufen im 
Breisgau 
HLC Cooling-ThermoMixer MKR 13  Ditabis, Pforzheim 
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IKA MS1 Minishaker Vortexer IKA-Werke, Staufen im 
Breisgau 
Incubator Kendro Laboratory Products, 
Hanau 
IndigoVision 9000 Encoder    IndigoVision Inc., UK 
inoLab® pH meter 7110    WTW, Weilheim 
Labcycler thermocycler    SensoQuest, Göttingen 
Lax Disco Box  Lax Stalleinrichtung, Geldern 
Leica DM IL LED Inverse microscope  Leica Microsystems, Wetzlar 
MS-196VUT microwave    LG Electronics, South Korea 
MSOT Acuity Echo protoype imaging system  iThera Medical, Munich 
Pipettes (1000 µL, 200 µL, 100 µl, 20 µL, 10 µL,  
 2 µL)       Gilson Inc., USA 
Platform Scale Kern und Sohn   Kern und Sohn, Balingen 
Power Pac 300 gel electrophoresis unit   BioRad, Munich 
Power Station 300 gel electrophoresis unit   Labnet International, USA 
Precision balanace Chyo MJ-3000   YMC Co. Ltd., Japan 
Precision balance Kern PCB 3500-2   Kern und Sohn, Balingen 
RH Basic magnetic stirrer with heating  IKA, Staufen 
Rotary microtome Microm HM 325  Thermo Scientific, USA 
Rotilabo® mini centrifuge    Carl Roth, Karlsruhe 
SANTEC color camera VTC-E220IRP  Santec, Ahrensburg 
Select vortexer     Select BioProducts, USA 
SimpliNano spectrophotometer   Thermo Scientific, USA 
Smart Weigh GLS50 instecho   Better Basics, USA 
TES 99 modular paraffin embedding system  Medite, Burgdorf 
Thermo-Shaker TS-100    BioSan, Lettland 
Tilting table Rocky® Froebel Laboratory 
Technology, Lindau 
Tissue cool plate COP 30  Medite, Burgdorf 
Tissue float bath 1052  GFL, Burgwedel 
UVP GelStudio PLUS    Analytik Jena, Jena 
Zeiss Axiovert 200 M     Zeiss, Oberkochen 
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2.2. Chemicals 
Acetic Acid (glacial)     Carl Roth, Karlsruhe 
Agarose Universal      Bio&SELL, Nuremberg 
Bromphenolblue Sodium Salt    Carl Roth, Karlsruhe 
di-Sodium hydrogen phosphate, ≥ 99%, water free Carl Roth, Karlsruhe 
EDTA (Ethylenediaminetetraacetic acid)   Roth, Karlsruhe 
Eosin Y (yellowish) powder (C.l. 45380)  Merck, Darmstadt 
Ethanol Rotipuran® 99.8%    Carl Roth, Karlsruhe 
Formaldehyde 37%     Carl Roth, Karlsruhe 
GelRed® Nucleic Acid Gel Stain   Biotium, USA 
Histokitt      Karl Hecht, Sondheim/ Rhön 
Hydrochloric acid 25%    VWR, USA 
Hydrogen chloride 37%    Carl Roth, Karlsruhe 
Hydrogen peroxide 35% pure, stabilised  Carl Roth, Karlsruhe 
Mayer’s Hemalum Solution    Merck, Darmstadt 
Methanol      Carl Roth, Karlsruhe 
NaOH (Sodium hydroxide 2N)    Roth, Karlsruhe 
Roti Histofix 4%     Carl Roth, Karlsruhe 
Sodium chloride Emsure®    Merck, Darmstadt 
Sodium dihydrogen phosphate monohydrate  Carl Roth, Karlsruhe 
≥ 98% 
Sodium hydroxide 2 mol / l (2 N ) in aqueous VWR, USA 
solution, AVS TITRINORM 
Tissue Tek O.C.T.TM Compound   Sakura, Staufen 
Tris (Tris-(hydroxymethyl)-aminomethane)   Roth, Karlsruhe 
TRIS PUFFERAN® ≥ 99%    Carl Roth, Karlsruhe 
Tri-Sodium- citrate 2-hydrate    Carl Roth, Karlsruhe 
Tween®20      Sigma-Aldrich, Steinheim 
Xylene       VWR, USA 
2.3. Consumables 
Cellstar® tubes (15 ml, 50 ml)   Greiner BioOne, Austria 
Cover slips for histology    Carl Roth, Karlsruhe 
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Disposable plastic pipettes    Greiner BioOne, Austria 
Disposable scalpel #21    Henry Schein, Munich 
Embedding molds premium    Medite, Burgdorf 
Feather® microtome blades S35   pfm medical, Cologne 
FreeStyle Freedom Lite Blood glucose Test Strips Abbott Laboratories, USA 
Glass pasteurpipettes     Brand, Wertheim 
K3E Monovette®     Sarstedt, Nümbrecht 
LH Monovette®     Sarstedt, Nümbrecht 
Microscope slides Marienfeld SuperiorTM Marienfeld Superior, Lauda-
Königshofen 
Microscope slides Star Frost®   Engelbrecht, Edermünde 
NitriSense nitrile gloves    Süd-Laborbedarf, Gauting 
Parafilm® M      Carl Roth, Karlsruhe 
PCR reaction tubes (0.2ml)  Brand, Wertheim 
Petri dish 94×16     Greiner BioOne, Austria 
Pipet tips with filter     Greiner BioOne, Austria 
Pipet tips      Eppendorf, Hamburg 
Qualitative filter paper, grade 303, folded filter VWR, USA 
SafeGrip® latex gloves    SLG, Munich 
Safe-Lock reaction tubes (1.5 ml, 2 ml)  Eppendorf, Hamburg 
Serum Monovette®     Sarstedt, Nümbrecht 
Tissue-Tek® Cryomold® (25 mm × 20 mm × 5 mm 
and 15 mm × 15 mm × 5 mm)   Sakura, Staufen 
Uni-link embedding cassettes    Engelbrecht, Edermünde 
2.4. Enzymes, oligonucleotides and antibodies 
HotStarTaq DNA Polymerase   Qiagen, Hilden 
Oligonucleotides 
Oligonucleotides were manufactured by Thermo Scientific, USA. 
DMDqf1 5´-TGC ACA ATG CTG GAG AAC CTC A-3´ 
DMDqfr1 5´-GTT CTG GCT TCT TGA TTG CTG G-3´ 
neoPf  5´-CAG CTG TGC TCG ACG TTG TC-3´ 
neoSr  5´-GAA GAA CTC GTC AAG AAG GCG ATA G-3´ 
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Primary antibodies 
Monoclonal mouse anti-DYS1 (Rod domain,  Leica Biosystems, Wetzlar 
no. NCL-DYS1; clone no. Dy4/6D3) 
Secondary antibodies 
Biotinylated goat anti-mouse IgG    Jackson ImmunoResearch, 
(no. 115-065-146)     USA 
2.5. Buffers and solutions 
Unless indicated otherwise, water, deionized in a Easypure® II ultrapure water 
system (Werner, Leverkusen) or a Milli-RO 60 Plus device (Merck Millipore, 
USA), and termed as aqua bidest was used as solvent. 
Buffers and solutions for PCR and agarose gels 
DNA loading buffer (10×) 
10% glycerol in aqua bidest. 
Add 1 spatula tip of bromophenolblue. 
Add 0.5 M NaOH until the colour turns blue. 
Stored in aliquots at 4°C. 
dNTP-mix 
2 mM dATP, dCTP, dGTP, dTTP mixed in aqua bidest. 
Stored in aliquots at -20°C. 
GeneRulerTM 1 kb DNA molecular weight standard 
100 µl GeneRulerTM 1 kb DNA molecular weight standard. 
100 µl 6× loading dye. 
400 µl aqua bidest. 
Stored in aliquots at -20°C. 
TAE buffer (50×) 
242 g 2 M Tris, 
100 ml 0.5 M EDTA (pH8.0), 
57 ml gl acetic acid, 
add 1000 ml aqua bidest. 
Buffer was filtered, autoclaved and stored at room temperature. Before usage the 
buffer solution was diluted to single concentration with aqua bidest. 
Buffers and solutions for DNA isolation 
10 mM Tris/HCl, pH 8.0 
10 mM Tris 
Adjust pH to 8.0 with HCl. 
Buffers and solutions for fixation and immunological detection 
Phosphate-Buffer 
40 g Sodium dihydrogen phosphate monohydrate 
65 g di-Sodium hydrogen phosphate  
mixed and dissolved in 1000 ml aqua bidest. 
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4% Formalin solution  
100 ml Phosphate Buffer 
100 ml Formaldehyde 37% 
mixed in 800 ml aqua dest. 
Eosin 1% 
10 g Eosin Y powder 
dissolved in 1000 ml aqua bidest, 80°C. 
Cooled down to room temperature. 
Add 1.5 ml gl acetic acid. 
Filtrate the solution through a 5-13 µm filter. 
Stored in darkness, at room temperature. 
Note: Solutions stored over an extended period can be refreshed with gl acetic 
acid. 
HCl 25% 
675 ml hydrogen chloride 37% 
mixd with 325 ml aqua bidest. 
EtOH 70% 
700 ml EtOH 100% 
mixed in 300 ml aqua bidest. 
EtOH 96% 
960 ml EtOH 100% 
mixed in 40 ml aqua bidest. 
HCl-EtOH stock solution 
1500 ml Ethanol 96% 
mixed in 357 ml aqua bidest. 
Add 14.2 ml HCl 25%. 
0.5% HCl-EtOH solution 
100 ml HCl-EtOH stock solution. 
Add 100 ml 70% EtOH. 
10 mM Sodium citrate buffer pH 6.0 for IHC 
2.94g Tri-sodium-citrate 2-hydrate, 
mixed in 1000 ml aqua bidest.  
Adjust pH to 6.0 with HCl 25%. 
Add 0.5 ml Tween 20. 
Stored at room temperature for a maxium of 3 months. 
For extended storage, store at 4°C. 
10× TBS buffer for IHC 
83.33 g NaCl 
60.57 g Tris 
Ad 1000 ml aq. bidest. 
Adjusted to pH 7.6 using HCl 25%. 
Concentrated stock solution of buffer was autoclaved. 
The TBS stock was diluted to single concentration with aq. bidest. before use: 
100 ml TBS stock 
mixed in 900 ml aqua bidest. 
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2.6. Kits 
DNeasy® Blood & Tissue Kit (250)   Qiagen, Hilden 
HotStarTaq Plus DNA Polymerase   Qiagen, Hilden 
ImmPACTTM DAB Peroxidase (HRP) Substrate  Vetor Laboratories, Biozol, 
Eching 
nexttecTM Genomic DNA IsolationKit Nexttec, Leverkusen 
SK-4105      Vector Laboratories, USA 
Vectastain® Elite ABC-Peroxidase Kit Vetor Laboratories, Biozol, 
Eching 
2.7. Other reagents 
Buffer AE      Qiagen, Hilden 
dNTP Set (100 mM)     Thermo Scientific, USA 
Gene RulerTM 1 kb DNA Ladder   Thermo Scientific, USA 
Goat Serum      MP Biomedicals, USA 
PCR Buffer 10 ×     Qiagen, Hilden 
2.8. Software 
ASReml  VSNi, Hemel Hempstead, UK 
cLabs software v.2.66     iThera Medical, München 
IndigoVision control center software v.3.19.5 IndigoVision Inc., UK 
Leica Application Suite v.4.4.0   Leica Microsystems, Wetzlar 
AxioVision V 4..10 or newer    Zeiss, Oberkochen 
PathZoom LiveView 
Microsoft office Suite 2016 Standard   Microsoft, USA 
Graphad Prism v.5.04 or newer   GraphPad Software, USA 
UVP Software VisionWorksTM LS   Thermo Scientific, USA 
ViewMSOT software v.3.8    iThera Medical, München 
2.9. Drugs and supplementary feed 
astoral® Pet Lax     almapharm, Wildpoldsried 
Atropine sulfate (0.5 g/ 1 ml) (monohydrate)  B. Braun, Melsungen 
Azaperone (Stresnil®)     Elanco, USA 
Bonimal SB PowerMilk with blood plasma  Bonimal, Munich 
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Bromhexidinhydrochloride powder (Bisolvon®) Boehringer Ingelheim, 
Ingelheim am Rhein 
Buscopan® Boehringer Ingelheim, 
Ingelheim am Rhein 
Cloprostenol as sodium salt (Estrumate®)  MSD, USA 
Embutramid, Mebezonium, Tetracain (T61®) Intervet, Unterschleißheim 
Fentadon (50 µg/ 1 ml)    Dechra, Aulendorf 
Glucose solution 20%  B. Braun, Melsungen 
HS Cat Laxative     Henry Schein, USA 
Ketamine hydrochloride (Ursotamin® 10%) Serumwerk Bernburg, 
Bernburg 
Lactulose AL Syrup     Aluid Pharma, Laichingen 
Oxytocin 10 IE/ml  cp-pharma, Burgdorf 
Potassium choride 7.45%  B. Braun, Melsungen 
Propofol 2% (20 mg/ 1 ml) MCT Fresenius Fresenius Kabi, Bad 
Homburg 
Stomach tube 80 cm × 4 mm    Henry Schein, USA 
Ursoferran® (200 mg/ 1ml) Serumwerk Bernburg, 
Bernburg 
Xylazine Serumwerk 
Bernburg,Bernburg 
3. Methods 
3.1. Animal generation 
Generation of the DMDΔ52 founder sow 
The exon 52 deletion of the porcine DMD gene was generated by the working group 
of Nikolai Klymiuk of our institute, according to Klymiuk et al. (2013), as described 
in Moretti et al. (2020). In summary, the targeting bacterial artificial chromosome 
CH242-9G11 was modified to carry instead of exon 52 a neomycin selection 
cassette. Subsequently, the modified BAC was nucleofected into a female primary 
kidney cell line (PKCf). Single cell clones were generated, according to Richter et 
al. (2012). From a batch of each cell clone genomic DNA was isolated. In order to 
screen for correctly targeted cell clones with a heterozygous deletion of DMD exon 
52, the copy number of the DMD exon 52 was compared to the number of copies 
of two reference loci within the POU5F1 and the NANOG genes (Klymiuk et al., 
2013). Of 258 screened cell clones, 9 cell clones were identified to have one intact 
and one modified allele. For the generation of DMDΔ52 carrier sows, the cell clones 
with the heterozygous deletion of DMD exon 52 were used for somatic cell nuclear 
transfer (SCNT), carried out by Prof. Dr. Valeri Zakhartchenko, Dr. Mayuko 
Kurome, Dr. Barbara Keßler and Tuna Güngör of our institute. A total of 14 
transfers of SCNT embryos to synchronized recipients were performed, resulting in 
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3 litters and 4 live piglets with the heterozygous DMDΔ52 (DMD+/-) genotype. Only 
one animal could be raised to adulthood: clone #3040, the founder sow of the DMD 
breeding herd. 
Generation of male DMDY/- piglet clones 
Furthermore, male DMDY/- clones were generated by SCNT as decribed by 
Klymiuk et al. (2013). 
3.2. Genotyping of piglets 
Isolation of genomic DNA from tail biopsies 
For the isolation of genomic DNA tail biopsies were obtained from individual 
piglets within 24 h after birth and stored at -20 °C until further processing. Genomic 
DNA was isolated with the nexttecTM Genomic DNA Isolation Kit for Tissues and 
Cells, according to the manufactorer’s instructions. A very small amount of tissue 
(3-4 pieces with an approximate diameter of 0.5 mm) was incubated in a 1.5-ml 
reaction tube with 303 µl lysis buffer mix, using a thermomixer attuned to 60 °C 
and 1200 rpm for at least 30 min. Each sample additionally containted 3 µl DTT to 
increase the DNA yield and to ensure proper lysis of the tissue. After the tissue 
samples were dissolved, 120 µl of the lysate was purified on an equilibrated 
nexttecTM cleaning column. The eluate, containing the purified DNA, was 
subsequently used for PCR. 
PCR 
Two different sets of primers were used to detect the intact (WT) and the mutant 
sequence. The presence of the wildtype DMD allele, containing exon 52, was 
detected by the specific primer pair DMDqf1 and DMDqfr1. The neomycin 
selection cassette, replacing DMD exon 52, was detected by the primer pair neoPf 
and neoSr. All PCR components were mixed on wet ice to a final volume of 20 µl 
in 0.2 ml PCR reaction tubes. Previously isolated genomic DNA of WT (#5142) 
and DMDY/- (#5143) piglets served as controls. As non-template control aq. dest. 
was used. Table 1 and 2 below list the details for master mix composition and PCR 
condition. 
Table 1: Master mix composition for genotyping PCR. 
aq. dest.  14 µl 
dNTPs (2 mM) 2 µl 
10× PCR Buffer 2 µl 
Primer f (10 µM) 0.4 µl 
Primer r (10 µM) 0.4 µl 
Taq Polymerase (5U/µl) 0.2 µl 
DNA template 1 µl 
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Table 2: Cycler protocol for genotyping PCR. 
Denaturation 95 °C 5 min  
Denaturation 95 °C 30 s 
35× Annealing 62 °C 30 s 
Elongation 72 °C 30 s 
Final elongation 72 °C 5 min  
Termination 4 °C 5 min  
 
Agarose gel electrophoresis 
After completion of PCR amplification, the presence of amplified DNA was proven 
by agarose gel electrophoresis. A 1.0% agarose gel was prepared, heating 1 g 
Universal Agarose per 100 ml 1 × TAE buffer solution in a microwave, panning 
from time to time, until total dissolution of the agarose. After cooling down the 
agarose gel to 50-60 °C, it was poured into a gel electrophoresis chamber, then left 
to settle. To each 20 µl PCR sample, 2.5 µl of a 1:250 mixture of GelRed® and 
DNA loading buffer (10×) (GR:BPB 1:250) was added. 1 × TAE buffer was used 
to fill the gel electrophoresis chamber. The samples as well as 6 µl GeneRulerTM 1 
kb DNA molecular weight standard mixed with 2.5 µl of GR:BPB 1:250 were 
loaded into individual gel slots. DNA fragments were seperated according to their 
size by applying an electric current to the gel electrophoresis chamber. Afterwards, 
the DNA fragments were visualized under UV light. PCR products were analyzed 
in relation to the DNA molecular weight standard. 
3.3. Rearing of DMDY/- piglets 
Rearing of the DMDY/- piglets required birth monitoring and subsequent intense 
nursing during the first days of life, including supplementary feeding. A reduced 
general condition of newborn DMDY/- piglets, due to a severe DMD phenotype, 
may lead to increased losses of animals resulting from severe energy deficit and/or 
crushing by the sow. To increase survival chances, different rearing conditions for 
suckling DMDY/- piglets were validated. In the described breeding systems, 
straddling piglets received anti-straddle cuffs until independent standing and 
walking, if not described otherwise. Furthermore, all piglets received an 
intramuscular iron supplementation of 1 ml Ursoferran® 200 mg/ml on day 5 of life. 
Motherless rearing in an artificial rearing unit 
First, motherless rearing in an artificial rearing unit for piglets was studied. To allow 
colostrum intake, piglets remained with the sow during the first 12 h of life under 
supervision by a veterinarian. After these 12 h, the piglets were separated from the 
mother and transferred into an artificial rearing unit, the Lax Disco Box. The unit 
was equipped with slatted floor, constant access to fresh water and an automatic 
temperature regulation were provided. Supplementary milk was manually mixed 
and replaced every 8 h. Piglets were trained to independently drink milk substitute 
out of an installed drinking trough. In case piglets were not able to drink 
independently, they received milk substitute orally via a syringe. The 
supplementary milk was fed for the normal suckling period of 4 weeks, with slowly 
reducing the amount to none. After the first week of life, dry piglet feed was 
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supplemented progressively. After weaning, piglets were rehoused in barn 
compartments, equipped with heating lamps. During the whole rearing period 
piglets had ad libitum access to food and water. 
48 h supervised suckling at the sows’ teats 
To reduce losses due to cruhsing by the sow, all DMDY/- piglets were separated 
from the sow right after birth by a disconnecting device for the first 48 h of life. 
Suckling at the sows’ teats only took place under the supervision by a veterinarian 
at approximately every 2 h. No further supportive actions were provided. 
5 d intense nursing  
During the first 5 days after birth DMDY/- piglets were left with the sow and intense 
nursing by a veterinarian, as explained in the following, was ensured: 
In a first approach, drinking at the sows’ teats was taught to piglets, which were not 
able to suckle without support. Soonest 24 h after birth, weak DMDY/- piglets were 
trained to drink milk substitute (Bonimal SB PowerMilk with blood plasma, 
Bonimal, Munich) independently out of a drinking trough, which was replaced after 
every 8 h. If independent milk intake out of the trough was not possible, adjuvant 
tube-feeding of a maximum of 20 ml milk substitute was offered. Pale DMDY/- 
piglets received 0.5 ml Ursoferran® 200 mg/ml i.m. injected ahead of schedule, 
followed by the regular 1 ml Ursoferran® 200 mg/ml i.m. injection on day 5 of life. 
Birth weight was documented and weight was subsequently controlled every 24 h 
for the first 5 days of life. In case of strongly reduced general condition and severe 
weight loss, 10 ml glucose solution 20% was injected intraperitoneally (i.p.), and 
heat supply, to support the increase of body temperature, was provided. After the 
first week of life, dry piglet feed was supplemented. Additional milk subsitute 
feeding was maintained for the normal suckling period of 4 weeks, with slowly 
reducing the amount to none. 
In a second approach all piglets appearing weak right after birth (before the 
completion of genotyping), received adjuvant tube-feeding of frozen stored and 
reheated colostrum to ensure sufficient colostrum intake and to avoid energy 
deficiency. Drinking at the sows’ teats was taught to the piglets, which were not 
able to suckle without support. Venous blood for blood glucose measurement was 
gained by puncturing the lateral ear vein. Glucose levels were measured using a 
FreeStyle Freedom Lite blood glucose meter. If the blood glucose level of a DMDY/- 
piglet was low compared to a WT piglet, adjuvant tube-feeding of frozen stored and 
reheated colostrum was provided to the individual animal. In case of severe energy 
deficiency and strongly reduced general condition, 10 ml glucose solution 20% was 
injected i.p., and heat supply was provided. Straddling piglets received anti-straddle 
cuffs, which were enhanced by supportive taping, and manual physiotherapy was 
applied to stimulate circulation, to prevent contructions and to strengthen the 
muscles. The individual birth weight was documented and weight was subsequently 
controlled every 24 h for the first 5 days of life. If the weight loss within 24 h 
exceeded 50 g, adjuvant tube-feeding of a maximum of 20 ml freshly retrieved 
breast milk and/or milk substitute at approximately every 5-8 h was continued 
during the first 2-3 days of life, depending on the general condition of the individual 
animal. After 24 h of life, all DMDY/- piglets were trained to independently drink 
milk substitute out of a drinking trough, replaced every 8 h. Pale DMDY/- piglets 
received 0.5 ml Ursoferran® 200 mg/ml i.m. ahead of schedule, followed by the 
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regular 1 ml Ursoferran® 200 mg/ml i.m. on day 5 of life. Additional milk subsitute 
feeding was maintained for the normal suckling period of 4 weeks, with slowly 
reducing the amount to none. After the first week of life, dry piglet feed was 
supplemented. In a further approach, the rearing conditions in later litters were 
extended by an automatic wet-nursing unit (HCP Technology, Notrup), providing 
freshly mixed supplementary milk every hour, automatically calculating the 
necessary milk amout per day. In a last experimental approach, piglets noted with 
increasing abdominal girth and loss of appetite at the same time, received laxatives 
and digestion-aiding nutritional supplements. 
3.4. Blood collection and clinical chemistry 
Blood samples of DMDY/-, DMD+/- and WT pigs were taken with Serum 
Monovettes®. Animals had free access to food and water before blood collection. 
Blood was collected from the jugular vein. After clotting at room temperature for 
30 min, serum was separated by centrifugation at 1.800 rcf for 10-20 min at 4 °C. 
The blood serum was transferred into 1.5 reaction tubes and stored at –80 °C until 
further processing. Serum samples for creatine kinase (CK) measurement did not 
exceed a storage period of 6 months until further processing. CK values were 
determined by the Clinic for Swine LMU Munich, Oberschleißheim. 
CK analysis 
For the characterization of the DMD breeding herd (VI. 3), CK values were 
monitored over a longer time period. Therefore, blood of DMDY/-, DMD+/- and WT 
pigs was collected in the first, second, third and fourth week of life, and at the 
second and third month of life, and CK levels were determined subsequently. 
In the therapeutic trial (IV.5.), CK levels were analysed as biomarker for the 
severity of the disease. Therefore, blood was collected before application of the 
therapeutic agent and right before euthanasia, and CK levels were determined. 
Longitudinal CK measurement was not feasible due to the occurrence of sudden 
cardiac death in some DMDY/- pigs. 
3.5. Necropsy 
All animals were euthanised at a predetermined timepoint, or if the state of health 
necessitated euthanasia. Generally, for euthanasia, pigs were sedated with 
Ursotamin® at a dosage of 20 mg ketamine/kg body weight (BW) in combination 
with Stresnil® (2 mg Azaperone/kg BW), applicated intramuscularly (i.m.). To 
deepen anesthesia, Ursotamin® (20 mg ketamine/kg BW) in combination with 
xylazine (1 mg/kg BW) was injected intraveniously (i.v.). Animals were euthanised 
with an i.v. or intracardial (i.c.) application of T61® in a dosage of 1 ml/10 kg BW. 
Animals used in the therapeutic trial (IV.3.) were presedated with an i.m. 
application of Ursotamin® (20 mg ketamine/kg BW) in combination with Stresnil® 
(2 mg Azaperone/kg BW) and atropine sulfate (0.025 mg/kg BW). To deepen and 
maintain anesthesia during veterinary-accompanied transportation and subsequent 
examination of the individual animal, Propofol (1.5-4.4 mg/kg BW/h, depending 
on the effect) was applied intravenously. Fentanyl was administered i.v. as bolus 
(0.5-1 ml) before surgery or euthanasia. Animals were euthanised with an i.c. 
overdose of potassium chloride (30-60 mg/kg BW, depending on the effect), 
generating an atrioventricular block and cardiac arrest. 
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Post-mortem examination for cLDLA study 
Necropsy of the animals included in the genome-wide cLDLA (IV.4.) contained the 
macroscopic evaluation of the severity of musular dystrophy, apparent as 
macroscopically visible white striated muscle bundles, exemplarily shown in Figure 
5, and laparatomy. 
 
Figure 5: Exemplary presentation of macroscopically striated muscle 
phenotype of short-term surviving DMDY/- piglets. a, Extensor muscles of the 
lower arm of piglet #6311 on day 3 after birth. b, Mylohyoid muscle of piglet #6837 
on day 4 after birth. c, Latissimus dorsi muscle of piglet #5970 on day 2 after birth. 
d, Cut surface of triceps brachii muscle of piglet #6311. Arrows: macroscopically 
striated muscle bundles. 
 
Necropsy done for somatic gene therapy trial 
Of the animals included in the therapeutic trial (IV.5.), tissue specimens of different 
organs (lung, liver, spleen and kidney) were taken following a systematic sampling 
protocol. A proportion of the obtained tissue specimens was fixed in 4% formalin 
solution and processed as described below for staining. Another part of the tissue 
samples was cut into pieces of desired sizes, placed into tissue tek cryo molds, 
surrounded with Tissue Tek® O.C.T.TM compound and shock frozen on dry ice. 
Samples embedded in Tissue Tek® O.C.T.TM compound were stored at -80 °C. 
Furthermore, around 10 small pieces of approximately 3 mm × 3 mm × 3 mm of 
each tissue specimen were cut, shock frozen on dry ice and transferred into 1.5-ml 
reaction tubes for storage at -80 °C. The whole heart of each animal was sampled 
following a systematic sampling protocol. Tissue samples were obtained and stored 
as described above. Tissue specimens of different skeletal muscles (masseter, 
longissimus dorsi, triceps brachii, biceps femoris, lower limb muscles and 
diaphragm) were taken. Importantly, for the i.m. treated animals skeletal muscles 
of both sides (treated and non-treated) of the body were sampled. Tissue samples 
were obtained and stored as described above. 
  
III. Animals, material and methods     48 
Necropsy done for diagnostic trial, validating MSOT 
From all animals including the four anatomical regions previously imaged with the 
MSOT imaging system for validation as an imaging biomarker (IV.6.) 
representative tissue biopsies were taken. A schematic description of the anatomical 
regions is shown in Figure 6. One proportion of the obtained tissue specimens was 
fixed in 4% formalin solution and processed as described below for staining. The 
other part of the tissue samples was cut in around 10 small pieces of approximately 
3 mm × 3 mm × 3 mm, shock frozen on dry ice and transferred into 1.5 ml reaction 
tubes for storage at -80 °C. 
 
Figure 6: Schematic overview over the tissue specimens taken at MSOT 
necropsy. Tissue samples were extracted of both body sides, since both sides were 
imaged with MSOT imaging system. a, As palpable landmarks of the upper arm, 
elbow and shoulder joint were used to locate piglet muscles before imaging. The 
area between the shoulder and elbow joint, mainly containing the triceps femoris 
muscle, was taken at necropsy. b, For the thigh, the ischiadic tuber and the stifle 
joint were used. Tissue specimens were taken in the area between the two 
landmarks, mainly containing biceps femoris muscle. 
 
3.6. Tissue preparation 
Formalin fixation and paraffin embedding 
For formalin-fixed, paraffin-embedded (FFPE) sampling, harvested tissue samples 
were directly transferred into 4% formalin solution for a maxium of 24 h for pre-
fixation. Subsequently, tissue was cut into desired sizes, placed into embedding 
cassettes, and fixed further in 4% formalin solution for another 6 h at maximum. 
After fixation, tissue underwent automated processing in the Thermo Scientific 
Excelsior, as described in Table 3. 
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Table 3: Tissue processing in Scientific Excelsior. 
 
Dehydration 
Ethanol 70% 2 × 1.5 h 
Ethanol 90% 1.5 h 
 
Ethanol 90%  1 h 
 
Ethanol 100% 2 × 1 h 
Intermedium Xylol 3 × 1 h 
Infiltration 
Paraffin 2 × 1.75 h 
Paraffin 2 h 
 
In the following, the paraffin-impregnated tissue samples were paraffin embedded 
with the TES 99 modular paraffin embedding system. With a Rotary microtome 
Microm HM 325 sections of about 4 µm were cut and mounted on microscope 
slides Star Frost® for immunohistochemistry stain (IHC) or on microscope slides 
Marienfeld SuperiorTM for hematoxylin and eosin stain (H.E.). Sections were stored 
at 37 °C until staining. 
Tissue fixation for cryo-conservation 
Three different methods for cryo-conservation of tissue specimens were applied, 
depending on further processing. For expression data analysis, homogenous tissue 
specimens were cut into pieces of approximately 3 mm × 3 mm × 3 mm, frozen on 
dry ice, and stored in 1.5 ml reaction tubes on –80 °C. For staining of cryosections, 
obtained tissue samples were cut into pieces of approximately 10 mm × 5 mm × 2 
mm before embedding in the correct orientation in OCT compound and snap-
freezing on dry ice. This conservation method should not interfere with antigenicity 
of epitopes and should lead to better conservation of tissue morphology than FFPE 
tissue. 
3.7. Staining methods 
Hematoxylin and eosin stain 
H.E. staining results in blue dyed nuclei and pink to red dyed cytoplasm. It was 
used to visualize cellular and tissue structure detail. H.E. staining was performed 
on slices of FFPE tissue, mounted on Marienfeld SuperiorTM microscope slides. It 
was applied following a standard H.E. protocol as shown in Table 4. After the 
clearing the tissue slice in the last step, the tissue was mounted with Histokitt 
mounting medium. All steps were performed at room temperature. 
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Table 4: Standard H.E. protocol. 
Dewaxing Xylol 20 min 
Rehydration 
EtOH 100% 2 × 2 min 
EtOH 96% 2 × 2 min 
EtOH 70% 2 min 
Washing Aqua bidest. 2 min 
Staining Mayer’s Hemalum 5 min 
Rinsing Floating tap water, warm 5 min 
Differentiation 0.5% HCl-EtOH solution  1-2 × 1 s 
Rinsing Floating tap water, warm 5 min 
Counterstaining Eosin 1% 2 min 
Washing  Aqua bidest.  2-3 × 1 s 
Dehydration EtOH 70% 2 min 
Dehydration 
Clearing 
EtOH 96% 2 × 2 min 
EtOH 100% 2 × 2 min 
Xylol ≥ 5 min 
 
H.E. staining for the diagnostic trial (IV.6.) was performed by the Department of 
Pediatrics and Adolescent Medicine, University Hospital Erlangen, FAU Erlangen-
Nuremberg, according to the laboratory protocols. 
Masson Trichrome, Sirius Red, Von Kossa staining 
For Masson trichrome (MT), Sirius Red (SR) and Von Kossa staining tissue 
samples were fixed in 4% formalin solution and subsequently embedded in paraffin 
as described above. MT and SR staining of skeletal muscle sections for the 
diagnostic trial (IV.6.) as well as analyses of the collagen content of these sections 
was performed by the Department of Pediatrics and Adolescent Medicine, 
University Hospital Erlangen, FAU Erlangen-Nuremberg, as described in 
Regensburger et al. (2019). Therefore, the MT and SR stained sections were 
photographed using an AXIO Scope.A1 (Carl Zeiss, Oberkochen) and the AXIO 
Vs40 software (v.4.8.10, Carl Zeiss, Oberkochen) at 10 × magnification. TIF 
images were split into three channels (red, blue and green) and the red and green 
channels were used for collagen quantification. Therefore, the respective positive-
stained areas were calculated as a fraction of the whole image. 
For the characterization of the DMD breeding herd (IV.3.) cutting of 4 µm sections 
and staining with MT, SR and Von Kossa was performed by the paraffin laboratory 
of the Institute for Veterinary Pathology, LMU Munich. 
Immunohistochemical staining 
Immunostaining of muscle sections of DMDY/- pigs compared to WT littermates 
was performed using monoclonal mouse anti-DYS1 as primary antibody, reacting 
with the rod domain (between amino acids 1181 and 1388) of human dystrophin, 
with cross-reactivity to porcine dystrophin. As secondary antibody biotinylated 
goat anti-mouse IgG was used. In detail, for immunohistochemical staining (IHC) 
staining, all tissue sections were mounted on Star Frost® microscope slides and 
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stored at 37 °C before further processing. All steps were performed at room 
temperature, if not indicated otherwise. Dilutions of H2O2, normal serum and 
antibodies were prepared with TBS buffer. In a first step, FFPE tissue sections were 
deparaffinized and rehydrated through a descending alcohol row, according to 
Table 5. In Table 6, an overview over the workflow of the used IHC protocol is 
given. 
Table 5: Dewaxing and rehydration of FFPE tissue sections.  
Dewaxing Xylol 20 min 
Rehydration 
EtOH 100% 2 × 2 min 
EtOH 96% 2 × 2 min 
EtOH 70% 2 min 
Washing Aqua bidest. 2 × 2 min 
 
Table 6: IHC protocol for dystrophin detection. 
 Procedure Agent Conditions 
STEP 1 Heat induced 
antigen-retrieval 
10 mM Citrate 
buffer pH 6.0 + 
0.05% Tween  
800 W until 
boiling, then 
subboiling (320 
W) for 15 min 
STEP 2 Cooling  30 min 
STEP 3 Washing 1 × TBS buffer 10 min  
STEP 4 Blocking of 
endogenous 
peroxidase activity 
1% H202  15 min  
STEP 5 Washing 1 × TBS buffer 10 min  
STEP 6 Blocking in normal 
serum 
5% NS goat   1 h 
STEP 7 Primary antibody    4 °C over night  
STEP 8 Washing 1 × TBS buffer 10 min 
STEP 9 Secondary 
antibody 
   1 h  
STEP 10  Washing 1 × TBS buffer 10 min 
STEP 11 Detection Avidin-biotin-
complex 
30 min 
STEP 12 Washing 1 × TBS buffer 10 min 
STEP 13 Substrate DAB  
STEP 14 Rinsing Floating tap water    5 min 
STEP 15  Counterstaining Meyer’s Hemalum  
STEP 16 Rinsing Floating tap water   5 min 
 
Heat induced antigen-retrieval (HIAR), to restore hidden antigen sites, was 
performed by heating the tissue sections mounted on Star Frost® microscope slides 
in a microwave at subboiling temparature for 15 min, with 10 mM sodium citrate 
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buffer as agent, applied to break the protein cross-links, which were formed during 
formalin fixation. After cooling down for 30 min, endogenous peroxidase activity 
was blocked with 1% H2O2 for 15 minutes. Following a 10 min washing step in 1 
× TBS buffer, 5% normal goat serum was used for blocking non-specific antibody 
binding. Primary antibody was NCL-DYS1 (dilution 1:20; overnight at 4 °C), 
secondary antibody was biotinylated AffiniPure goat anti-mouse IgG (dilution 
1:250, 1 h at room temperature). For the detection of dystrophin in striated muscles, 
the Vectastain Elite ABC HRP Kit with 3.3-diaminobenzidine tetrahydrochloride 
dihydrate (DAB) as chromogen (brown color) was used. Meyer’s Hemalum was 
applied as counterstain. 
Immunofluorescence staining 
Concerning the somatic gene editing therapy study (IV.5.), described and published 
by Moretti et al. (2020), immunofluorescence (IF) staining was applied for the 
visualization of dystrophin in striated muscles. The staining process, imaging and 
analyses of the stained samples, were performed by Tarik Bozoglu of the Clinic and 
Policlinic for Internal Medicine I, Klinikum Rechts der Isar, TU Munich. As 
primary antibody against dystrophin, Leica NCL-DYS2 (1:25, Novocastra) was 
used. The IF staining protocol, as described in Dorn et al. (2018), was used. For 
imaging of the stained samples, inverted and confocal laser scanning microscopes 
were used (DMI6000B and TCS Sp8, Leica Microsystems, Wetzlar). 
3.8. Total protein and total collagen quantification 
Total collagen (hydroxyproline) quantification was calculated in relation to total 
protein content to confirm MSOT collagen signal (IV.6.). All analyses were 
performed by the Department of Pediatrics and Adolescent Medicine, University 
Hospital Erlangen, FAU Erlangen-Nuremberg. In brief, a Total Protein Assay and 
a Total Collagen Assay (both QuickZyme Biosciences, Leiden) were performed 
according to the manufacturer’s instructions. Per muscle, five FFPE muscle tissue 
sections of 10 µm were analyzed, as described in Regensburger et al. (2019). 
3.9. Proteomic experiments 
Sample preparation for proteomic experiments 
Tissue samples were homogenized using an ultrasonic device (Sonoplus GM3200 
with BR30 cup booster, Bandelin, Berlin) in 8 M urea/0.4 M NH4HCO3 (15 µl/mg 
frozen tissue). Protein concentrations were measured photometrically using the 
Pierce 660 nm Protein Assay (Thermo Scientific, USA). The lysates were analyzed 
either by selected reaction monitoring or by a holistic proteome analysis. 
Selected reaction monitoring 
Selected reaction monitoring (SRM) was performed in cooperation with Thomas 
Fröhlich and Florian Flenkenthaler, Gene Center - Laboratory for Functional 
Genome Analysis (LAFUGA), LMU Munich, as described in Moretti et al. (2020) 
and explained in the following: 
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In detail, samples containing 100 µg of total protein were diluted with equal 
volumes of 2-fold sample buffer (0.125 M Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 
10% β-mercaptoethanol, 0.002% bromophenol blue) and separated on a 4–20% 
Mini-PROTEAN® TGXTM precast gel (Bio-Rad, Hercules, USA). After Coomassie 
staining (Roti-Blue, Carl Roth, Karlsruhe), the gel slices with proteins >250 kDa 
were excised, de-stained using 50% acetonitrile (ACN) in 50 mM NH4HCO3 and 
subjected to in-gel digestion. For reduction, the gel pieces were incubated in a 
reduction solution of 45 mM dithioerythritol (DTE) dissolved in 50 mM NH4HCO3 
for 30 min at 55°C. By incubating the gel slices in 100 mM iodoacetamide (IAA) 
dissolved in 50 mM NH4HCO3 in the dark for 30 min at room temperature, the 
alkylation of sulfhydryl (–SH) groups was achieved. Prior to digestion, 50 fmol of 
the synthetic heavy peptides (JPT, Berlin) were spiked in. Using 70 ng Lys-C 
(FUJIFILM Wako Chemicals Europe, Neuss), a first digestion step for 4 h at 37°C 
was performed. A second digestion step was carried out using 70 ng porcine trypsin 
(Promega, Fitchburg, WI, USA) overnight at 37°C. Subsequently, extraction of 
peptides was performed utilizing 70% ACN. 
Before mass spectrometry, samples were dried using a SpeedVac vacuum 
concentrator. The SRM runs were carried out using a nanoACQUITY UPLC® 
system (Waters Corporation, USA), which is coupled to a triple‐quadrupole linear 
ion trap mass spectrometer (QTRAP 5500, AB SCIEX, USA). The tryptic peptides 
were transferred to a trap column (PepMap100 C18, 5 μm, 300 μm i.d. × 5 mm, 
Thermo Scientific, USA) with a flow rate of 10 μl/min. A reversed‐phase C18 nano‐
LC column (ReproSil‐Pur 120 C18‐AQ, 1.9 μm, 75 μm i.d. ×15 cm, Dr. Maisch 
HPLC, Ammerbuch) separated the tryptic peptides at 280 nl/min. As consecutive 
linear gradients 1-5% B (0.1% formic acid in acetonitrile) in 1 min, 5–35% B in 45 
min and 35-85% B in 5 min were used. Three transitions were measured for every 
peptide. 
To increase the sensitivity and specificity of the approach, proteins > 250 kDa were 
enriched using 1D-SDS-PAGE. Proteins within the corresponding gel slice were 
digested using LysC and Trypsin. The resulting peptides were separated by liquid 
chromatography and detected by a mass spectrometer. A triple-quadrupole analyzer 
was used with the first quadrupole (Q1) selecting the targeted precursor peptide and 
transferring it to the second quadrupole (Q2), where it undergoes collision-induced 
dissociation (CID). 
For an accurate absolute quantification, internal standards, consisting of synthetic 
peptides labeled with 13C/ 15N (so called heavy peptides), were spiked into the 
sample. Since the „heavy peptide” is chemically identical to the corresponding 
endogenous peptide, it shows identical behavior, concerning chromatography and 
ionization. Therefore, the “heavy” and the corresponding endogenous peptide both 
coelute from the chromatography column, but can be detected individually by the 
mass spectrometer due to their difference in molecular weight. The coelution of the 
synthetic internal standard and the endogenous peptide proves the specificity of the 
signal and further allows the accurate absolute quantification of the target protein. 
For dystrophin quantification, the two peptides NILSEFQR (Dystrophin AA 2207-
2214) and LSALQPQIER (Dystrophin AA 876-885) as well as corresponding 
heavy internal standard peptides were used. 
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Holistic proteome analysis 
Beside targeted approaches, the combination of liquid chromatography and tandem-
mass spectrometry (LC-MS/MS) allows the quantitative comparison of proteomes. 
Since LC-MS/MS can more effectively be performed at the peptide level, the 
proteins were cleaved by LysC and trypsin in a first step. Subsequently, during the 
LC-MS/MS run, the mass spectrometer measured the masses as well as the 
intensities of the peptides eluting from the chromatography system. Since beside 
pure peptide molecular weights, structural information is mandatory for the peptide 
identification, ions of individual peptides were fragmented and a second mass 
spectrum of the peptide fragments (a so-called MS/MS or MS2 spectrum) was 
acquired. Using latest high-performance mass spectrometers, such an analysis 
allows the identification and quantification of thousands of proteins. 
Holistic proteome analyses for the therapeutic trial (IV.5.) as well as for the 
diagnostic trial (IV.6.) were performed in cooperation with Thomas Fröhlich and 
Florian Flenkenthaler, Gene Center - LAFUGA, LMU Munich, as described in 
Moretti et al. (2020) and Regensburger et al. (2019). The detailed procedure was as 
follows: Using 8 M Urea/ 0.4 M NH4HCO3, the lysates’ protein concentration was 
adjusted to a concentration of 2.3 µg/µl. Using DTE at a final concentration of 5 
mM, 250 µg of total protein was reduced for 30 min at 37°C. Cysteines were 
alkylated with iodoacetamide (final concentration 15 mM) at room temperature for 
30 min in the dark. Adding 2.5 µg LysC (FUJIFILM Wako Pure Chemicals, Osaka, 
Japan), digestion of the proteins for 4 h at 37 °C was carried out. Samples were 
diluted with water to 1 M urea and a second digestion step overnight with 5 µg 
porcine trypsin (Promega, USA) at 37°C was carried out. 1.5 µg of tryptic peptides 
were seperated on an Ultimate 3000 nano-LC system (Thermo Scientific, USA). A 
50-cm column (Column: PepMap RSLC C18, 75 µm x 50 cm, 2 µm particles, 
Thermo Scientific, USA) was used for separation. A 160 min gradient from 5% 
solvent A (0.1% formic acid in water) to 25% solvent B (0.1% formic acid in 
acetonitrile) was followed by a 10 min gradient from 25% to 40% solvent B. Using 
an online coupled Q Exactive HF-X mass spectrometer (Thermo Scientific, USA) 
the identification of the tryptic peptides was performed with a top 15 data dependent 
method. For protein identification (false discovery rate < 1%) and label-free 
quantification the obtained spectra were analyzed using the porcine subset of the 
NCBI refseq database combined with the MaxQuant software platform (V1.6.1). 
3.10. Combined linkage disequilibrium and linkage analysis (cLDLA) 
DNA isolation for cLDLA 
For the isolation of genomic DNA from freshly docked tails of newborn piglets for 
the GWAS, the DNasy® Blood & Tissue Kit was employed. Therefore, the tail 
biospsies were cut into little pieces (3-4 pieces with an approximate diameter of 0.5 
mm). Afterwards, the manufacturer’s instructions for the treatment of tissue were 
performed. No optional steps to increase DNA yield were implemented. DNA 
concentration was measured at 260 nm using the SimpliNano spectrophotometer. 
DNA purity was examined by measuring 260 nm/280 nm and 260 nm/230 nm 
ratios. The DNA samples were diluted to a concentration of 70 ng/µl using 10 mM 
Tris buffer, pH 8.0. In cases of a DNA concentration lower than 70 ng/µl, high-salt 
precipitation was performed. Therefore, 20 µl NaOAc 3M were added to the 200 µl 
DNA sample, diluted in buffer AE. Afterwards, 500 µl 100% EtOH were added. 
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Subsequently, the sample was incubated at -80 °C for 30 min. After centrifugation 
at 13.000 rpm for 30 min at 4 °C, the supernatant was removed with a pipette and 
the pellet was washed in 500 µl 70% EtOH. The sample was stored at 4 °C 
overnight. Afterwards, the sample was centrifuged at fullspeed for 3 min. The 
supernatant was removed with a pipette and the pellet was left to air-dry at room 
temperature for 6 min. The pellet was resuspended in 32 µl of buffer AE. DNA 
concentration was measured again and DNA was diluted to a concentration of 70 
ng/µl as described previously. 
The SNP genotyping was performed by the working group of Doris Seichter, TZF 
Poing-Grub, using the PorcineSNP60 (Illumina, USA). 
Study criteria 
A subset of male DMDY/- pigs, based on the following criteria, was selected for 
SNP genotyping: 1.) Phenotype observed as continuous trait was abbreviated as 
PhContinous and was coded as “length of life in days”; 2.) Phenotype observed as 
discrete trait was abbreviated as PhDiscrete and coded as category 1 if DMDY/-pigs 
“died within 2-9 days of life” and as category 2 if DMDY/-pigs “died within ≥ 10 
days of life”. The selected subset consisted of n = 52 male DMDY/-pigs (for further 
details see section IV.4.1.). Markers of PorcineSNP60 chip were remapped to the 
Sus scrofa reference genome assembly Sscrofa11.1 (Genome - Assembly - NCBI). 
The data was analyzed by Ivica Međugorac, Population Genomics Group, 
Department of Veterinary Science, Faculty of Veterinary Medicine, LMU Munich, 
Martinsried, as described in Gehrke et al. (2020). In brief, markers with a call rate 
per marker < 0.9, minor allele frequency (MAF) of < 0.025 and with unknown 
position were excluded during quality control. Missing genotypes were imputed 
and haplotypes reconstructed using the software BEAGLE 5 (Browning et al., 
2018). The genome-wide quantitative trait loci (QTL) mapping was performed 
using a combined linkage disequilibrium and linkage analysis (cLDLA) approach, 
as described in Medugorac et al. (2017). In brief, first a genomic relationship matrix 
(G) (Powell et al., 2010) was estimated. To correct for potential polygenic effects 
and population structure in the model of the subsequent QTL mapping its inverse 
(G-1) was applied. For sliding windows consisting of 40 SNPs identical by descent 
(IBD) probabilities for pairs of haplotypes (Meuwissen and Goddard, 2001) were 
estimated. The estimated IBD probabilities were than summarized into a diplotype 
relationship matrix (DRM). The computation of a DRM is performed similarly to 
the additive genotype relationship matrix (GRM) (Lee and Van der Werf, 2006). 
cLDLA mapping of PhContinous and PhDiscrete coded phenotype was performed 
using a procedure similar to that reported in (Meuwissen et al., 2002), considering 
random QTL and polygenic effects. In the middle of each of the sliding windows 
of 40 SNPs a variance component analysis was performed using the ASReml 
package (https://www.vsni.co.uk/downloads/asreml/release3/UserGuide.pdf) and a 
mixed linear model as already described in and adopted from Medugorac et al. 
(2017) and Gehrke et al. (2020). 
The cLDLA mapping was performed in two runs: first, the DMD phenotype was 
considered as continuous variable (PhContinous), i.e. “length of life in days”, in a 
second run the DMD phenotype was considered as discrete variable (PhDiscrete), 
i.e. group 1, including all piglets “death within 0-9 days of life” and group 2, 
including all piglets “death within ≥ 10 days of life”. cLDLA mapping was only 
performed for male affected DMDY/- pigs. Genotyping and haplotyping of parental 
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animals was performed as well, with the results not directly involved in the cLDLA 
mapping. 
The parental genotypes included female DMD+/- mother sows and WT boars. SNP-
genotypes of the WT sires were provided by Martin Heudecker (EGZH, Poing-
Grub) and Kay-Uwe Götz (ITZ, Poing-Grub). Haplotyping of DMDY/- pigs in trios 
(sire-dam-offspring) ensured high quality haplotypes for the cLDLA mapping. 
3.11. Therapeutic approach 
Somatic gene editing approach 
As described in Moretti et al. (2020), adeno-associated viral vectors, serotype 9, 
coated with PAMAM-G2 nanoparticles and carrying an intein-split Cas9 and a pair 
of guide RNAs, targeting exon 51 flanking sequences (G2-AAV9-Cas9-gE51), 
were used to introduce somatic gene editing in DMDY/- piglets. Therefore, the 
intein-split Cas9 and gRNAs were established by the working group of Wolfgang 
Wurst of the Institute of Developmental Genetics, Helmholtz-Centre and Munich 
School of Life Sciences Weihenstephan, TU Munich, Freising. The AAV9-vectors 
were generated and raised by Tarik Bozoglu, Tilman Ziegler and Anja Wolf, and 
G2-optimization in vitro and in vivo was introduced by Seungmin Lee, Tilman 
Ziegler, members of the Clinic and Policlinic for Internal Medicine I, Klinikum 
Rechts der Isar, TU Munich, and DZHK, Munich Heart Alliance, and Manfred 
Ogris, MMCT Laboratory of Macromolecular Cancer Therapeutics, Department of 
Pharmaceutical Chemistry, University of Vienna, Vienna, Austria. 
As therapeutic approach, AAV9-Cas9-gE51 was tested as a somatic gene editing 
agent. In brief, as described above, DMDY/- piglets lack exon 52 (DMDΔ52), with 
the frameshift mutation resulting in an unstable mRNA leading to nonsense-
mediated mRNA decay and therefore a total loss of dystrophin. G2-AAV9-Cas9-
gE51 was aimed to restore the open reading frame as shown in Figure 7, introducing 
the expession of an internally truncated, but partially functional, dystophin protein, 
thus converting the Duchenne muscular dystrophy into the milder Becker muscular 
dystrophy. 
 
Figure 7: Schematic description of the somatic gene editing approach in 
DMDΔ52 pigs. The treatment aims to achieve a corrected reading frame (ΔE51-52) 
by Cas9-mediated excision of exon 51 (adapted from Moretti et al., 2020). 
 
Conduction of the pig transduction 
Whenever possible, matched pairs (siblings treated or untreated) with equally 
distributed birthweights were choosen for the experimental study. During 96 h after 
the injection of G2-AAV9-Cas9-gE51, piglets were seperated in metabolism cages 
for the collection and safe disposal of all excrements. General condition of all 
animals was monitored and scored daily throughout the entire duration of the study. 
Animals injected i.m. received pain-relieving agents before application of the 
therapeutic agent and on two consecutive days.  
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In a first proof-of-principle study, with the aim to show local dystrophin expression 
and functional improvement of skeletal muscle fibers, n = 6 DMDY/- piglets, at day 
14 after birth, received unilateral i.m. injections of 200 µl each (100 µl of each virus 
subsequently) at a total of 15 injection sites (6 × upper arm, 9 × thigh). Of both 
Cas9-intein-halfs (N-Cas9 and C-Cas9), 2.5 × 1013 vector genomes (vg) / kg BW 
were injected. The muscular part of the contralateral side of the body served as 
untreated control. For a further experimental set-up, with the aim to also achive 
diaphragm and heart muscle additionally to skeletal muscle, DMDY/- piglets 
received either low-dose (1-5 × 1013 coated virus particles (vp)/ kg BW for each, 
N-Cas9 and C-Cas9) or high-dose (2 × 1014 vp / kg BW for each strain) G2-AAV9-
Cas9-gE51 i.v. injections, applied into the ear vein. Intravenously injected animals 
received G2-AAV9-Cas9-gE51 not before weaning from the mother, due to the 
potential presence of colostral antibodies against AAV. 
The duration of the experiment varied between the individual animals, on the basis 
of the following reasons: studies were terminated due to animal protection 
regulations (DMD characteristic physical deterioration, e.g. stridor, tachypnea or 
exhaustion), or DMDY/- pigs succumbed to sudden cardiac death, occurring at rest 
or following environmental stressors (e.g. dominant behavior of siblings, trapping, 
transportation, or anaesthetic induction). To overcome these obstacles, pigs to be 
euthanized at a predetermined time point, received anaesthetic introduction directly 
followed by intubation, ensuring sufficient oxygen supply. 
Off-target anaysis 
The analysis to detect undesired off-target effects triggered by CRISPR/Cas9 was 
performed by the research unit Genomics of LAFUGA, Gene Center Munich, LMU 
Munich, using a targeted and a holistic approach, as described in Moretti et al. 
(2020). 
Concerning the targeted sequencing approach, potential off-targets were predicted 
using the CRISPOR and the CHOPCHOP web tool (Labun et al., 2019). For intron 
50 and 51 gRNA, the top five predicted off-targets were amplified by PCR, 
performed by Florian Giesert, Institute of Developmental Genetics, Helmholtz-
Centre and Munich School of Life Sciences Weihenstephan, TU Munich, Freising. 
Therefore, genomic DNA from muscle tissue of n = 1 WT pig, n = 2 i.m. treated 
pigs and n = 1 i.v. treated pig, was used. For each reaction, 400 ng of genomic DNA 
was utilized. The PCR products were analyzed subsequently, using next-generation 
sequencing (NGS). Therefore, NGS libraries of the PCR-products were created. 
The sequencing of these libraries was performed in paired-end mode, with a read 
length of 100 nucleotides, using the HiSeq® 1500 system (Illumina, USA) and the 
received sequences were compared to the original PCR-products, respectively. The 
Bioconductor package CrispRVariants was used for data analysis (Lindsay et al., 
2016). 
As holistic approach, genome wide sequencing of human DMDΔ52 induced 
Pluripotent Stem Cells (iPSCs) and an isogenic edited DMDΔ51-52 iPSC clone was 
applied. The reads were sequenced in paired-end mode, with a read length of 100 
bases, using a HiSeq® sequencer (Illumina, USA). Applying the GATK somatic 
SNV + INDEL pipeline (Van der Auwera et al., 2013), insertions or deletions of 
bases (INDELs) and single nucleotide variants (SNVs) in each sample were called 
and filtered for variants specific to the edited DMDΔ51-52 iPSC clone. 
Subsequently, a minimal Levenshtein distance analysis was applied to clarify, if the 
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identified variants represented off-target effects due to the use of CRISPR/Cas9, or 
randomly occurring variants, due to the clonal expansion of the edited DMDΔ51-
52 iPSCs. Therefore, two gRNAs were aligned in a sliding window, which covered 
25 base pairs (bp) upstream and 25 bp downstream of each variant position. The 
alignment with the smallest distance, i.e. the smallest number of mismatches with 
which a gRNA could have bound and cause an off-target effect, was determined. 
3.12. Movement and gait analysis 
To assess functional muscle parameters as biomarker for the clinical course of the 
disease was indispensible for the evaluation of the somatic gene editing approach 
achieved by G2-AAV9-Cas9-gE51 (IV.5.). Due to sudden arrhythmia-induced 
death as difficulty in working with the DMDY/--pig model, performing treadmill 
tests to assess muscle strength and endurance was not feasible. Therefore, a video 
surveillance system was installed, allowing to observe the animals at any time of a 
day, on seven days a week (24/7). 
Video surveillance 
Digital night and day vision infrared cameras provided a 24/7 video surveillance of 
the pigs. Each stable compartment contained one camera, allowing an overview 
over the whole sector. Clear distinction of the observed animals was possible either 
by individual coat patterns, tags with animal marker pens, colored ear tags, or by 
great variation in body sizes within the compared couple. On site, a control room 
served for monitoring all cameras. Camera signals were digitalized by encoders of 
the type IndigoVision 9000. Encoders were connected to a computer via an AT-
FS708 switch, as represented schematically in Figure 8. The evaluation of the 
videos was performed using the IndigoVision control center software (v.3.19.5). 
 
Figure 8: Schematic representation of the monitoring unit for 24/7 video 
surveillance of pigs. 
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Evaluation of behavioral patterns 
For analysing behavioral patterns, two behavioral observation methods were used, 
according to Martin et al. (1993). Instantaneous sampling was used to record the 
state of an individual animal at predetermined time intervals. Therefore, the animals 
were observed over a total period of 24 h and the behavioral information at every 
5th min was assessed. Only the instant moment (measured down to the centisecond) 
was graded. However, to ensure reliability, the seconds before and after grading 
were involved in the evaluation. Continous recording allowed the observation of 
total activity and total resting time in 24 hours. For this purpose, only two states, 
upright and lying posture, were measured to the second. Subsequently, the duration 
of standing and lying postures, as well as the frequency for these events, were 
evaluated. 
3.13. Multispectral optoacoustic tomography 
MSOT imaging was performed with the MSOT Acuity Echo prototype imaging 
system (iThera Medical) as described in Regensburger et al. (2019). In brief, MSOT 
is based on a photoacoustic effect. Using a 25-Hz pulsed Nd:YAG laser, the system 
induces thermoelastic expansion of endogenous absorbers in the examined tissue, 
allowing the detection of resulting pressure waves, which can be subsequently 
identified by spectral unmixing. Thus, it enables the visualization and quantification 
of different endogenous chromophores, such as hemoglobin, melanin and oxygen 
saturation. Illumination in the near- and extended near-infrared rages (exNIR) from 
680-1.100 nm enables the visualization and quantification of lipids and collagens. 
A 2D concave handheld detector (4-MHz center frequency, 256 transducer 
elements) enables cross-sectional imaging. It provides a spatial resolution of < 150 
µm and a field of view of 30 mm. For anatomic guidance during examination, the 
device is combined with a reflective ultrasound computed tomography (RUCT) 
unit. With a 3D hemispherical handheld detector (8-MHz center frequency, 256 
transducer elements), isotropic volumetric optoacoustic imaging is provided. This 
detector offers a spatial resolution of 100 µm and a field of view of 15 mm. 
Study design 
At the time point of imaging, genotypes of all animals were already determined. 
The investigator and persons carrying out analysis, however, were blinded to the 
genotypes. To ensure a stress-free handling during imaging procedure, piglets 
underwent a daily training from birth onwards. Only WT piglets were sedated with 
midazolam, administered intranasally, if required. To reduce interfering signals, 
skin-locations, in the regions to be examined, were shaved cautiously shortly before 
imaging procedure. During imaging, the piglets were hold gently. To improve the 
level of comfort during imaging, piglets were placed on a heat cushion, whenever 
necessary. Warmed transparent ultrasound gel (AQUASONIC clear, Parker 
Laboratories, USA) was used for optimal coupling between the MSOT detector and 
the skin. 
In a first step, a proof-of-concept study was performed in the DMD pig model, 
scanning newborn WT and DMDY/- piglets. Therefore, standardized 2D MSOT 
transverse imaging was applied to the muscles of the upper arm (triceps brachii) 
and the thigh (biceps femoris). In a subsequent longitudinal study, WT and DMDY/- 
piglets underwent standardized 2D transversal and 3D scanning of bilateral upper 
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arm and thigh muscles. Here, MSOT imaging was performed on a total of 4 
successive time points: days 1/2 (week 1), days 8/9 (week 2), days 15/16 (week 3) 
and days 22/ 23 (week 4) of life. 
In a second step, the approach was applied to pediatric patients and correlation of 
MSOT collagen signal to magnetic resonance imaging and patients’ functional 
status was investigated (not shown). 
3.14. Exclusion criteria for individual DMDY/- piglets from the studies 
Concerning the GWAS to investigate phenotype variability in DMDY/- piglets, all 
stillbirths, crushed piglets and animals, which died due to an infectious disease or 
due to questionable reasons were excluded from the analysis. Concerning the 
therapeutic approach, aiming at somatic gene editing, DMDY/- piglets, which died 
during the first week of life (d 0-6), were excluded from the study. For the diagnostic 
approach, using the MSOT device to detect collagens, all alive piglets were 
included in the study. 
3.15. Statistics 
In all results, differences between groups were considered as significant at P < 0.05. 
P-values were presented as: *: P < 0.05; **: P < 0.01; ***: P < 0.001; ****: P < 
0.0001. 
In chapter IV. 1.-3. results are presented as mean±s.e.m. Two experimental groups 
(WT vs. DMDY/-) were compared using independent samples t-test. Kaplan-Meier 
survival curves were used in Fig. GraphPad Prism v.5.04 was used for statistical 
analyses. 
In chapter IV.4. in the middle of each of the sliding windows of 40 SNPs a variance 
component analysis was performed using the ASReml package (VSNi, Hemel 
Hempstead, UK) and a mixed linear model as already described in and adopted 
from Medugorac et al. (2017) and Gehrke et al. (2020). 
In chapter IV.5.-6., concerning selection reacted monitoring (SRM), 
chromatograms were evaluated using Analyst V 1.5.1. (AB SCIEX, USA). 
Regarding holistic proteome analysis principal component analysis, hierarchical 
clustering, and Student's t-test were calculated with Perseus (V 1.5.3.2), part of the 
MaxQuant proteomics software package. 
In chapter IV.5., results are presented as mean±s.e.m., unless indicated otherwise. 
If more than two experimental groups were compared, one-way analysis of variance 
(ANOVA) was applied and whenever a significant effect was obtained multiple 
comparison tests between the groups were performed, using the Bonferroni 
procedure (parametric). The SPSS statistical program (version 25) was used for 
statistical analyses in IV.5.2. GraphPad Prism v.5.04 was used for statistical 
analyses in IV.5.3. 
In chapter IV.6., continous variables were presented as mean±s.d. Categorial 
variables were presented as numbers and percentages. For testing the normal 
distribution, Shapiro-Wilk test was used before inferential analysis. Two 
experimental groups (WT vs. DMDY/-) were compared using independent samples 
t-test. Welch’s correction was applied in cases of unequal variance in independent 
samples t-test. A Mann-Whitney U-test was applied for comparison of independent 
samples if the assumption of normal distribution was violated. To compare 
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longitudinal 3D MSOT collagen signals, Tukey’s honest significant difference 
(HSD) test following a two-way ANOVA, including time points and piglet group, 
was performed. For the comparison of longitudinal 2D MSOT collagen signals, post 
hoc Tukey’s HSD following a mixed-effects model were applied (with fixed 
effects: time points and piglet group, and random effect: piglet), due to missing 
values in week 1. All scans of WT and DMDY/- in each week were compared using 
independent samples t-test. Welch’s correction was applied in cases of unequal 
variance in independent samples t-test. A Mann-Whitney U-test was chosen for 
comparison of independent samples if the assumption of normal distribution was 
violated. Correlations are given by the Spearman correlation coefficient (rs), two-
tailed test. GraphPad Prism v.7.00 or newer was used for statistical analyses. 
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IV. RESULTS 
1. Animal generation by a DMD breeding herd 
A total of 29 litters were generated by the DMD breeding herd, consisting of 9 
DMD+/- sows, at the Lehr- und Versuchsgut, LMU Munich, Oberschleißheim. The 
DMD+/- founder animal #3040, born in 2014, generated a total of 10 litters. As 
shown in Table 7, n = 5 F1-sows (#5153, 3 litters; #5381, 3 litters; #5382, 4 litters; 
#5383, 4 litters; #6314, 1 litter) and n = 3 F2-sows (#6225, 1 litter; #6243, 1 litter; 
#6245, 2 litters), were used to complete the DMD breeding herd. 
Table 7: DMDY/- pigs generated breeding. 
 
 
Sows were inseminated with sperm of WT boars of Bayern Genetik, Poing-Grub. 
In total, n = 97 affected DMDY/- piglets were produced by breeding. The DMDY/- 
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phenotype was confirmed by PCR analysis of DNA isolated from individual tail 
biopsies, with the primer pair 5´-TGC ACA ATG CTG GAG AAC CTC A-3´ and 
5´-GTT CTG GCT TCT TGA TTG CTG G-3´ detecting the intact DMD allele and 
a second primer pair 5´-CAG CTG TGC TCG ACG TTG TC-3´ and 5´-GAA GAA 
CTC GTC AAG AAG GCG ATA G-3´ detecting the mutated (DMDΔ52) allele by 
the neomycin selection cassette. Of all DMDY/- piglets generated by breeding, n = 
6 piglets were still born and n = 13 piglets were crushed by the sow (n = 8 crush 
secured, n= 5 possibly crushed). Another n = 44 animals died within the first week 
of life (d 0-6), equivalent to 50.55% survivors of day 6 of life. 
2. Validation of different rearing conditions for DMDY/- 
piglets 
For the validation of the different husbandry conditions for rearing, a total of 27 
litters was considered, as shown in Table 8. 
Table 8: Color coding for the 4 different husbandry conditions applied for a 
total of 27 litters. Litters highlighted in orange indicate motherless nursing of 
DMDY/- piglets in an artificial rearing unit. Litters highlighted in pink indicate 48 
h supervised suckling at the sows’ teats. Litters highlighted in green indicate 5 d 
intense nursing (first approach) and in dark blue 5 d intense nursing (second 
approach). The litters colored in light blue indicate 5 d intense nursing (second 
approach) combined with a further experimental approach (explained in IV.3.). 
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Artificial rearing unit 
n = 5 litters, resulting in n = 12 alive DMDY/- piglets, were nursed in an artificial 
rearing unit, the Lax Disco Box. Despite supervision by a veterinarian, n = 3 piglets 
were crushed by the sow during birth or during the first 12 h of suckling at the sows’ 
teats. Another n = 7 DMDY/- piglets died or had to be euthanized due to poor general 
condition or the inability of drinking milk substitute by themselves. Only 17% of 
all animals (equivalent to n = 2 out of n = 12 DMDY/- piglets) survived the suckling 
period, as shown in Figure 10a. 
48 h of supervised suckling at the sows’ teats 
Due to the low efficiency of rearing DMDY/- piglets in an artificial rearing unit, as 
a second nursing approach, 48 h of supervised suckling at the sows’ teats was 
evaluated. The main intention was to increase the colostrum and breast milk intake. 
After 48 h of supervised suckling, no further supplementation or nursing was 
provided and piglets were left alone with the sow. Under these conditions, the 
survival success increased to 44% (equivalent to n = 7 out of n = 16 DMDY/- piglets), 
as shown in Figure 10b. These results indicated, that colostrum intake over a longer 
time period and the further nutrition with natural mother milk instead of milk 
replacers, plays a major role in survival of DMDY/- piglets. In total, n = 3 litters, 
resulting in n = 16 alive DMDY/- piglets, underwent the named breeding conditions, 
of which n = 3 animals were crushed by the sow during birth or supervised suckling. 
In the first two named approaches, n = 16 out of n = 28 alive DMDY/- piglets showed 
severe loss of body weight within the first 1-3 days after birth, combined with a 
complex of symptoms, appearing as lateral positioning, rowing with the four limbs, 
salivation and, in part, nystagmus. A meningitis infection with Staphylococcus 
aureus was suspected at first. Therefore, n = 3 animals (n = 1 WT and n = 2 DMDY/-
) were examined in the Institute for Veterinary Pathology, LMU Munich, where a 
meningitis infection could be ruled out. For all animals, appearing with the 
described symptoms, every attempt to retrieve a normal general condition failed 
and piglets had to be euthanized immediately. To evaluate a putative link between 
the described complex of symptoms and hypoglycemia, which might be caused by 
an insufficient milk intake due to suckling problems, a special focus was drawn on 
macroscopic examination of head muscles. As displayed in Figure 9, facial muscles 
used for suckling motions, neck muscles important for keeping the head upright, 
and forelimb muscles, enabling standing posture and forward pressure, showed 
white striated bundles of muscles, indicating a severe DMD phenotype. 
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Figure 9: Representative pictures of muscles of short-term surviving DMDY/- 
piglets. All shown muscle areas are important for the positioning at the sows’ teats 
and the suction process. Facial and neck muscles, as well as muscles of the forelegs 
show paleness when compared to healthy musculature. Furthermore, a different 
amount of bundles of muscles appearing with a white striated pattern were 
observed. Upper row: DMDY/- piglet #6215 shows pale depressor rostri and 
depressor labii muscles; DMDY/- piglet #6215 shows a pale mylohyoid muscle. 
Middle row: DMDY/- piglet #6311 shows a pale trapezius muscle, equally as 
DMDY/- piglet #6972. Bottom row: DMDY/- piglet #6215 shows pale 
cleidobrachialis and pectoralis muscles, DMDY/- piglet #6311 shows pale extensor 
muscles of the lower arm. Pale and white striated muscle bundles were always 
observed in conjunction with a severe DMD phenotype. 
 
5 days of intense nursing 
Due to the results above, two further approaches for nursing DMDY/- piglets were 
developed. In a first attempt, the main goal was to avoid energy deficiency, 
particularly dangerous within the first 24 h after birth. The first approach was 
applied for 7 litters (n = 23 DMDY/- piglets). 35% of DMDY/- piglets (equivalent to 
n = 8 out of n = 23 DMDY/-) survived day 6 of life utilizing this rearing approach, 
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as shown in Figure 10c. 
The second approach was applied for a total of n = 9 litters (n = 23 alive born 
DMDY/- piglets). It was extended by hedging colostrum intake and subsequently 
upgraded by further parameters. To varify if colostrum intake was sufficient, the 
blood glucose levels of weak appearing DMDY/- piglets (n = 17 newborn DMDY/- 
piglets) was measured. 
A glucose level lower than 50 mmol/l (present in n = 7 newborn DMDY/- piglets) 
was considered as threshold to initiate supplementary gastric tube feeding of frozen 
stored and reheated colostrum. Using this advanced approach of 5 days of intense 
nursing, 70% (equivalent to n = 16 out of n = 23 DMDY/- piglets) survived day 6, 
as shown in Figure 10d. 
 
 
Figure 10: Kaplan-Meier survival curve of all alive born DMDY/- pigs reared 
under four different nursing conditions. a, Survival of DMDY/- piglets in the 
artificial rearing unit (motherless rearing). Only 17% of all alive born DMDY/- 
piglets survived day 6 of life. b, Survival of alive born DMDY/- piglets under 
conditions of 48 h supervised suckling at the sows’ teats with 44% surviving day 6 
of life. c, 5 days intense nursing, approach 1, shows similar effectiveness as 48 h 
supervised suckling at the sows’ teats. 35% survived day 6 of life. d, 5 days intense 
nursing, approach 2, was the most successful rearing condition with 70% of alive 
born DMDY/- piglets surviving day 6 of life. 
 
Survival of DMDY/- piglets severely increased within the improvement of rearing 
conditions, highlighting the importance of specially adapted nursing in the DMD 
pig model. 
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The impact of supplementary milk substitute feeding 24 h after birth on the 
body weight of DMDY/- piglets 
The severe loss of body weight in DMDY/- piglets within the first 24 h of life could 
be compensated by the supportive administration of milk substitute from 24 h after 
birth onwards. The effect of this milk supply on body weight of DMDY/- piglets is 
shown in Figure 11. The data is generated from the husbandry system “5 d intense 
nursing” only. Due to insufficient breast milk intake resulting of an inability to 
suckle well at the sows’s teats, as shown above, nearly none of the DMDY/- piglets 
which did not learn to drink milk substitute out of a piglet drinking trough were 
able to survive. This indicates, that for affected DMDY/- piglets suckling at the 
sows’s teats is not sufficient for generating and maintaining sufficient energy 
reserves. 
 
Figure 11: Impact of supplementary milk substitute feeding 24 h after birth on 
the body weight of DMDY/- piglets. Newborn DMDY/- piglets show a significantly 
reduced birth weight when compared to male WT littermates. A further severe loss 
of body weight within the first 24 h, as observed in most DMDY/- piglets, can be 
partly compensated the supplementary feeding of milk substitute. 
  
IV. Results   68 
3. Phenotypic characteristics of DMDY/- pigs generated by 
breeding 
3.1. Immunohistochemical staining of dystrophin 
Skeletal muscle of WT animals exhibited a clear dystrophin staining (Figure 12). 
In contrast, no dystrophin signal was detected in skeletal muscle sections of DMDY/- 
pigs, with exception of single isolated revertant (dystrophin positive) fibers (not 
shown). 
 
Figure 12: Representative skeletal muscle samples of a WT and a DMDY/- pig 
stained immunohistochemically for dystrophin. Compared to WT controls no 
dystrophin is detectable in the skeletal muscle sections of DMDY/- pigs. This finding 
reflects the situation found in human DMD patients. Dystrophin: brown color. 
 
3.2. Creatine kinase levels 
CK levels of a total of n = 89 pigs (n = 25 WT, n = 35 DMD+/- and n = 29 DMDY/-) 
were measured at different timepoints. A CK level ≤ 2000 U/l was considered to be 
normal. As shown in Figure 13, CK levels in week 1 of life were already severely 
elevated in DMDY/- piglets compared to their WT littermates (42956±29020 U/l 
versus 274±59 U/l). Female DMD+/- carrier did not show an elevation of CK in 
week 1 of life (602±273 U/l), whereas between week 2 and 11 of life a mild 
elevation of CK (3771±1080 U/l) was observed for this group. CK levels of DMDY/- 
piglets compared to their WT littermates continued to be severely elevated between 
week 2 and week 11 of life (54041±9058 U/l versus 1513±259 U/l). 
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Figure 13: Comparison of creatine kinase levels. CK measuements of n = 89 pigs 
(n = 25 WT, n = 35 DMD+/- and n = 29 DMDY/-) are shown. Threshold: CK ≤ 2000 
U/l is considered as normal. 
 
3.3. Body weight of DMDY/- compared to WT pigs 
Newborn DMDY/- piglets (n = 51) showed a significantly (p = 0.0091) lower 
birthweight, compared to male WT littermates (n = 54), however with a large 
variance of values ranging between 612 and 1766 g for DMDY/- piglets and between 
640 and 2240 g for male WT littermates (Figure 11). Subsequently, nearly all 
newborn DMDY/- piglets showed a severe loss of body weight within the first 24 h 
of life, with a mean loss of 69.8±10.5 g (n = 47 DMDY/- piglets). In comparison to 
male WT piglets (n = 45) that gained 90.9±12.9 g within the first 24 h of life, the 
loss of body weight in DMDY/- piglets was highly significant (Figure 14, Insert). 
Figure 14 exemplarily shows the external appearance of 4-day-old DMDY/- piglets 
(marked in blue) compared to male WT littermates. In Figure 16 an adolescent 
DMDY/- pig compared to an age-matched female DMD+/- littermate is shown. 
DMDY/- pigs show a reduced body size as well as generalized muscle atrophy 
compared to WT or DMD+/- littermates. 
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Figure 14: Representative pictures of 4-day-old DMDY/- piglets (blue marked) 
and a male WT littermate. DMDY/- piglets appear thinner and weaker, compared 
to age-matched WT animals. 
 
From day 2 onwards, DMDY/- piglets started to gain body weight (as displayed in 
detail in Fig. 11). However, body weight increase always stayed below the body 
weight levels of male WT littermates, as shown in Figure 15. 
 
 
Figure 15: Comparison of body weight of DMDY/- and male WT littermates in 
the first 27 days of life. The first 5 time points display body weight values of n ≥ 
16 pigs for each genotype (max. n = 48, min. n = 16). From day 5 onwards time 
points display body weight values of n ≥ 5 for each genotype. Not all animals could 
be weighed at exactly the same time points, therefore raw data were adjusted to 
defined ages by linear interpolation. Insert shows the change in body weight from 
birth to 24 h after birth of DMDY/- (n = 47) and male WT littermates (n = 39). 
Compared to male WT littermates, DMDY/- piglets show a highly significant weight 
loss within the first 24 hours of life. 
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Figure 16: Representative picture of an adolecent male DMDY/- pig and a 
female DMD+/- littermate. DMDY/- pigs show a reduced body size as well as 
generalized muscle atrophy compared to WT or DMD+/- littermates. Foreground: 
DMDY/- pig (black asterisk); background: DMD+/- pig; age of pigs shown: 126 days 
of life. 
 
3.4. High mortality of DMDY/- pigs generated by breeding 
As indicated above, DMDY/- pigs generated by breeding displayed a high mortality. 
Of a total of n = 97 DMDY/- animals, n = 44 animals died within the first week of 
life (d 0-6), in the further referred to as “short-term surviving DMDY/- piglets”. 51% 
of all DMDY/- pigs survived day 6 of life (in the further referred to as “long-term 
surviving DMDY/- piglets”). 36% of all DMDY/- piglets survived day 50 of life. 
Results are presented in a Kaplan-Meier survival curve, Figure 17. To prevent 
competition at the sows’ teats between affected DMDY/- and WT piglets, WT 
littermates were removed from the individual litters as soon as possible. Therefore, 
a Kaplan-Meier survival curve comparing survival of DMDY/- and WT pigs was 
only feasible for the first 7 days of life (Insert Fig. 17). 
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Figure 17: Kaplan-Meier survival curve for all n = 91 alive born DMDY/- 
piglets, produced by breeding. Only one animal survived 173 days of life (#6790). 
Insert shows the neonatal death rate in week 1 of life of DMDY/- piglets compared 
to male wild-type littermates (WT) (n = 61 DMDY/-, n = 56 male WT). 
 
In week 1 of life, DMDY/- piglets mainly had to be euthanized due to hypoglycemia, 
severely reduced general condition, the inability to drink independently, severe 
contractures and/ or muscle alterations or gastrointestinal symptoms. Adolescent 
DMDY/- pigs died either due to sudden cardiac death, observed in several DMDY/- 
pigs by analysing 24 h video surveillance data of the animals, or had to be 
euthanized due to severe physical deterioration (exhaustion, stridor or tachypnea) 
following the animal protection regulation. 
3.5. Gross anatomical findings in short-term surviving DMDY/- piglets 
The majority, but not all short-term surviving DMDY/- piglets (death during day 0 
to day 6 of life) showed macroscopic muscle alterations in form of white 
discoloration at least in some muscle bundles of the intercostal muscles (Fig. 18), 
the neck muscles or the fore limb muscles, with the triceps brachii muscle being 
most frequently affected. Long-term surviving DMDY/- pigs (surviving week 1 of 
life and longer) only rarely showed macroscopic muscle alterations, with the 
masseter being most frequently affected in these animals. 
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Figure 18: Macroscopic alterations of striated muscles in a 2-day-old DMDY/- 
piglet. The picture section shows the white striped pattern observed in different 
muscle groups, here shown for the intercostal respiratory musculature. 
 
3.6. Muscle histology of short- and long-term surviving DMDY/- pigs 
Histological findings in skeletal muscle of short-term surviving DMDY/- piglets 
Histology of skeletal muscles was performed at the paraffin laboratory of the 
Institute for Veterinary Pathology, LMU Munich. As shown in Figure 19a, skeletal 
muscle of 3-day-old WT pigles exhibited healthy striated muscle fibers with 
peripherically located nuclei and homogeneously stained cytoplasm. In contrast, in 
skeletal muscle of short-term surviving 3-day-old DMDY/- piglets some muscle 
fibers had centrally located nuclei (Fig. 19b-c). In addition, skeletal muscles 
exhibited increased interstitial fibrosis and numerous foci with lymphohistiocytic 
infiltrations (Fig. 19b and d). Furthermore, several local foci with calcifications 
were observed in skeletal muscles of 3-day-old DMDY/- piglets, which might 
explain the above mentioned macroscopic white striated pattern (Fig. 19b, e, f). 
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Figure 19: Histomorphological analysis of the triceps brachii muscle of a 3-
day-old WT control pig (a) and a 3-day-old DMDY/- littermate (b-f). Short-term 
surviving DMDY/- pig shows local foci with calcifications (black arrows), 
centralized nuclei (red arrows) and lymphohistiocytic infiltrates (asterisks). 
Staining: a-e: H.E., f: Von Kossa. 
 
An increased amount of collagenous connective tissue fibers was found in skeletal 
muscle tissue of short-term surviving DMDY/- piglets compared to WT littermates 
(Fig. 20). 
 
Figure 20: Representative images of skeletal muscle (triceps brachii) of 3-day-
old WT and DMDY/- piglets. Skeletal muscles of short-term surviving DMDY/- 
piglets exhibited increased interstitial fibrosis. Staining: Masson Trichrome. 
 
Histological findings in skeletal muscle of long-term surviving DMDY/- piglets 
Long-term surviving DMDY/- pigs did not exhibit the macroscopic white striated 
muscle alterations as seen in young DMDY/- piglets, except for mild to moderate 
white striping of masseter muscle found in some long-term surviving animals. 
Histologic examinations of triceps brachii muscle of long-surviving DMDY/- pigs 
(> 84 d) revealed muscle fibers of varying diameters, in part angular shaped fibers. 
Several muscle fibers contained centralized nuclei or were round shaped and 
hypereosinophilic stained in H.E. staining, consistent with muscle fiber 
hypertrophy and degeneration. Endo- and perimysial tissue focally appeared with 
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moderate to marked lymphohistiocytic infiltrates occasionally surrounding and 
invading athrophic and necrotic myofibers, indicating myophagocytosis (Fig. 21). 
Interstitial fibrosis was highly apparent (Fig. 22a), whereas fatty replacement (Fig. 
21d) was only occasionally present. Focal calcifications as seen in newborn DMDY/- 
piglets were not observed (Fig. 22b). 
 
Figure 21: Histomorphology of triceps brachii muscle of long-term surviving 
DMDY/- pigs. a, Overview of transverse sections reveal muscle fibers of varying 
diameters, hypercellularity with lymphohistiocytic infiltrates, muscle fiber 
hypertrophy and cell degeneration. b, Hypertrophic rounded fibers (black asteriks), 
angular shaped fibers (white asterisks), lymphohistiocytic infiltrates in endo- and 
perimysial tissue (arrows). c, Centrally located nuclei (arrows). d, Focal fatty 
replacement (arrows). Staining: H.E., scale bars: a: 250 µm, b-d: 100 µm. Age of 
pigs shown: 15th week of life. 
 
In skeletal muscle of long-term surviving DMDY/- piglets collagenous connective 
tissue was highly increased (Fig. 22a), whereas no calcium deposits were detected 
(Fig. 22b). 
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Figure 22: Representative histological sections of triceps brachii muscle of 
long-term surviving DMDY/- pigs. Staining: a: Masson Trichrome, b: Von Kossa 
(brown color: calcium deposits). Age of pigs shown: 15th week of life. 
 
In conclusion, the observed alterations in skeletal muscle of newborn and adolecent 
DMDY/- pigs both illustrate severe muscular dystrophy, including muscle 
degeneration and regeneration processes. However, skeletal muscles of DMDY/- 
piglets which died during week one (d 0-6) of life, in general appeared to be more 
severily affected by focal calcium deposits, whereas in skeletal muscle of adolecent 
DMDY/- pigs the subsequent replacement of muscle tissue by fatty and connective 
tissue, reflecting the conditions in human DMD patients, was more prominent. 
3.7. Gastrointestinal alterations in DMDY/- piglets 
DMDY/- pigs of the short-surviving group died or where euthanized due to different 
reasons, as described above. A severely reduced general condition of newborn 
DMDY/- piglets was often consistent with reduced blood glucose levels (a glucose 
level below 50 mmol/l was set as threshold to induce supplementary gastric tube 
feeding). Therefore, within the last applied rearing approach glucose levels were 
measured in all weak appearing newborn DMDY/- piglets (n = 24 analyzed). 
However, few newborn DMDY/- piglets (n = 2; 8% of newborn DMDY/- piglets 
analyzed) exhibited acute poor general condition in combination with an 
abnormally high blood glucose level (up to 237 mmol/l). Other DMDY/- animals 
were registered with difficulties in defecation (repeated strain to eliminate feaces) 
and increasing abdominal girth and, at later stages, anorexia. One DMDY/- animal 
had to be euthanized due to increased abdominal girth combined with abdominal 
edema and ascites (detected by ultrasound scan). In total n = 11 DMDY/- piglets (out 
of 28 DMDY/- piglets resulting of n = 9 litters) were registered presenting at least 
one of the described symptoms. Therefore, necropsy of animals euthanized after 
showing either one or more of the described conditions, was extended by 
macroscopic evaluation of the entire gastrointestinal tract. Accumulation of gas and 
ingesta in the jejunum and large intestine, consistent with an obstipation, and dark 
coloration of the intestinal wall, consistent with an infarction of the intestinal wall, 
were observed, as exemplarily shown in Figure 23. In case of complete ileus, 
present in n = 2 animals, the intestinal wall already showed porosity, and the 
subsequent part of the intestine was empty. A submucosal rupture site was mainly 
found at the peak of the ascending large intestine (colon ascendens), anatomically 
presenting a 180° curve (Fig. 23c). 
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Figure 23: Macroscopic findings in a 6-day-old DMDY/- piglet, presenting 
symptoms of a gastrointestinal phenotype. DMDY/- piglet #6836 was found lying 
in lateral position with the legs tightened to the body and an increased abdominal 
girth. The animal was immediately euthanized and examined. a, Opening of the 
abdominal cavity shows dilated intestinal loops. b, Extracted intestine. c, Peak of 
the ascending large intestine with porous site. d, Descending large intestine 
subsequent to the obstructed part of the intestine, presenting as empty intestine 
section. White arrows: accumulation of gas; red arrows: infarction of the intestinal 
wall; black arrows: completely empty intestine, subsequent to ileus site; orange 
arrow: porous intestine site. Scale bars: a-d: 1 cm. 
 
In some few animals, ascites and fibrinous layers in the abdominal cavity consistent 
with a peritonitis were present, indicating an already longer-lasting, clinically 
undetected, process. 
Initial histologial studies of DMDY/- piglets with gastrointestinal phenotype, 
performed by Christian Loch at the Institute for Veterinary Pathology, LMU 
Munich, indicate a putative increased amount of Type I collagen fibers, exemplarily 
shown in Figure 24. However, more research on this topic is needed and currently 
in work. 
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Figure 24: Representative histological images of colon ascendens of a 3-day-
old DMDY/- compared to an age-matched WT littermate. Staining: Masson 
Trichrome. 
 
On the basis of the gastrointestinal findings, all DMDY/-piglets of litters, in which 
one or more animals showed gastrointestinal symptoms, received laxatives and 
digestion-aiding nutritional supplements from day 1 after birth onwards. In total, 
this medication was applied for n = 7 DMDY/- piglets (out of 2 litters, colored in 
light blue in VI.2. Table 8). Of these, 86% (equivalent to n = 6 DMDY/- animals) 
survived day 62 of life, indicating an effect of laxatives and digestion-aiding 
nutrients on the DMD phenotype in DMDY/- pigs. 
4. Identification of potential modifier loci in the DMDY/- pig 
It is known that the severity and manifestation of the DMD phenotype in human 
DMD patients can be strongly influenced by modifier genes. In human individuals 
with DMD, the most common phenotypic variation is the age at loss of ambulation 
(Bello et al., 2016). However, most studies rely on hypothesis, thus investigate only 
pre-specified candidate genes of interest. As already implied in the previous 
sections, the phenotypic characteristics in our DMDY/- pigs generated by breeding 
varied. Therefore, modifier genes, which might influence the manifestation and 
severity of the phenotype in the DMDY/- pig were studied. To identify candidate 
loci influencing the DMD phenotype, a genome wide combined linkage 
disequilibrium and linkage analysis (cLDLA) mapping study, scanning the entire 
genome for common genetic variations by detecting known single nucleotide 
polimorphisms (SNPs), was commenced. 
4.1. Selection of survival time as study criteria for SNP genotyping 
In total n = 97 DMDY/- pigs were generated by breeding. As as shown in Table 9, 
all genotypes (WT male, WT female, DMDY/- and DMD+/-) were inherited equally 
following Mendelian segregation. 
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Table 9: Overview of all animals generated by breeding. 
 
 
Among the phenotypic parameters determined in DMDY/- pigs, survival time 
appeared to be the best defined and unbiased parameter for a genome-wide cLDLA 
mapping study. To avoid assignment erros, all still births and short-term survivors, 
which were crushed or possibly crushed by the sow or died due to an uncertain 
reason (e.g. infection), had to be excluded from the genome-wide cLDLA mapping 
study. Consequently, only a subset of n = 52 male DMDY/- animals could be 
integrated. 
Partial pedigrees of all DMD litters were created, showing only the DMDY/- 
decendants. A color-coding helped to distinguish at first sight between short-term 
survivors (death within day 0-9 of life) and a long-term survivors (death after ≥ 10 
days of life; Fig. 25-31). 
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Figure 25: Partial pedigree of founder sow #3040 (black semi-marked circle, 
middle). Breeding boars are indicated in blank black squares. For each litter only 
DMDY/- decendants (colored squares) and DMD+/- pigs used to expand the breeding 
herd (black semi-marked circles) are shown. Symbols: Light blue squares: either 
still born, crushed or possibly crushed short-term survivors (d 0-9 of life) excluded 
from the GWAS; dark blue squares: short-term survivers (d 0-9 of life) included 
in the GWAS, which most likely died due to a severe DMD phenotype; Light 
orange squares: long-term survivors (≥ 10 d of life) excluded from the GWAS 
(here: no DNA available); dark orange squares: long-term survivors (≥ 10 days 
of life) included in the GWAS. 
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Figure 26: Partial pedigree of F1 sow #5153 (black semi-marked circle). 
Symbols: light blue squares: either still born, crushed or possibly crushed short-
term survivors (d 0-9 of life) excluded from the GWAS; dark blue squares: short-
term survivers (d 0-9 of life) included in the GWAS, which most likely died due to 
a severe DMD phenotype; light orange squares: long-term survivors (≥ 10 d of 
life) excluded from the GWAS (here: no DNA availible); dark orange squares: 
long-term survivors (≥ 10 days of life) included in the GWAS; II: macroscopic 
white striated muscle bundles (if “Masseter”: only masseter muscle was white 
striated); II: no macroscopic white striated muscle bundles found; complex of 
symtoms: in part observed lateral positioning, rowing with the four limbs, 
salivation and, nystagmus (described in IV.2.). 
 
 
Figure 27: Partial pedigree of F1 sow #5381 (black semi-marked circle). 
Symbols: dark blue squares: short-term survivers (d 0-9 of life) included in the 
GWAS, which most likely died due to a severe DMD phenotype; dark orange 
squares: long-term survivors (≥ 10 days of life) included in the GWAS; complex 
of symtoms: in part observed lateral positioning, rowing with the four limbs, 
salivation and nystagmus (described in IV.2.). 
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Figure 28: Partial pedigree of F1 sow #5382 (black semi-marked circle). 
Symbols: Light blue squares: either still born, crushed or possibly crushed short-
term survivors (d 0-9 of life) excluded from the GWAS; dark blue squares: short-
term survivers (d 0-9 of life) included in the GWAS, which most likely died due to 
a severe DMD phenotype; Light orange squares: long-term survivors (≥ 10 d of 
life) excluded from the GWAS (here: crushed at 12 days of life, or infection); dark 
orange squares: long-term survivors (≥ 10 days of life) included in the GWAS; II: 
macroscopic white striated muscle bundles (if “Masseter”: only masseter muscle 
was white striated); II: no macroscopic white striated muscle bundles found. 
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Figure 29: Partial pedigree of F1 sow #5383 (black semi-marked circle). 
Symbols: Light blue squares: either still born, crushed or possibly crushed short-
term survivors (d 0-9 of life) excluded from the GWAS; dark blue squares: short-
term survivers (d 0-9 of life) included in the GWAS, which most likely died due to 
a severe DMD phenotype; Light orange squares: long-term survivors (≥ 10 d of 
life) excluded from the GWAS (here: crushed at 12 days of life, or infection); dark 
orange squares: long-term survivors (≥ 10 days of life) included in the GWAS; II: 
macroscopic white striated muscle bundles; II: no macroscopic white striated 
muscle bundles found. Gray shaded litter: excluded from SNP genotyping, due to 
the questionable effect of laxatives on survival of DMDY/- pigs. 
 
 
Figure 30: Partial pedigree of F1 sow #6314 (black semi-marked circle). 
Symbols: dark blue squares: short-term survivers (d 0-9 of life) included in the 
GWAS, which most likely died due to a severe DMD phenotype; dark orange 
squares: long-term survivors (≥ 10 days of life) included in the GWAS. 
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Figure 31: Partial pedigree of F2 sows #6225, #6243 and #6245 (black semi-
marked circles Symbols: Light blue squares: either still born, crushed or possibly 
crushed short-term survivors (d 0-9 of life) excluded from the GWAS; dark blue 
squares: short-term survivers (d 0-9 of life) included in the GWAS, which most 
likely died due to a severe DMD phenotype; dark orange squares: long-term 
survivors (≥ 10 days of life) included in the GWAS; gray shaded litter: excluded 
from SNP genotyping, due to the questionable effect of laxatives on survival of 
DMDY/- pigs. 
 
4.2. Identification of candidate regions within the genome of DMDY/- pigs 
DNA was isolated from all DMD+/- sows and male DMDY/- offspring. The purified 
DNA was subsequently employed for a genome wide cLDLA mapping. SNP-
genotypes of the WT sires were provided. 
Male DMDY/- animals were analysed according to two different criteria: 
PhContinous categorized “length of life in days”, and PhDiscrete categorized 
phenotype 1 as short-term survivors (death within 2-9 days of life) and phenotype 
2 as long-term survivors (death within ≥ 10 days of life). Using PhDiscrete as 
cirterion, n = 19 animals were rated as short-term survivors and n = 33 as long-term 
survivors. 
Positions with significant likelihood ratio test (LRT)-values 
A likelihood ratio test (LRT) was calculated at each SNP interval midpoint. Using 
PhDiscrete phenotype coding, an LRT peak suggesting linkage between underlying 
haplotypes and observed phenotype, was estimated on chromosome 7 (19.8 Mb) 
with estimated LRT-value of 12.0. Using PhContinous phenotype coding, a QTL 
was estimated on chromosome 1 (at 46.6 Mb) with an indicative LRT peak of 12.2. 
Nevertheless, chromosome 1 in total revealed a noisy LRT pattern, relativizing the 
probability of this locus. Another QTL was estimated on chromosome 8 (109.7 Mb) 
with an estimated LRT-value of 12.6. For both criterions further indicative LRT-
values have been found on other chromosomes, however, not revealing marked 
peaks. On 17 chromosomes (chrom. 2, 3, 4, 5, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 
19, 20) an evenly low, homogeneous pattern of LRT values was observable, making 
these chromosomes unlikely to contain modifying loci influencing the survival 
phenotype of DMDY/- pigs. The results for all chromosomes are shown in Figure 
32, with chromosome 8 selected as example to illustrate a candidate for a potential 
modifying locus. 
Summarizing, using PhContinous and PhDiscrete as criteria, so far no genome-wide 
significant QTL responsible for the variable survival phenotype of DMDY/- pigs 
could be identified. However, with a continously increasing number of animals 
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included in the study, the LRT curves became smoother and less peaked. On some 
chromosomes indicative values were observed. Thus, a higher number of animals 
and, eventually, a more explicit classification system, might reveal a clearer picture. 
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Figure 32: Manhattan plot used to display candidate regions 
suggesting modifying loci with influence on survival time of 
DMDY/- pigs. Results of the cLDLA for DMDY/- pigs with sliding 
window of 40 SNPs are displayed. The pig chromosomes are 
presented on the x-axis. On the y-axis, the calculated likelihood 
ratio test (LRT)-values are shown. The blue horizontal line marks 
the chromosome-wide (i.e. indicative), the red horizontal line the 
genome-wide significance threshold. PhDiscrete categories 
phenotype 1 as short-term survivors (death within 2-9 days of life) 
and phenotype 2 as long-term survivors (death within ≥ 10 days 
of life). PhContinous categories “length of life in days”. In total, 
n = 52 DMDY/- decendants were included in the GWAS. For 
PhDiscrete n = 19 DMDY/- animals were rated as phenotype 1 and 
n = 33 as phenotype 2. Insert: Chromosome 8 was selected as 
example to illustrate a candidate for a potential modifying locus.
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5. Somatic gene editing ameliorates muscle failure in the 
DMD pig 
In a therapeutic trial in DMDY/- pigs, somatic gene editing to restore the open 
reading frame (ORF) of the DMD gene was performed, analysed and validated. The 
aim of the therapeutic approach was to excise exon 51 in DMDΔ52 pigs after self-
assembly of both intein-carrying Cas9 halves, and thereby to restore the ORF, 
which leads to the expression of an internally truncated but largely functional 
dystrophin protein. It thus aims at converting Duchenne muscular dystrophy into 
the milder Becker muscular dystrophy. The complete results are published in 
Moretti et al. (2020). 
Transduction of DMDY/- pigs with G2-AAV9-Cas9-gE51 
For the therapeutic trial, a total of n = 25 DMDY/- pigs were used. Of these, n = 6 
animals served as untreated controls, n = 6 animals received local i.m. injections in 
the fore- and hindlimb of the right side of the body and n = 13 animals received 
systemic i.v. injection of G2-AAV9-Cas9-gE51. Of the i.v. injected DMDY/- pigs n 
= 6 animals received a low dose (1-5 × 1013 vp/kg BW), wheras n = 7 animals 
received a high dose (2 × 1014 vp/kg BW) of G2-AAV9-Cas9-gE51. 
5.1. Dystrophin expression in skeletal muscle of treated DMDY/- pigs 
In a first in vivo approach in the DMDY/- pig, the expression of internally truncated 
stable dystrophin was assessed after local application of AAV9-Cas9-gE51Cas9. 
Therefore, 10- to 14-day-old DMDY/- pigs were injected unilaterally into their fore- 
and hindlimb muscles with AAV9-Cas9-gE51 in doses of 2 × 1013 viral particles 
(vp) per kg BW. 6 weeks after AAV9-Cas9-gE51 transduction, pigs were 
euthanized and histologic analysis was performed, revealing the restoration of 
membrane-localized dystrophin in the treated muscle sites. Low dystrophin levels 
at the contralateral limbs could be detected. As might be expected, vital organs such 
as diaphragm and heart were not affected by i.m. limb injection. Therefore, 
dystrophin expression in these organs was aimed at by systemic application of 
AAV9-Cas9-gE51. For this approach, AAV9-Cas9-gE51 was coated with G2-
PAMAM nanoparticles for the enhancement of myotropism of the viral vectors. A 
first low-dose approach (1-5 × 1013 vp/kg BW) with G2-AAV9-Cas9-gE51 
revealed only sporadic transduction of skeletal muscle specimens. A second 
approach using high-doses (2 × 1014 vp/kg BW) of G2-AAV9-Cas9-gE51 enabled 
the expression of dystrophin in skeletal muscles, as well as in diaphragm and heart. 
All results were confirmed at the genomic (successful elimination of exon 51) and 
transcript level (the expression of a DMDΔ51-52 transcript) (not shown). 
Immunofluorescence analysis visualized the expression of dystrophin in striated 
muscles. Targeted absolute quantification of dystrophin in skeletal muscle of 
treated DMDY/- pigs by selected reaction monitoring (SRM) likewise proved the 
expression of dystrophin. In a holistic proteome analysis, an insight on the effect of 
DMD treatment on the skeletal muscle proteome of DMDY/- pigs was provided. 
Analyses of 24 h behavioral observations of WT, treated and untreated DMDY/- pigs 
substantiated the effectiveness of DMD treatment. Furthermore, two different 
approaches to analyze potential intracellular off-target effects were applied. 
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Immunofluorescence analysis for the visualization of dystrophin expression in 
skeletal muscle 
Immunofluorescent staining, performed by Tarik Bozoglu of the Clinic and 
Policlinic for Internal Medicine I, Klinikum Rechts der Isar, TU Munich, visualized 
the results explained above. Dystrophin expression was observed in the locally 
treated muscle sites of i.m. injected DMDY/- pigs. A wide spread expression of 
dystrophin was visible in all considered muscles of systemically high-dose treated 
DMDY/- pigs. In muscles of systemically low-dose treated DMDY/- animals nearly 
no dystrophin expression was detectable (Figure 33). 
 
Figure 33: Representative immunofluorescence (IF) analysis. IF staining was 
applied for the visualization of dystrophin in striated muscles (quadriceps muscle, 
diaphragm and masseter) of WT, i.m. treated DMDY/- (Quadriceps right = treated 
side, Quadriceps left = non-treated side) and i.v. treated DMDY/- pigs (low- and 
high-dose). Scale bars indicate 200 µm (adapted from Moretti et al., 2020). 
 
Targeted absolute quantification of dystrophin in skeletal muscle of treated 
DMDY/- pigs by selected reaction monitoring analysis 
Targeted absolute quantification of dystrophin in skeletal muscle by selected 
reaction monitoring (SRM) analysis likewise confirmed the expression of 
dystrophin. The approach was performed in cooperation with Thomas Fröhlich and 
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Florian Flenkenthaler, Gene Center - LAFUGA, LMU Munich. 
SRM analysis of representative samples from indicated skeletal muscles of i.m. 
treated or high-dose i.v. treated DMDY/- pigs confirmed the expression of 
dystrophin in either the injected muscle sites (i.m. treated) or analyzed muscle sites 
(high-dose i.v. treated). As shown in Figure 34, the quantification of dystrophin 
expression revealed highly variable dystrophin levels between different muscle 
specimens, varying from < 1% up to 62% (of WT dystrophin level) in i.m. treated 
and from < 1% up to 38% (of WT dystrophin level) in high-dose i.v. treated DMDY/- 
pigs. However, different analytical methods (genomic analysis, transcriptomic 
analysis) of the same muscle specimens revealed similar results, indicating varying 
distribution of the pair of intein-split Cas9 and gRNA-encoding virus particles from 
the application site. 
 
Figure 34: Representative results of mass spectrometry-based (SRM) 
dystrophin quantification. Dystrophin quantity of samples of indicated skeletal 
muscles of i.m. treated (n = 2) and high-dose i.v. treated (n = 3) DMDY/- pigs are 
shown. Dystrophin expression levels are shown in % of WT. Expression data of 
i.m. treated DMDY/- pigs reveals highly variable dystrophin expression in different 
muscle specimens of locally treated quadriceps muscle, whereas untreated muscle 
shows a total lack of dystrophin. Variable levels of dystrophin expression can also 
be observed in different muscle samples of i.v. high-dose treated DMDY/- animals, 
in part reaching nearly 40% of WT (adapted from Moretti et al., 2020). 
 
Holistic proteome analysis provides insights into the effect of DMD treatment 
on the skeletal muscle proteome of DMDY/- pigs  
Holistic proteome analysis was performed in cooperation with Thomas Fröhlich 
and Florian Flenkenthaler, Gene Center - LAFUGA, LMU Munich. In total 2414 
different proteins were identified. Of label-free, normalized quantification intensity 
values for skeletal muscle specimens of WT, i.m. treated and untreated DMDY/- 
pigs, unsupervised hierarchical clustering (Fig. 35a) and a principal component 
analysis (Fig. 35b) were performed. Except for triceps #1 (i.m. treated DMDY/-), the 
samples clustered into 3 groups according to genotype (WT vs. DMD) and 
treatment (DMD i.m. treated vs. DMD untreated). The proteome pattern of 
triceps#1 (i.m. treated DMDY/-), which was the sample showing the highest 
dystrophin recovery, was even more shifted towards the WT proteome, indicating 
that DMD treatment had a clear effect to normalise the skeletal muscle proteome of 
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DMDY/- pigs. 
 
Figure 35: Holistic proteome analysis to validate the effect of DMD treatment 
on the skeletal muscle proteome of DMDY/- pigs. a, Unsupervised hierarchical 
clustering of label-free quantification (LFQ) values for skeletal muscle specimens 
of WT, i.m. treated and untreated DMDY/- pigs. Z-score-normalized expression 
values for the different proteins are color coded. b, For principal component 
analysis, proteins were isolated from the same triceps and biceps muscle samples 
from WT, i.m. treated and untreated DMDY/- pigs (n = 2 per group) as used in a. 
Each symbol is equivalent to an individual sample (n = 4 samples per group). The 
proportion of variance explained by each component is shown (adapted from 
Moretti et al., 2020). 
 
5.2. Creatine kinase levels decreased in high-dose treated DMDY/- pigs 
Serum creatine kinase (CK) levels of DMDY/- animals were measured at two 
timepoints: between week 1-3 of life (before treatment), and at the day of 
termination of the experiment. However, blood collection before treatment was not 
possible in all DMDY/- animals due to individual high suspectibility to stress. 
Concerning CK values at termination of the experiment, only plausible values could 
be used for analysis. Implausbility of values included for example death due to 
external stressors (e.g. transportation, harrassment by littermates), unobserved 
death and a resulting long timespan between death and blood collection, or obvious 
severe hemolysis. Consequently, only selected CK values were analyzable, 
reducing the statistic validity. However, of n = 4 WT, n = 3 untreated DMDY/-, n = 
4 i.m. injected DMDY/- and n = 3 i.v. high-dose i.v. treated DMDY/- pigs the 
evaluation of CK values was feasible. CK levels of WT animals were low as 
expected (below the threshold of 2000 U/l). A derease of CK levels in i.v. high-
dose treated DMDY/- compared to untreated or i.m. treated DMDY/- animals was 
observable. The results are shown in Figure 36. 
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Figure 36: Serum creatine kinase (CK) values. CK levels of n = 4 WT, n = 3 
untreated DMDY/-, n = 4 i.m. injected DMDY/- and n = 3 i.v. high-dose i.v. treated 
DMDY/- pigs are shown. Statistics: one-way ANOVA with Bonferroni’s multiple 
comparison test, results are presented as mean±s.e.m. (adapted from Moretti et al., 
2020). 
 
5.3. Functional muscle improvement due to somatic gene editing 
To validate the effect of DMD treatment on muscle function as biomarker for the 
clinical course of the disease, locomotion had to be assessed in WT, treated and 
untreated DMDY/- pigs. Therefore, different approaches, such as treadmill tests and 
supervision with step counters, were examined. Due to the occurrence of sudden 
arrhythmia-induced death of DMDY/- pigs in low stress situations (e.g. handling 
such as weighing and blood taking, veterinary accompanied transportation, or 
ranking order fights between littermates), the performance of treadmill tests was 
not feasible. Step-counters to objectively monitor activity and resting periods and 
to compare the numbers of steps were likewise figured out to be inappropriate when 
used for pigs kept in groups, as littermates damaged the detectors affixed to the hind 
limbs. 
Therefore, a video surveillance system was installed monitoring the animals 24 
hours on seven days a week (24/7) and the obtained video data was analysed with 
regard to motion patterns and activity. As major advantage when compared to 
treadmill tests, video surveillance did not require interaction with the animals, 
facilitating a random and objective evaluation. Furthermore, a current lack of 
motivation of the individual animal or a reluctance to move did not influence 
analyses, as always 24 hours at a time were evaluated. As further benefit, errors of 
assessment due to interaction triggered behavioral changes were avoided. 
Furthermore, analyses could be repeated to avoid errors of observation. 
As stated in Klymiuk et al. (2013), dystrophin-deficient pigs exhibit striking muscle 
weakness, occurring as reduced mobility in comparison with age-matched WT 
controls. To validate the effect of DMD treatment by somatic gene editing on 
muscle function, the activity of age-matched WT, treated and untreated DMDY/- 
pigs was evaluated and compared. Therefore, a total of n = 12 animals (n = 4 male 
IV. Results   92 
WT pigs, n = 2 untreated DMDY/-, n = 2 i.m. injected DMDY/- pigs, n = 4 high dose 
i.v. injected DMDY/- pigs), were analyzed due to their behavior and activity on day 
64 of life (64.4±3.5 days). As i.m. injection of G2-AAV9-Cas9-gE51 was attributed 
exclusively to the muscles of one side of the body, and no behavioral changes or 
functional impairment was expected in these animals when compared to untreated 
DMDY/- pigs, all i.m. treated DMDY/- and untreated DMDY/- animals were 
considered as one group, in the further designated as DMDY/- untreated. 
As shown in Figure 37a, untreated DMDY/- pigs showed a significantly decreased 
standing time (270±29 min/24 h) when compared to male age-matched WT 
littermates (429.3±33.5 min/24 h), consistent with premature fatigue. In high dose 
i.v. treated DMDY/- pigs, the total duration of standing events was significantly 
(p<0.05) increased (388.8±20.7 min/24 h). Additionally, the average duration of 
standing events in untreated DMDY/- pigs (3.05±0.69 min) was as a trend shorter 
than in WT pigs (5.97±1.19 min), but increased after high dose i.v. treatment 
(5.89±1.08 min). However, these differences were not statistically significant (Fig. 
37b). 
 
Figure 37: Continuous recording of motion patterns. Quantification of a, total 
and b, average duration of standing events per pig, performed for n = 4 WT, n = 4 
DMDY/- untreated and n = 4 DMDY/- high dose i.v. treated pigs on day 64.4±3.5 of 
life. Statistics: one-way ANOVA with Bonferroni’s multiple comparison test, 
results are presented as mean±s.e.m. 
 
To highlight the above described impression of an increased duration of standing 
periods observed in high dose i.v. treated DMDY/- animals, timelines of the 24 h 
video monitoring were generated, showing the frequency of adopting an upright 
posture. Figure 38 exemplarily shows timelines for a WT, an untreated and a high 
dose i.v. treated DMDY/- pig. 
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Figure 38: Representative timelines for 24 h video monitoring. 24-hour timelines of n = 1 WT, n = 1 untreated DMDY/- and n = 1 high dose i.v. 
treated DMDY/- pig are shown. Standing in upright posture is marked in blue color compared to lying or sitting posture. Generated timelines stress the 
impression of an increased standing duration in high dose i.v. treated DMDY/- compared to untreated DMDY/- pigs. However, no significant differences 
were found between WT, untreated DMDY/- and high dose i.v. treated DMDY/- pigs. 
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With instantaneous sampling the instant picture of every fifth minute (measured 
down to the centisecond) within 24 hours was evaluated in regards to activity versus 
lying or sitting posture. The number of activity events within 24 h significantly (p 
<0.05) decreased in untreated DMDY/- pigs (54.3±7.5 activity events/24 h) 
compared to WT pigs (82.8±7.7 activity events/24 h). High dose i.v. treatment 
increased the activity of DMDY/- pigs almost to WT levels (76.5±4.0 activity 
events/24 h). In Figure 39 data for all n = 12 animals (n = 4 WT, n = 2 DMDY/- i.m., 
n = 2 DMDY/- untreated, n = 4 DMDY/- high dose i.v. treated) is shown. Here, 
DMDY/- untreated and DMDY/- i.m. treated pigs are again splitted into two groups, 
as a difference in the number of activity events between these two groups was 
observed. 
 
Figure 39: Instantaneous sampling of activity profiles. n = 12 pigs ( n = 4 WT, 
n = 2 DMDY/- i.m., n = 2 DMDY/- untreated, n = 4 DMDY/- high dose i.v. treated) 
were analysed. Activity versus lying or sitting posture was evaluated at every fith 
minute in 24 hours. Every box shows the activity pattern of one animal in 24 hours. 
Activity is coloured in orange, lying or sitting posture is colored in blue. White 
numbers in the boxes represent the sum of activity events counted for each box (i.e. 
animal). 
 
During evaluation of the surveillance material, several additional individual 
behavior patterns were detected, such as pattering of the hind limbs, maintaining a 
sitting posture over an extended period, getting up over a sitting posture instead of 
immediate rising or eating in lying posture. Pattering of the hind limbs was observed 
for n = 2 animals (n = 1 i.m. treated DMDY/- and n = 1 high dose i.v. treated DMDY/- 
pig). However, for the high dose i.v. treated DMDY/- animal the behavior was 
observed only one time in 24 h, compared to 7 times in 24 h for the i.m. treated 
DMDY/- animal. n = 1 i.m. treated DMDY/- pig showed positioning of the hind limbs 
in cranial direction during standing, leading to a frequent sliding away of the hind 
limbs. The same animal showed pattering of the hind limbs and eating in lying 
posture. For n = 7 animals (n = 2 WT, n = 1 untreated DMDY/-, n = 2 i.m. treated 
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DMDY/- and n = 2 high dose i.v. DMDY/-) getting up over a sitting posture or the 
maintainance of a sitting posture over an extended period was observed. As animals 
of all groups showed this behavior it was approved as normal individual behavior. 
However, one untreated and one i.m. treated DMDY/- pig showed severely 
prolonged sitting periods at nearly every getting up. n = 1 untreated DMDY/- animal 
showed breathing through the mouth, consistent with stenotic breathing or limited 
respiratory function. For n = 3 pigs (n = 1 untreated, n = 1 i.m. treated and n = 1 
high dose i.v. treated DMDY/-) eating in lying posture was observed. 
5.4. Off-target analysis 
As described in Moretti et al. (2020), two approaches were used to detect possible 
off-target effects triggered by the treatment with G2-AAV9-Cas9-gE51. First, 
targeted sequencing was used to detect mutations at the most likely predicted off-
targets. Second, whole genome sequencing was performed as holistic approach to 
detect further potential off-target mutations. 
Regarding the first approach, no mutations were found in the five most likely 
predicted sites for off-target effects. In the treated samples, no concordant 
alterations were found for the insertions or deletions of bases (INDELs) in the target 
regions. The observed mean alteration frequency of 0.01% (SD±0.3) ranged within 
the background error level of the DNA sequencer (0.1%). 
By whole-genome sequencing in isogenic human DMDΔ51-52 iPSCs compared to 
the parental human DMDΔ52 iPSC line, a total of 88 INDELs and 769 single 
nucleotide variants (SNVs) were identified. The performed minimal Levenshtein 
distance analysis, calculating the smallest number of mismatches between one of 
the two DMD-E51 gRNAs and a putative off-target mutation site revealed that at 
least 7 operations (insertions, deletions or base exchanges) around a variant were 
required to match a gRNA (Figure 40), indicating that the identified INDELS and 
SNVs do not represent off-target effects of CRISPR-Cas treatment. 
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Figure 40: Minimal Levenshtein distance. The Levenshtein distance is the 
minimum number of mismatches (here: 7 mismatches) between a gRNA and a 
putative off-target mutation site. As no variants with <7 mismatches were found, 
the identified INDELS and SNVs cannot be considered as off-target effects of G2-
AAV9-Cas9-gE51 treatment. 
 
6. Multispectral optoacoustic tomography detects collagens 
in skeletal muscle 
As dystrophic muscle tissue is gradually replaced by connective and fatty tissue, 
MSOT was validated as new noninvasive in vivo diagnostic imaging biomarker to 
assess the degree of muscle deterioration, apparent as fibrotic muscular 
transformation in DMD patients (Klingler et al., 2012). Therefore, the feasibility of 
the MSOT technology was first demonstrated in the DMD pig model, and later 
applied to pediatric patients. The complete results are published in Regensburger et 
al. (2019). 
In the proof-of-concept study MSOT imaging of n = 17 piglets (n = 10 WT and n = 
7 DMDY/-) was performed within 1-3 days after birth. In the longitudinal study, n = 
11 piglets (n = 6 WT and n = 5 DMDY/-) underwent MSOT imaging at 4 time-points 
(week 1, week 2, week 3, week 4). 
In the second step, applying the approach to pediatric patients (not shown), MSOT 
collagen signal was shown to highly correlate to the patients’ functional status. 
When comparing MSOT imaging to magnetic resonance imaging, MSOT was 
found to provide additional information on molecular features. 
All analysis of MSOT signals, as well as the bioanalytical analyses of collagen and 
protein content of individual muscle specimens and analysis of stained histologic 
slices of individual skeletal muscles were performed by the Department of 
Pediatrics and Adolescent Medicine, University Hospital Erlangen, FAU Erlangen 
Nuremberg, Erlangen. 
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6.1. Proof-of-principle study for collagen detection in DMDY/- pigs 
Collagen detection in DMDY/- pigs by MSOT in single measurement 
As described in Regensburger et al. (2019), in the proof-of-concept study a total of 
n = 58 scans (n = 34 in WT and n = 24 in DMDY/- piglets) were acquired from 
independent muscle regions of n = 17 animals (n = 10 WT and n = 7 DMDY/-piglets) 
within day 1-3 of life. For every scan, a region of interest (ROI) was drawn within 
the assessed muscle, using ultra-sound guidance, exemplarily shown in Figure 41. 
 
 
Figure 41: Representative presentation of skeletal muscle images from WT 
and DMDY/- piglets, generated by MSOT imaging. ROIs are determined in the 
reflective ultrasound computed tomography (RUCT) image, which is used to 
anatomically guide the investigator. After spectral unmixing of the optoacoustic 
signals, qualitative differences of collagen signals between WT and DMDY/- are 
visible (turquoise). In the merged RUCT/MSOT image, the collagen distribution 
within the muscle is visualized (adapted from Regensburger et al., 2019). 
 
For the collagenmean/max signal, a significant difference was observed, when all 
independent muscle regions were compared between the two groups (n = 34 WT / 
n = 24 DMDY/-), as shown in Figure 42a-b (collagenmean = 14.41±2.66 a.u. versus 
23.14±3.87 a.u. and collagenmax = 27.68±2.72 a.u. compared to 41.05±7.43 a.u). 
When comparing 2d MSOT collagenmean/max signal per animal between groups (n = 
10 WT and n = 7 DMDY/- piglets), likewise a highly significant difference was 
observed between MSOT signals of the two groups, as shown in Figue 42c-d 
(collagenmean = 14.23±1.96 a.u. compared to 22.67±3.59 a.u. and collagenmax = 
27.70±1.67 a.u. versus 41.01±5.16 a.u.). For oxygenated, deoxygenated and total 
hemoglobin no differences in MSOT signal levels were observed (P > 0.05) (not 
shown). 
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Figure 42: Diagrams represent the MSOT collagen signals from WT and 
DMDY/- piglets generated within the proof-of-concept study. MSOT collagen 
signals are shown in arbitrary units (a.u.). a-b, 2D MSOT collagenmean/max signal, 
with each filled circle representing one MSOT signal per independet skeletal 
muscle region (n = 34 scans in WT and n = 24 scans in DMDY/- piglets). c-d, 
Comparison of 2D MSOT collagenmean/max signal per animal between groups (n = 
10 WT and n = 7 DMDY/- piglets). Each filled circle represents the mean MSOT 
signal of an independent animal. Statistics: Two-tailed independent samples t-test, 
Welch’s correction in cases of unequal variances, Mann-Whitney U-test if 
assumption of normal distribution was violated. Data are shown as mean±s.d. 
(adapted from Regensburger et al., 2019). 
 
Receiver operator characteristic analysis 
To distinguish between muscles from WT and DMDY/- piglets, an exploratory 
receiver operator characteristic (ROC) analysis was performed (Figure 43), plotting 
the true-positive rate (sensitivity) against the false-positive rate (specificity). For 
the obtained 2D collagenmean/max signals the area under the curve (AUC), giving the 
discriminatory abilities of the method, with the respective 95% CI were calculated. 
MSOT-derived imaging parameters showed an excellent ability to distinguish 
healthy (WT) from diseased muscles (DMDY/-). 
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Figure 43: Receiver operating characteristic (ROC) curve. The area under the 
curve (AUC) and 95% confidence inerval (CI) show the ability of MSOT collagen 
signals to distinguish between healty (WT) and diseased muscles (DMDY/-). 
Analyses were performed using data from n = 58 independent muscle regions (n 
=34 WT, n = 24 DMDY/-) of n = 17 independent animals (n = 10 WT and n = 7 
DMDY/- piglets). ROC analysis showed a high specificity and a high sensitivity for 
collagenmean/max, indicating that the collagen signals detected by the MSOT 
technology show a high ability to distinguish between muscles of WT and DMDY/- 
pigs (adapted from Regensburger et al., 2019). 
 
Histologic examination reveals severly increased collagen content in skeletal 
muscle of DMDY/- piglets 
By H.E. staining, disrupted muscular structure was observed in the previously 
scanned muscle regions of DMDY/- piglets. DYS1 immunohistochemistry 
confirmed the total loss of dystrophin in DMDY/- piglets. Masson Trichrome (MT) 
and Sirius red (SR) staining revealed an increased collagen content in skeletal 
muscle of DMDY/- compared to WT piglets (Figure 44a). Quantitation of collagen 
in MT and SR stained histological sections of skeletal muscle of WT and DMDY/- 
piglets confirmed the increased collagen content in skeletal muscle of DMDY/- 
piglets (Figure 44b). 
IV. Results   100 
 
Figure 44: Histological examinations reflect the increase of collagen in skeletal 
muscle of DMDY/- piglets. a, Representative skeletal muscle samples of the 
previously imaged regions from WT (upper row) and DMDY/- piglets stained with 
HE, DYS1 immunohistochemistry, MT and SR. Scale bars: 100 µm in main 
micrographs, 50 µm in inserts. b, Quantitation of collagen in MT and SR stained 
histological sections of skeletal muscle of WT and DMDY/- piglets and correlations 
between the MSOT collagen signals and positively stained collagen areas (MT: rs= 
0.58; SR: rs=0.65) are shown. Statistics: Two-tailed independent samples t-test, 
Welch’s correction in cases of unequal variances, Mann-Whitney U-test if 
assumption of normal distribution was violated. Data are shown as mean±s.d. 
Correlations are given by the Spearman correlation coefficient (rs), two-tailed test. 
Black lines display linear regression (adapted from Regensburger et al., 2019). 
 
6.2. Quantitative visualization of disease progression in DMDY/- pigs 
In a subsequent longitudinal study in the DMDY/- pig, the feasibility of MSOT for 
the in vivo monitoring of disease progression was conducted as described in 
(Regensburger et al., 2019). Therefore, n = 11 male piglets (n = 6 WT and n = 5 
DMDY/-) were used, of which n = 1 WT piglet was excluded after the first imaging, 
to generate an identical group size. The imaging was performed in week 1 (days 1 
or 2), week 2 (days 8 or 9), week 3 (day 15 or 16) and week 4 (days 22 or 23) of 
life to quantitatively visualize the early-stage progression of the disease. n = 5 
animals (n = 3 WT and n = 2 DMDY/-) completed the full experimental protocol and 
were euthanized after fulfillment of all four MSOT imaging sessions (at day 24 and 
day 26 of life). n = 3 DMDY/- piglets died or had to be euthanized prematurely (at 
day 5, day 6 and day 7 of life), and thus n = 2 corresponding age-matched WT 
piglets were sacrificed (at day 5 and 6 of life). 
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Figure 45: Longitudinal MSOT study to quantitatively visualize early-stage 
disease progression in DMDY/- piglets. Imaging sessions were performed in week 
1, 2, 3 and 4 of life. Initially, n = 11 animals (n = 6 WT and n = 5 DMDY/-) were 
used for MSOT imaging. N = 3 DMDY/- died or were euthanized in week 1 of life, 
thus n = 2 age-matched WT piglets were sacrificed as controls. N = 5 piglets (n = 3 
WT and n = 2 DMDY/-) completed the full experimental protocol (adapted from 
Regensburger et al., 2019). 
 
In week 1, n = 44 independent muscles (biceps femoris and triceps muscle, both 
bilaterally; equivalent to n = 24 WT and n = 20 DMDY/-) were imaged. Throughout 
the whole 4-week experiment, n = 20 independent muscles (n = 12 WT and n = 8 
DMDY/-) were investigated. 
By in vivo MSOT imaging over time visible tissue changes consistent with 
increased fibrotic transformation of the skeletal muscle tissue were observed in the 
DMDY/- cohort, as exemplarily shown in Figure 46a. Likewise as in the previous 
proof-of-principle study, a significant MSOT collagenmean/max signal difference was 
found for both, 2D and 3D MSOT imaging, in all independent muscle regions of 
WT and DMDY/- for all imaging timepoints of the study. For the remaining n = 5 
animals (n = 3 WT and n = 2 DMDY/-), imaged at every time point of the 4-week 
experiment, a steady increase in collagen signals (2D and 3D MSOT) over the time 
was observed only in independent muscle regions of DMDY/- piglets (Figure 46b). 
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Figure 46: Early-stage disease progression quantitatively visualized over time 
by MSOT imaging. a, Representative 3D MSOT images of one DMDY/- piglet for 
all 4 imaging timepoints. Color coded maps show mean collagen in turquoise, total 
hemoglobin in red and lipid in yellow. b-c, 2D and 3D MSOT collagenmean signals 
in muscles of WT and DMDY/- are quantified over time. b, MSOT signals of 
independent muscles of all WT and DMDY/- animals were compared to each other 
at all four time points (w1-w4), with each filled circle representing one MSOT 
signal per independent muscle region. Data are shown as mean±s.d. c, MSOT 
signals of independent muscles of the WT and DMDY/- animals surviving over the 
whole 4-week experiment were compared to each other at all four time points (w1-
w4), with each filled circle/ square representing mean±s.d. MSOT signals of 
independent muscle regions over the course of the study. Statistics: Two-tailed 
independent samples t-test (Welch’s correction in case of unequal variance), Mann-
Whitney U-test if the assumption of normal distribution was violated, Bonferroni-
Holm adjustment to control type I error due to four comparisons (w1-4) for each 
parameter (adapted from Regensburger et al., 2019). 
 
At the time of the last imaging (week 4), clearly evident differences between the 
WT and the DMDY/- cohort were found in vivo and ex vivo, both macroscopically 
and histologically, as exemplarily shown in Figure 47a. Using histological and 
bioanalytical collagen quantification, within 4 weeks increased collagen deposition 
of up to 248% (from baseline) for MT staining (10.40±5.41 in week 1 to 25.80±7.93 
in week 4, p = 4.94 × 10-5) and 170% (from baseline) for SR staining (19.59±5.40 
in week 1 to 33.30±5.71 in week 4, p = 3.63 × 10-5) were observed in the DMDY/- 
cohort (Fig. 47b). The content of total collagen (TC) per total protein (TP) increased 
by up to 139% (77.57±38.80 TC/TP µl/mg in week 1 to 107.80±42.02 TC/TP µl/mg 
in week 4, p = 0.12) (Figure 47c). 
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Figure 47: Histologic examinations reflect the increase of collagen in skeletal 
muscle of DMDY/- piglets visualized over time by MSOT imaging. a, 
Macroscopic and histologic alterations in skeletal muscle of 4-week-old WT (upper 
row) and DMDY/- pigs. Scale bars: 1 cm in macroscopic images, 100 µm in main 
histological images, and 50 µm in inserts. b, Quantification of areas stained positive 
for collagen by MT and SR staining of muscles of 1-week and 4-week-old WT and 
DMDY/- piglets. c, Quantitation of total collagen abundance in WT and DMDY/- 
piglets. Statistics: Two-tailed independent samples t-test, Welch’s correction in 
cases of unequal variances, Mann-Whitney U-test if assumption of normal 
distribution was violated. Data are shown as mean±s.d. (adapted from 
Regensburger et al., 2019). 
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6.3. Quantitative proteome analysis confirms muscular fibrosis and the 
potential origin of MSOT signals 
To confirm muscular fibrosis in DMDY/- pigs as the potential origin of MSOT 
signals, quantitative proteome analysis was performed in cooperation with Thomas 
Fröhlich and Florian Flenkenthaler of the Gene Center - LAFUGA, LMU Munich. 
Therefore, n = 16 shock-frozen independent muscle samples (n = 8 WT, n = 8 
DMDY/-) of n = 8 independent piglets (n = 4 WT and n = 4 DMDY/-) were analyzed. 
Thereby, a total of 2820 different proteins was identified. 
In a principal component analysis and an unsupervised hierarchical clustering of 
LFQ values for biceps femoris and triceps brachii muscle specimens of 1-week and 
4-week-old WT and DMDY/- piglets the proteomes separated exactly according to 
the genotype and the age (Fig. 48). When comparing the collagens of of the both 
genotypes, collagen VI was found to be already enriched in 1-week-old DMDY/- 
piglets, whereas in 4-week-old DMDY/- piglets, besides the most abundant collagen 
VI, also the collagens III and XIV were increased. 
 
Figure 48: Holistic proteome analysis of skeletal muscle tissue from 1- and 4-
week-old WT and DMDY/- piglets, previously imaged by MSOT. a, 
Unsupervised hierarchical clustering of LFQ values for previously imaged triceps 
brachii and biceps femoris muscle specimens of 1- and 4-week-old WT and DMDY/- 
piglets. Z-score-normalized expression values for the different proteins are color 
coded. b, Principal component anaysis, with each symbol equivalent to an 
individual sample (n = 4 samples per group) (adapted from Regensburger et al., 
2019). 
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V. DISCUSSION 
DMD is a severe progressive muscular wasting disease, which leads to premature 
death of the affected patients (Blake et al., 2002). Even though there is considerable 
progress concerning the therapy of DMD and many genetic approaches have been 
tested in the past few years (reviewed in Birnkrant et al., 2018b) there is no cure for 
the most frequent mutations triggering the disease. Moreover, diagnostic tools to 
assess disease progression in DMD are still initial. Most clinical trials rely on 
measures of muscle function and strength only (Zaidman et al., 2017). Especially 
in young pediatric DMD patients, noninvasive in vivo imaging modalities to 
monitor disease progression are of need. Animal models play a major role in the 
establishment of new treatments and the discovery and validation of new 
biomarkers (Aigner et al., 2010). However, in the case of DMD, the existing animal 
models display advantages but also several limitations, depending on the study 
question (McGreevy et al., 2015). Pigs as animal models have been proven to be 
appropriate with regard to various applications in the field of biomedical research 
(Aigner et al., 2010). Therefore, a tailored DMD pig model, lacking exon 52 in the 
DMD gene (DMDΔ52), has been generated at our institute (Klymiuk et al., 2013). 
In this work we aimed to establish a stable DMD breeding herd to obtain large 
animal numbers, first for the development of a new therapeutic approach aiming at 
somatic gene editing, and second for the validation of a new noninvasive in vivo 
imaging biomarker for DMD. 
The DMD pig generated by breeding as adequate animal model for DMD 
In this work, a total of n = 97 affected DMDY/- piglets were produced by breeding 
over a period of approximately four years. The DMDY/- genotype was confirmed by 
PCR analysis of DNA isolated from individual tail biopsies, with one primer pair 
detecting the intact DMD allele and a second primer pair detecting the mutated 
(DMDΔ52) allele by neomycin selection cassette. All genotypes (WT male, WT 
female, DMDY/- and DMD+/-) were inherited equally following Mendelian laws. 
As rearing of DMDY/- piglets was highly complicated by a reduced general conditon 
of newborn affected animals, different rearing conditions for the period of suckling 
were established and evaluated. Moreover we took a closer look at the cause of the 
reduced general condition present in most of the newborn DMDY/- piglets. DMDY/- 
pigs generated by breeding were characterized with regard to expression of 
dystrophin, creatine kinase levels, body weight, mortality, macroscopic and 
histologic phenotypic characteristics of skeletal muscle, macroscopic and histologic 
gastrointestinal alterations and muscle function. 
All DMD models which are severely affected by the disease, such as double-
knockout mice (either utrophin/dystrophin or integrin/dystrophin) or different 
dystrophin-deficient dog breeds, are difficult to generate and to care for (Ambrosio 
et al., 2009; McGreevy et al., 2015). Therefore, in our DMD pig breeding herd, we 
evaluated different rearing conditions with regard to survival chances. In all cases, 
rearing of affected DMDY/- piglets required birth monitoring and intense nursing 
during the first days of life. A reduced general condition of newborn DMDY/- piglets 
by reason of a severe premature expression of the DMD phenotype, led to increased 
losses of animals due to severe energy deficit and/or crushing by the sow. To reduce 
losses caused by crushing, the separation of the piglets from the sow after 12 h of 
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supervised suckling at the sows’ teats and subsequent motherless rearing in an 
artificial rearing unit was evaluated. With 83% the mortality in this approach was 
quite high. As the preweaning mortality is highly associated with colostrum intake 
even in healthy newborn piglets (Declerck et al., 2016), the colostrum intake was 
seen as crucial factor and suckling at the sows’ teats was prolonged in subsequent 
rearing approaches. Thus, in a second approach “48 h of supervised suckling at the 
sows’ teats” was evaluated. With 56% DMDY/- piglets surviving this approach, a 
definite advance was achieved. In a third and fourth approach, rearing conditions 
were further improved step by step, with the main focus on supervision of the 
individual energy demand and individual colostrum supplementation. A generally 
satisfactory decrease of mortality down to 30% was achieved within the last rearing 
approach. 
When characterizing DMDY/- pigs generated by breeding, a high accordance of 
phenotypic characteristics compared to human DMD patients was found. A 
comparison of disease severity and development and expression of the phenotype 
in dystrophin deficient mice, dogs, pigs and humans is shown in Table 10. 
Table 10: Comparison of phenotypic characteristics and disease severity in 
dystrophin deficient mice, dogs, pigs and humans (adapted from Duan, 2015; 
and McGreevy et al., 2015). 
Disease Phenotype 
 mdx-Mice Dogs Pigs Humans 
Body weight at 
birth 
= normal = normal < normal = normal 
Grown-up body 
weight 
≥ normal < normal < normal < normal 
Disease 
progression 
mild, non-
progressive 
severe, 
progressive 
severe, 
progressive 
severe, 
progressive 
“Honeymoon” 
Period 
no (mild, 
non-
progressive 
phenotype) 
at 6-10 months 
of age 
n.d. 
between 5-8 
years of 
age, 
symptoms 
are often 
stabilized or 
even 
slightly 
improved 
Loss in 
ambulation 
rare rare 
no, but 
progressive 
activity 
decrease 
Wheelchair-
bound by 
early 
teenage 
Life span 
= 75% of 
normal (≈ 22 
months of 
age) 
= 25% of 
normal (≈ 3 
years of age) 
see Kaplan-
Meier 
curve (≈ 4 
month of 
age) 
= 25% of 
normal (≈ 
20 years of 
age) 
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Neonatal death rare 
15-30% within 
2 weeks after 
birth (likely due 
to diaphragm 
failure) 
49.45% 
within 1 
week after 
birth 
rare 
Age at first 
symptoms 
≥ 15 months 
birth to 3 
months 
birth 
(reduced 
general 
condition) 
to latest 1 
month 
(reduced 
weight 
gain) 
2-4 years 
Muscle wasting minimal until 
≥ 15 months 
progressive progressive progressive  
Limb weakness n.d. 
2 to 3 months of 
age 
yes, partly 
(see 
IV.5.3.) 
≈ 3 years 
Creatine kinase 
(CK) 
severely 
elevated 4 
severely 
elevated 5 
severely 
elevated 
severely 
elevated 
Respiratory 
Dysfunction 
no7 
severe, 
progressive3 
partly, 
severe & 
progressive 
(see IV.5.3) 
moderate to 
severe, 
progressive 
Gastrointestinal 
impairment 
decreased 
intestinal 
transit and 
fecal output1 
detected 
(dysphagia, 
salivation and 
mega-
esophagus)2 
partly 
detected 
(severe & 
progressive 
obstipation) 
markedly 
disturbed in 
several 
individuals8 
ECG 
abnormalities 
frequent frequent n.d. (work 
in progress) 
frequent 
Cardiomyopathy 
≥ 20 months; 
DCM in 
female and 
HCM in 
male mice 
detectable at 6 
months via 
ECG 
detectable 
6; sudden 
cardiac 
death due 
to mild 
stressors 
evident at 
16 years 
Cognitive & 
CNS defects 
mild n.d. n.d. (work 
in progress) 
1/3 of 
DMD 
patients Histopathology & Biomolecular Changes 
 mdx-Mice Dogs Pigs Humans 
At birth minimal minimal severe minimal 
Acute necrosis 
of muscle fibers 
2-6 weeks none 1
st week of 
life 
none 
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Limb muscle 
fibrosis 
minimum in 
adult 
extensive and 
progressive 
extensive 
and 
progressive 
extensive 
and 
progressive 
Skeletal muscle 
regeneration 
robust poor poor n.a. 
Alterations in 
the 
gastrointestinal 
tract 
increased 
concentration 
of collagen 
fibers in 
submucosal 
region1 
Not reported 
Colon: 
putative 
increase of 
Type I 
collagene 
fibers 
Esophagus: 
marked 
fibrosis, 
loss of 
circular and 
longitud. 
Muscle9; 
stomach: 
loss of 
smooth 
muscle, 
marked 
fibrosis10 
1(Feder et al., 2018; Mulè et al., 2010), 2(Ambrosio et al., 2009), 3(DeVanna et al., 
2014; Kornegay, 2017), 4(Spurney et al., 2009), 5 (Sharp et al., 1992), 6(Moretti et 
al., 2020), 7 (Burns et al., 2019), 8 (Kraus et al., 2016), 9 (Leon et al., 1986), 10 
(Barohn et al., 1988) 
 
Tabe 10 highlights the limitations of the mdx-mice, compared to dogs and pigs as 
model of DMD. There are several different mouse models of DMD. However, none 
of them appropriately mirrors the phenotype of DMD patients. Furthermore, the 
mouse as animal model imposes limitations on analysis, such as dose-finding in 
therapeutic trials of new treatments, due to its small body size. With regard to the 
body size, the dog model of DMD is a more appropriate animal model for DMD. It 
furthermore reflects most of the phenotypic characteristics of DMD (Brinkmeyer-
Langford and N Kornegay, 2013). Nevertheless, the big disadvantage of all DMD 
dog models is the high phenotypic dog-to-dog diversity. Great individual variations 
result in difficulties of reaching the size of an experimental group and in showing 
clear statistically significant results (reviewed in Wells, 2018). In our DMD pig 
breeding herd, likewise a variation in phenotype was observed. Several newborn 
DMDY/- piglets needed to be euthanized due to a severely reduced general 
condition. In part, these animals showed gross anatomic muscle alterations. 
Concerning histological findings, in the examined short-term surviving DMDY/- 
piglets local calcium deposits were observed in the striated muscles, whereas no 
foci with calcifications were found in muscles of examined long-term surviving 
DMDY/- piglets. Apart from this, some DMDY/- piglets were observed with 
gastrointestinal impairment. 
Similar to the DMD dog models there is also a variability in phenotype in the short-
term surviving DMDY/- cohort, which might potentially influence the results of 
studies. However, a stable phenotype can be ensured by selecting only the long-
term surviving DMDY/- animals as experimental cohort, as it was done for the 
therapeutic trial which is part of this work. Statistically relevant experimental group 
sizes could be obtained. 
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In human DMD patients the first clinical manifestations of the disease appear in the 
early childhood (average at 2.5 years) (Ciafaloni et al., 2009). Compared to human 
DMD patients, DMD pigs show an accelerated course of the disease. The weight at 
birth of affected piglets was already reduced in comparison to WT littermates. Body 
weight increase was delayed and always stayed below the mean body weight of 
male WT littermates. Severe histologic alterations consistent with the DMD 
phenotype were observable already in newborn DMDY/- animals. In adolescent 
DMDY/- pigs, histologic samples showed a severe DMD phenotype as well. An 
increase of connective tissue was highly apparent in newborn as well as in adolecent 
DMDY/- pigs, whereas fatty infiltration, which was expected to be likewise 
increased in adolecent DMDY/- animals, was putatively low. These observations are 
in line with previous reports about findings in human DMD patients: the 
intramuscular fat content in biceps and quadriceps femoris muscles of DMD 
patients ranged from 0.89±0.70% (Bettica et al., 2016) to 3.4±4.1%, whereas 
fibrosis (peri- and endomysial) exceeded 30% (Desguerre et al., 2009). The 
accelerated appearance of the phenotype can be beneficial with regards to 
therapeutic trials, as ameliorations of the phenotype due to a therapeutic agent can 
be validated prematurely, compared to other DMD animal models (see Table 10), 
reducing the total experimental duration. 
Concerning the gastrointestinal impairment found in some DMDY/- piglets, a more 
detailed examination of the abdominal symptoms and correlating pathologic 
alterations is in progress. However, impairment of the gastrointestinal function, 
mainly occuring in the form of constipation, is described as very frequent 
complication in DMD patients (Kraus et al., 2016). Therefore, the examination of 
the underlying cause of gastrointestinal impairment in DMD is of need. First 
investigations in DMDY/- piglets showed an increased survival rate after therapeutic 
measures (treatment with laxatives and digestion-aiding nutritional supplements of 
all n = 7 DMDY/- piglets of 2 litters, of which one or more animals showed 
gastrointestinal symptoms). This supports the in Birnkrant et al. (2018b) indicated 
importance of gastrointestinal and nutritional management. As possible reason for 
gastrointestinal problems in DMDY/- piglets, hypomotility or atonia, caused by a 
reduced innervation, is discussed. As second hypothesis, an increase of fibrotic 
tissue in the intestinal wall might lead to strictures, disturbing the intestinal passage 
and leading to obstruction, as found in human patients with ulcerative colitis (Parray 
et al., 2012). As the DMD pig model seems to mirror DMD in regards to 
gastrointestinal impairment, investigations of this aspect in the DMD pig can 
promote the research in this area. 
Identification of potential modifier genes in the DMDY/- pig 
The manifestation and severity of the DMD phenotype in human DMD patients can 
be strongly influenced by modifier genes. Several modifying loci have already been 
identified, but the overall knowledge in this field still is initial and incomplete. As 
individual differences in disease progression highly complicate the interpretation 
of results of clinical trials, a more detailed knowledge about modifier genes in DMD 
is of need (reviewed in Aartsma-Rus and Spitali, 2015). In human DMD patients, 
as well as in the mdx mouse, most studies investigating potential genetic modifiers 
rely on previously drawn up hypotheses. Thus, most of the discovered candidate 
genes are pre-specified genes of interest, which are already known to play a role in 
muscle health and with their pathways beeing already well understood. 
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Instead of investigating only putative mutations, genome-wide combined linkage 
disequilibrium and linkage analyses (cLDLA) scan the whole genome for common 
genetic variations. As hypothesis-free, unbiased approach, cLDLA is able to 
identify also unexpected associations in DMD. To investigate the origin of the 
variable survival time observed in our DMDY/- pigs generated by breeding, cLDLA 
was applied for a selected subset of animals. 
A scoring system, to accurately identify subgroups which share the same potential 
modifiers was developed. In human individuals with DMD, the the age at loss of 
ambulation (LoA) is used to determine subgroups with potential common genetic 
modifiers (Bello et al., 2016). As the DMDY/- animals only show an activity 
decrease but no LoA, and all other detected phenotypic variations in DMDY/- pigs 
were only imprecisely determinable, the survival time was chosen as a most reliable 
categorizing parameter. Color-coded partial pedigrees were created to illustrate the 
survival time of the individual animals at first sight. The SNP-genotypes were 
analysed using two different aspects of survival as criterion: PhContinous 
categorized “length of life in days”; and PhDiscrete, categorized phenotype 1 as 
short-term survivors (death within 2-9 days of life) and phenotype 2 as long-term 
survivors (death within ≥ 10 days of life). Using PhDiscrete, a splitting in these two 
subgroups of 1:1.7 (equivalent to n = 19 short-term survivors and n = 33 long-term 
survivors) was shown. The uneven distribution of the two subgroups is explainable 
by a lower number of short-term survivors due to an exlcusion of all short-term 
survivors which were crushed or possibly crushed by the sow or died due to an 
uncertain reason (e.g. infection). 
Using PhContinous and PhDiscrete as criteria, so far no genome-wide significant 
quantitative trait loci (QTL) responsible for the variable phenotype in DMDY/- pigs 
could be identified. However, with a continously increasing number of animals 
included in the study, the likelihood ratio test (LRT) curves became smoother and 
less peaked. On some chromosomes highly indicative values were observable. On 
other chromosomes indicative, but no marked peaks were found. On most 
chromosomes an evenly low, homogenous pattern of LRT-values was observed.  
One of the most researched genetic modifieres in human DMD patients is SPP1, 
encoding SPP1 or Osteopontin. According to the Sus scrofa reference genome 
assembly Sscrofa11.1 (Genome - Assembly - NCBI) SPP1 is located on pig 
chromosome 8 (131,077,787-131,085,264 bp). Here used cLDLA mapping 
procedure mapped an indicative QTL on pig chromosome 8 at 109.7 Mb (LRT = 
12.6). However, this indicative QTL is far (21.4 Mb) from candidate modifier 
SPP1. 
LTBP4, encoding latent TGFB binding protein 4, is another frequently researched 
genetic modifier in DMD. It is located at pig chromosome 6 (48,833,008-
48,861,246). In our study pig chromosome 6 displayed an evenly low, homogenous 
pattern of LRT values. No significant LRT value was observable at the LTBP4 
locus. 
For the less researched genetic modifiers ACTN3 (encoding α-actinin-3), CD40 
(encoding CD40 or tumor necrosis factor receptor superfamily member 5, 
TNFRSF5) and THBS1 (encoding thrombospondin-1, THBS1), likewise no 
significant LRT values were observable on the corresponding pig chromosomes. 
Due to these results, the described known modifiers in human DMD patients are 
unlikely to be also responsible for a variable phenotype in our DMDY/- pigs. 
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Supposing monogenic inheritance of underlying modifier, and according to 
previous experiences with cLDLA mapping applied to monogenic traits (Kunz et 
al., 2016), we would expect clear and significant mapping in the here presented 
design. The absence of such clear signal strengthens our presumption, that not only 
one, but several modifying loci reveal the observed phenotypic variation in DMDY/- 
pigs. Therefore, a higher number of animals and, eventually, a more explicit 
classification system, are necesscary for further investigations. According to 
mapping results at this stage we decided not to perform any further candidate gene 
analyses at only indicative regions. 
The DMDΔ52-pig is a suitable animal model for the establishment of new 
treatments 
Animal models play a substantial role in the establishment of new treatments in 
clinical application (Aigner et al., 2010). In this therapeutic trial we showed that the 
DMD pig represents an ideal model for the establishment and validation of a new 
therapeutic approach aiming at somatic gene editing by sequence-specific 
nucleases. 
In human DMD patients 60 - 72% of the disease causing mutations are exon 
deletions (Aartsma‐Rus et al., 2006; Muntoni et al., 2003), located in two 
mutational hot spots: one minor hot spot spanning from exons 2 to 20 and one major 
hot spot between exons 47 and 53 (Den Dunnen et al., 1989; Koenig et al., 1987). 
Exon deletions can lead to a shift of the open reading frame resulting in unstable 
mRNA products, which are subsequently eliminated by nonsense-mediated mRNA 
decay. The consequence is a total loss of the muscle structure protein dystrophin, 
resulting in the typical DMD phenotype. The DMD pig established at our institute 
lacks exon 52 of the DMD gene (DMDΔ52) (Klymiuk et al., 2013). This mutation 
leads to the above described pathway, resulting in a total absence of dystrophin. As 
the deletion of exon 52 is one of the more frequent mutations in DMD patients, the 
generation of DMDΔ52 pigs was considered as appropriate in therapeutical 
research. 
Somatic gene editing restores dystrophin expression and ameliorates muscle 
function in DMDY/- pigs 
The therapeutic approach used in this study is described in detail in Moretti et al. 
(2020). In brief, adeno-associated viral vectors, serotype 9, coated with PAMAM-
G2 nanoparticles and carrying an intein-split Cas9 and a pair of guide RNAs, 
targeting exon 51 flanking sequences (G2-AAV9-Cas9-gE51), were used. G2-
AAV9-Cas9-gE51 was aimed to restore the open reading frame, introducing the 
expession of an internally truncated (DMDΔ51-52), but partially functional, 
dystophin protein, thus converting Duchenne muscular dystrophy into the milder 
Becker muscular dystrophy. 
This principle approach of exon skipping to reframe DMD transcripts has already 
been established using antisense-oligonucleotides (AONs) (Sharp et al., 2011) and 
has been successfully translated into clinical trials (Goemans et al., 2011; Van 
Deutekom et al., 2007). However, the AON-mediated exon skipping only shows a 
limited expression of dystrophin and has solely a temporary effect (Verhaart et al., 
2014). In contrast, somatic gene editing by sequence specific nucleases is able to 
permanently correct the open reading frame and is already confirmed to be more 
effective, as demonstrated in the mdx mouse (Long et al., 2016; Xu et al., 2016). 
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The success of this approach was recently confirmed in a dog model of DMD, 
demonstrating a restored expression of a shortened dystrophin in several muscles 
after i.v. application of AAV9 delivering CRISPR-Cas9 components (Amoasii et 
al., 2018). However, as yet, data demonstrating an improved muscle function due 
to somatic gene editing is still missing. 
Only long term surviving DMDY/- animals were used for the therapeutic trial to 
avoid incorrect interpretation of the results due to phenotypic variations. The results 
show, that G2-AAV9-Cas9-gE51 is capable to restore the disrupted reading frame 
of DMDΔ52 pigs by skipping exon 51. In intramuscularly treated DMDY/- pigs a 
robust expression of internally truncated but partially functional dystrophin was 
detectable in the injected muscle regions. Minimal editing of non-injected muscles 
(contralateral side, diaphragm, heart) due to leakage of the vector into blood-
vessels, was observable. In high-dose systemically treated DMDY/- pigs a broad 
transduction in muscles, including the vital organs such as diaphragm and heart, 
was achieved. 
The expression of dystrophin was confirmed by immunofluorescence staining. 
Among other methods, selected reaction monitoring (SRM) was used to detect 
dystrophin. There are several advantages concerning this method. First, SRM 
allows the sensitive and targeted absolute quantification of proteins out of highly 
complex protein mixtures, such as cell lysates. Second, when compared to classical 
techniques like ELISA/RIA or Western Blot, antibodies, which often have a limited 
specificity and selectivity, are not needed for the SRM approach. Beside the high 
specificity and sensitivity of the technique, a large dynamic range of quantification 
of at least three orders of magnitude is a further benefit. SRM allowed the exact 
quantification of dystrophin, given as “% of normal”. As even low levels of 
dystrophin (>4%) have been estimated to improve muscle function and prolong 
survival, and dystrophin levels approaching 20% were found to prevent the 
development of dystrophic symptoms (Godfrey et al., 2015), the detected 
dystrophin levels of up to 62% (of WT dystrophin level) in i.m. treated and up to 
38% (of WT dystrophin level) in high-dose i.v. treated DMDY/- pigs were counted 
as success of the therapeutic approach. The effective elimination of exon 51 was 
confirmed at the genomic and transcript level. To examine whether the dystrophin 
expression and the maintained muscle integrity are sustained, prolonged studies are 
of need. Likewise, as an irregular distribution of dystrophin expression was 
observable in different analyzed muscle specimens of systemically treated DMDY/- 
pigs, there is still optimization-potential to achieve a more homogeny dystrophin 
coverage. 
The results of the holistic proteome analysis of muscle specimens of high dose i.v. 
treated DMDY/- pigs indicated a partial normalization of proteins, which are 
normally dysregulated in DMD. A principal component analysis revealed, that the 
global protein profile of G2-AAV9-Cas9-gE51-treated muscles resided closer to 
WT than to untreated DMDY/- animals. These results likewise confirmed the 
therapeutic effect of G2-AAV9-Cas9-gE51-mediated somatic gene editing. 
Furthermore, the muscle-damage indicating enzyme creatine kinase was measured 
in serum of all animals. However, only plausible values were used for 
interpretation, whereas implausible values (e.g. blood sample was taken several 
hours after death, or animal died under conditions of severe stress) were excluded 
from analysis. The creatine kinase (CK) levels in high-dose i.v. treated DMDY/- pigs 
decreased in comparison to CK levels measured in untreated DMDY/- pigs. The 
parameter was used as biomarker in evaluating the tested somatic gene editing 
V. Discussion   113 
approach. The decrease of CK levels was interpreted as a reduction of muscle 
damage in high-dose i.v. treated DMDY/- pigs. Elevated CK levels indicate a floride, 
i.e. active, state of the disease. As CK elevation is directly associated with muscle 
damage, the parameter is seen as useful biomarker the evaluation of new therapeutic 
approaches. However, it is discussed that a decline of CK can stand for both, a 
reduced CK-leakage and hence the success of a therapeutic approach or a further 
progressed muscle quality decrease (reviewed in Aartsma-Rus and Spitali, 2015; 
Jensen et al., 2017). As shown in chapter IV.3.2., CK levels measured in our 
DMDY/- pigs did not decrease over time but stayed highly elevated above the 
threshold of 2000 U/l. Thus, in the case of our DMD pig model the use of CK as 
biomarker to validate the efficiency of the applied therapeutic approach was 
reasonable. 
In human DMD patients the 6-minute walk test (6-MWT) is the one of the primary 
used outcome measures for the assessment of physical capacity and the validation 
of therapeutic interventions (Bushby et al., 2014; McDonald et al., 2010; Mendell 
et al., 2016). In DMD animal models treadmill tests are performed to evaluate 
functional muscle parameters, as they are thought to most precisely mirror the 
assessment criteria used in human DMD patients (Capogrosso et al., 2018; Xu et 
al., 2016). However, physical examinations in humans as well as in animals 
normally rely on the individual performance of the day and on an active 
cooperation. This highly limits their diagnostic validity in DMD patients as well as 
in DMD animal models. Nevertheless, the assessment of functional muscle 
parameters in our DMDY/- pigs as biomarker for the clinical course of the disease 
was indispensible for the evaluation of the somatic gene editing approach achieved 
by G2-AAV9-Cas9-gE51. Since some DMDY/- individuals died due to sudden 
arrhythmia-induced death following mild environmental stressors such as 
weighing, taking blood samples or transportation, performing treadmill tests to 
assess muscle strength and endurance was decided to be not feasible. Therefore, to 
overcome the obstacles of the above explained limited diagnostic validity of 
physical examinations and the possiblity of sudden cardiac death in DMDY/- pigs, a 
video surveillance system was installed, allowing to observe the animals at any time 
of a day, on seven days a week (24/7). Video surveillance does not require 
interaction with the animals and thus facilitates random objective evaluation, 
preventing assessment errors due to interaction triggered behavioral changes. 
Furthermore, it allows repeated analysis, which avoids analysis errors. Thus, video 
surveillance was the most objective, stressfree and closest-to-reality method to 
assess physical capacity in WT, high-dose i.v. treated and untreated DMDY/- pigs. 
Analyses were performed with regards to activity- versus resting-phases and 
individual behavior. For all animals one whole day (24 hours) was viewed, analyzed 
and interpreted. On average day 64 of life was choosen for analysis, as at this 
timepoint the therapy was expected to already be fully effective and most animals 
included in the study were still alive. As i.m. injection of G2-AAV9-Cas9-gE51 
was attributed exclusively to the muscles of one side of the body, and no behavioral 
changes or functional impairment was expected in these animals when compared to 
untreated DMDY/- pigs, all i.m. treated DMDY/- and untreated DMDY/- animals were 
considered as one group, designated as DMDY/- untreated. All DMDY/- animals were 
analysed blinded for the treatment status, whenever possible. 
Already during review of the videosurveillance material, several individuals 
showed obviously increased resting-phases. Analysing the total standing time in 24 
hours, untreated DMDY/- pigs showed a significantly decreased total standing time 
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when compared to male age matched WT littermates, whereas for high-dose i.v. 
treated DMDY/- pigs a significant increase in total duration of standing events was 
observed. In addition, the average duration of standing events was as a tendency 
decreased in untreated DMDY/- pigs. However, no significant difference could be 
shown here. Using instantaneous sampling, a randomized analytical method, the 
increased activity in high-dose i.v. treated DMDY/- compared to untreated DMDY/- 
pigs could be visualized. Interestingly, here a difference between untreated and i.m. 
treated DMDY/- animals was observable, with a mild but obvious activity increase 
in i.m. treated compared to untreated DMDY/- animals. However, as animal numbers 
of the individual treatment groups were low, no statistical analysis was possible. 
Increased resting-phases were interpreted as premature fatigue, most probable due 
to muscle weakness. This interpretation was supported by observed individual 
behaviors, consistent with signs of fatigue, such as pattering of the hind limbs, or 
eating in lying posture. 
Concerning the detection of possible off-target effects triggered by the treatment 
with G2-AAV9-Cas9-gE51 two different approaches were used to ensure the 
generation of reliable results: targeted sequencing was used to detect the most likely 
predicted off-targets and whole genome sequencing was performed as holistic 
approach to detect further potential off-targets. Results showed, that even in highly 
transduced peripheral muscle tissue no intracellular off-targets were detected.  
Just recently, vector-dose-dependent toxicity of AAV vectors in non-human 
primates and piglets was reported (Hinderer et al., 2018). To achieve a sufficiently 
effective muscle transduction, including transduction of vital organs such as 
diaphragm and heart, the utilized virus particles in our therapeutic approach were 
dendrimer coated with G2-PAMAMs. Thereby, the need of higher virus doses, 
potentially exceeding levels of toxicity, could be avoided. Concerning efficacy and 
safety of new drugs, the evaluation of therapeutic approaches in animal models is 
indispensable. The pig as animal model resembles in body size and several 
similarities in physiology, anatomy, metabolism and pathology in comparison to 
humans (Aigner et al., 2010). Concerning dose finding, this model allows a cautious 
approach towards non-toxic but effective doses.  
Evaluation of MSOT, a new noninvasive in vivo molecular imaging technique 
to detect muscle degeneration, in the DMD pig 
Several new treatments for DMD are in focus of intense research. However, there 
is an unmet need of fast and sensitive methods to accurately measure symptom 
progression and the success of pharmaceutical interventions (Hrach and Mangone, 
2019). So far, manual (Brooke et al., 1983) and quantitative investigation of the 
muscles (Escolar et al., 2011) as well as timed function tests form the primary 
outcome measures in DMD. The 6-MWT to date presents the most frequently used 
primary endpoint to evaluate disease progression in DMD patients. This test and 
other muscular function tests do not require special equipment. However, they are 
dependent on the patients’ understanding (especially important for young DMD 
patients with congnitive impairment), active compliance and the individual 
performance of the day (Geiger et al., 2007; McDonald et al., 2010). These 
parameters may vary substantially between different measurement dates and thus 
can influcence the interpretation of results. Furthermore, these biomarkers for the 
evaluation of disease progression are only of use in ambulatory patients, thereby 
excluding very young (approximately 0-3 years of age) and wheelchairbound 
individuals (which build the majority of DMD patients (Straub et al., 2016)). 
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Objective monitoring techniques, such as ultrasound imaging and MRI, either 
necessitate long scan times or require immobilization, and in young pediatric 
patients, sedation. Thus, these procedures are typically avoided in early life periods, 
when they are not well tolerated (Birnkrant et al., 2018a). Additionally, MRI 
imaging protocols are limited regarding the detection of fibrosis, which however is 
a frequent finding in DMD and an informative biomarker for the progression of the 
disease. Due to sensitivity to edema, inflammation, fibrosis and necrosis, as well as 
the influence of glucocorticoid treatment, signals in T2-weighted, water sensitive 
MRI images are non-specific in this case (Arpan et al., 2014). 
To overcome this lack of noninvasive, age-independent, fast to apply, specific and 
sensitive biomarkers, we examined the feasability of a new noninvasive in vivo 
molecular imaging technique, called multispectral optoacoustic tomography 
(MSOT), in DMD. MSOT is based on a photoacoustic effect: using pulsed laser 
light, the system induces thermoelastic expansion of endogenous absorbers in the 
examined tissue, resulting in detectable acoustic pressure waves. By spectral 
unmixing, based on the specific absorption and reflection spectra of the emitted 
light of each chromophore, the different endogenous absorbers can be identified. 
This enables the visualization of endogenous molecular chromophores, such as 
hemoglobin (oxygenated or deoxygenated), oxygen saturation or melanin. The 
feasibility and clinical usability of this technique has already been demonstrated in 
breast cancer (Diot et al., 2017), skin cancer (Rey-Barroso et al., 2018), melanoma 
lymph nodes (Stoffels et al., 2015) and Crohn’s disease (Knieling et al., 2017; 
Waldner et al., 2016). We could demonstrate, that the illumination in the near- and 
extended near-infrared range (exNIR, from 680 to 1.100 nm) enables the 
visualization and quantification of collagens in affected muscles of DMDY/- pigs, as 
well as in human DMD patients (not shown). The complete results of this study are 
published in Regensburger et al. (2019). The increase of fibrotic proportions in 
muscles of DMD patients is an early aspect of the disease. The average proportion 
of connective tissue is already increased (16.5%) at young age (1-6 years of age), 
and rapidly peaks to 30% and more in subsequent years (Peverelli et al., 2015). 
Therefore, fibrosis is discussed as a useful imaging target in DMD. As DMDY/- pigs 
show an accelerated disease progression, with histologic muscle alterations  
including a severe increase of fibrotic tissue  already observable in newborn piglets, 
the animal was an optimal model for the detection of collagen by MSOT. 
Before imaging, all animals were shaved at the regions to be examined. For MSOT 
imaging, sedation of most of the animals was not necessary, as the method is 
painless and requires only short acquisition times. Only at older ages (4 weeks of 
age), some highly active WT pigs received mild sedation via noninvasive mucosal 
(intranasal) application. During imaging, a reflective ultrasound computed 
tomography (RUCT) image helped to anatomically guide the investigator. At the 
time point of imaging, genotypes of all animals were already determined. The 
investigator and persons carrying out analysis, however, were blinded to the 
genotypes. Genotypes were correctly classified by the investigators after analyzing 
MSOT collagen signals. This allowed a first conclusion in respect to the sensitivity 
of MSOT. 
In a first proof-of-principle study, newborn DMDY/- piglets and WT littermates 
were scanned by MSOT at days 1-3 of life. In a subsequent approach, muscles of 
DMDY/- and WT pigs at week 1, 2, 3 and 4 of life were imaged in a longitudinal 
study. Thereby, the quantitative visualization of disease progression at an early 
stage could be demonstrated by MSOT. In all individual muscle regions, the 
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visualization and quantification of collagen was feasible. Significant MSOT 
collagenmean/max signal differences between DMD
Y/- and WT animals were observed 
for all individually imaged muscle regions. In the proof-of principle study, n = 9 
animals (n = 6 WT and n = 3 DMDY/-) were euthanized after imaging. In the 
longitudinal study, n = 3 DMDY/- piglets had to be euthanized after the first scanning 
session, due to deterioration of the general condition. n = 2 WT littermates were 
euthanized in parallel, serving as controls. The remaining n = 5 animals (n = 3 WT 
and n =2 DMDY/-) were euthanized after the last scanning session (week 4 of life). 
Of all these animals muscle samples of the previously imaged anatomical regions 
were harvested and subsequently examined. 
Immunohistochemical staining was performed to representatively visualize the 
absolute loss of dystrophin in DMDY/- pigs. Hematoxylin and Eosin (H.E.) staining 
was used to assess cellular and tissue structure. Muscle tissue of all examined 
DMDY/- pigs showed the typical signs of severe dystrophy. With Masson Trichrome 
(MT) and Sirius Red (SR) staining intense fibrotic infiltrations in the muscle tissue 
of DMDY/- animals was visualized. In the MT and SR stained tissue sections, 
quantitative analyzes of positive-stained areas revealed a significantly increased 
collagen content in the DMDY/- compared to WT cohort. Performed assays for total 
collagen (hydroxyproline) and total protein quantification likewise confirmed the 
increase of collagens in DMDY/- animals. In the longitudinal study the progressive 
increase of MSOT collagenmean/max signal in accordance with an actual increasing 
collagen amount in the muscle tissue was demonstrated using the described 
methods. A receiver operator characteristics (ROC) analysis was applied to 
determine the ability of MSOT derived collagen signals to distinguish between 
muscles of affected and healthy animals and an excellent capacity of the MSOT 
technique was revealed. Additional performance of a holistic proteome analysis 
likewise confirmed muscular fibrosis in DMDY/- pigs as the potential origin of 
MSOT signals. When comparing the collagens in skeletal muscle tissue of both 
genotypes, collagen VI was found to be already enriched in 1-week-old DMDY/- 
piglets, whereas in 4-week-old DMDY/- piglets, besides the most abundant collagen 
VI, also the collagens III and XIV were increased. In a principal component analysis 
and an unsupervised hierarchical clustering of LFQ values the proteomes of 
examined muscle specimens separated exactly according to the genotype and the 
age. 
Premature phenotypic characteristics of DMD and an accelerated disease 
progression in DMDY/- animals allowed the detection of early-stage fibrotic 
muscular transformation and follow-up of the clinical course by MSOT. Thus, the 
DMD pig was highly appropriate for the evaluation of MSOT as new diagnostic 
biomarker in DMD. The ease of use of MSOT as noninvasive bedside imaging 
modality was highlighted by the fact, that sedation in most of the animals was not 
necessary, as the technique is painless and requires only short acquisition times. 
The exact scan times of the technique were evaluated in the MSOT study performed 
in pediatric DMD patients and healthy volunteers (not shown). The MSOT 
technique was shown to be suitable for the in vivo monitoring of muscle 
degeneration involving fibrotic processes. Especially for new therapeutic 
approaches which aim at an ultrastructural restoration of damaged muscle, such as 
the somatic gene editing approach also shown in this work (Moretti et al., 2020), 
direct visualization by MSOT might be a helpful tool to validate the therapeutic 
efficacy. 
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VI. SUMMARY 
Evaluation of emerging diagnostic and therapeutic strategies in a tailored pig 
model for Duchenne muscular dystrophy 
DMD is a severe and progressive neuromuscular disease, leading to premature 
death of affected patients. The reason lies in a loss of function of the muscle 
structure protein dystrophin. The most important therapeutic measures are 
treatment with glucocorticoids aiming to relieve the symptoms and to slow down 
disease progression, and multidisciplinary care. For the most frequent underlying 
genetic defects there is no cure. However, in the past few years considerable 
progress has been made concerning mutation-specific therapies intending to restore 
dystrophin expression. The most recent molecular therapy approaches under 
investigation aim to restore dystrophin expression permanently by editing the 
genome. Furthermore, diagnostic tools to accurately assess disease progression and, 
in particular, to reliably allow the validation of new therapeutic approaches, are of 
need. In a former work, a tailored DMD pig, mirroring one of the most frequent 
DMD causing mutations (lack of exon 52 of the DMD gene) has been generated by 
somatic cell nuclear transfer (SCNT) and characterized at our institute. 
One aim of this work was to establish a stable DMD pig breeding herd, allowing to 
generate high numbers of affected DMD knockout animals to provide statistically 
relevant experimental group sizes. Moreover, phenotypic characteristics of the 
DMD knockout pigs generated by breeding were investigated. Over a period of 
approximately four years, altogether n = 97 DMD knockout pigs were produced. 
Within this DMD cohort, a high mortality rate was observed (about 50% within 
week 1 of life). However, by a steady improvement of the parameters influencing 
rearing, the survival rate was increased from 17% up to 70%. The enzyme creatine 
kinase (CK) was already severely elevated in 1-week-old affected DMD piglets. No 
decrease of CK levels in adolecent DMD knockout pigs could be observed. 
Moreover, DMD knockout pigs showed a reduced birth weight, a severe weight-
loss within the fist 24 hours after birth, as well as a reduced body weight gain over 
time. Gross anatomical and histological findings of short- and long-term surviving 
DMD knockout animals revealed divergent findings between these two cohorts. 
Nearly exclusively in short-term surviving DMD piglets, macroscopically visible 
white bundels of muscles were observed, histologically, local calcium foci were 
prominent. Moreover, some DMD animals exhibited gastrointestinal impairment. 
As possible reason for the phenotypic variations genetic modifiers were discussed. 
Therefore, one further approach of this work was to identify potential genetic 
modifier loci in the DMD knockout pig. The application of a genome wide 
combined linkage disequilibrium and linkage analysis (cLDLA), using the survival 
time as objective study criteria for single nucleotide polymorphism (SNP) 
genotyping, was commenced. So far, three potential but not genome-wide 
significant quantitative trait loci (QTL) on chromosomes 1, 7, and 8 were identified. 
However, the results are still initial and might change with a higher number of 
animals. Thus, further investigations with a larger group size, and eventually an 
improved categorization system, are of need. 
Another item of this work was the validation of a new therapeutic approach, using 
somatic gene editing to permanently restore an internally truncated but partially 
functional dystrophin protein, in the DMDΔ52 pig. The correction of the open 
VI. Summary   118 
reading frame (DMDΔE51-52) was achieved by Cas9-mediated excision of exon 
51. The therapeutic agent was transmitted by adeno-associated viral (AAV) vectors. 
The successful restoration of dystrophin expression in skeletal muscle was 
demonstrated using different analytical methods. Furthermore, CK levels were 
observed to improve under treatment. As a further important aspect, functional 
improvement of the muscles was assessed by analysing video recordings of a 24-
hour surveillance audit with regards to individual activity patterns. The main 
outcome was a significant increase of activity of systemically (high-dose) treated 
animals, indicating a decrease of muscle weakness. Summarizing, in this study, the 
therapeutic approach was shown to ameliorate skeletal and cardiac muscle failure 
in DMD knockout pigs. 
The last aspect of this work was the validation of multispectral optoacoustic 
tomography (MSOT), a new noninvasive diagnostic imaging biomarker to assess 
the state of muscle degeneration in the DMD knockout pig. Illuminations in the 
near- and extended near-infrared ranges allowed the visualization and 
quantification of the endogenous absorber collagen in skeletal muscle. The 
feasibility of the approach to distinguish between healthy (WT) and diseased (DMD 
knockout) muscle was evaluated in a first proof-of-principle study. The ability of 
MSOT to also quantitatively visualize early-stage disease progression was 
confirmed in a second longitudinal study. A highly significant elevation of MSOT 
collagen signal was detected in skeletal muscle of DMD knockout piglets compared 
to WT littermates. A significant increase of MSOT collagen signal over time in 
affected DMD pigs could be shown. The increased collagen content was confirmed 
by the quantitation of positive-stained areas of Masson Trichrome and Sirius Red 
stained muscle slices, by total collagen and total protein quantification, and by a 
holistic proteome analysis. A study in pediatric DMD patients likewise confirmed 
an increased MSOT collagen signal in skeletal muscle of affected boys. Thus, 
MSOT was shown to be a feasible noninvasive imaging tool for the visualisation 
and quantification of collagens as biomarker in DMD. 
Summarizing, in this work the applicability of the DMD pig as adequate animal 
model for DMD was demonstrated. 
 
VII. Zusammenfassung   119 
 
VII. ZUSAMMENFASSUNG 
Evaluierung neuer Strategien zur Diagnostik und Therapie der Duchenne 
Muskeldystrophie anhand eines maßgeschneiderten Schweinemodells 
Die Duchenne Muskeldystrophie (DMD) ist eine schwerwiegende, progressiv 
verlaufende und letztendlich letale neuromuskuläre Erkrankung. Ursächlich sind 
verschiedene Mutationen im DMD Gen, welche eine Synthesestörung des 
Muskelstrukturproteins Dystrophin bewirken. Dies führt nachfolgend zu einem 
Untergang von Muskelfasern. Die Behandlung der Erkrankung beschränkt sich 
bisher auf die multidisziplinäre Versorgung betroffener Patienten. Weiterhin kann 
mit Glukokortikoiden eine Linderung der Krankheitssymptome und eine 
geringgradige Verlangsamung des Krankheitsverlaufs bewirkt werden. Für die 
meisten zugrunde liegenden genetischen Defekte gibt es dennoch keine effektiven 
Heilungsmöglichkeiten. Allerdings wurde in den letzten Jahren ein erheblicher 
Fortschritt im Hinblick auf die Entwicklung mutationsspezifischer Therapien 
gemacht, welche darauf abzielen die Dystrophin-Synthese wiederherzustellen. Die 
neusten molekularen Therapieansätze sind zudem darauf ausgerichtet, durch 
Veränderungen auf Genom-Ebene eine dauerhafte Wiederherstellung der 
Dystrophin-Expression zu ermöglichen. Für die Erforschung und Beurteilung neuer 
Therapiemöglichkeiten ist die Entwicklung diagnostischer Hilfsmittel wichtig, 
welche die präzise Beurteilung des Krankheitsverlaufs ermöglichen. In einer 
vorhergehenden Arbeit an unserem Institut wurde mittels somatischem 
Zellkerntransfer ein maßgeschneidertes DMD Schweinemodell erstellt, welches 
eine der häufigsten zugrunde liegenden Mutationen (nämlich das Fehlen von Exon 
52 im DMD Gen) widerspiegelt. 
Ein Hauptziel dieser Arbeit war der Aufbau einer stabilen Zuchtherde des DMD 
Schweinemodells, um die Bereitstellung statistisch relevanter Tierzahlen für 
experimentelle Versuchsgruppen zu ermöglichen. Weiterhin wurden die 
phänotypischen Eigenschaften der durch Zucht erzeugten DMD-Knockout Tiere 
untersucht. Innerhalb eines Zeitraums von etwa 4 Jahren wurden insgesamt 97 
DMD-Knockout Tiere erzeugt. Die DMD-Tiere zeigten insgesamt eine stark 
erhöhte Mortalitätsrate (ca. 50% innerhalb der ersten Lebenswoche). Durch eine 
stetige Verbesserung der Aufzuchtsbedingungen konnte jedoch eine Steigerung der 
Überlebensrate von anfänglichen 17% auf 70% erzielt werden. Erhöhte 
Kreatinkinase-Werte wurde bereits bei 1-Woche alten Ferkeln gemessen. Ein 
Absinken des CK-Wertes bei heranwachsenden DMD-Tieren wurde nicht 
beobachtet. Weiterhin wiesen DMD-Schweine ein reduziertes Geburtsgewicht auf, 
mit einer nachfolgend starken Gewichtsabnahme innerhalb der ersten 24 Stunden 
nach der Geburt. Die anschließende Gewichtszunahme überlebender Tiere lag stets 
unter der der Wildtyp-Wurfgeschwister. Bei der Sektion der DMD-Tiere wurden 
makroskopisch sowie histologisch unterschiedliche Befunde zwischen den 
Kurzzeit-Überlebern (≤ 1 Woche) und den Langzeit-Überlebern beobachtet. Unter 
anderem zeigten Kurzzeit-Überleber makroskopisch eine weiße Streifung der 
Muskulatur, histologisch wurden Kalkablagerungen in der Muskulatur 
nachgewiesen. Außerdem wiesen manche DMD-Tiere eine Beeinträchtigung der 
gastrointestinalen Funktion auf. Als mögliche Ursache für diese phänotypische 
Varianz wurden Modifier-Gene diskutiert. Deshalb wurde, mit Hilfe einer 
Kartierung per kombinierter Kopplungsungleichgewichts- und Kopplungsanalyse 
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(cLDLA), die Identifizierung möglicher modifizierender Genloci im DMD-
Schweinemodell untersucht. Als weitestgehend objektives Kriterium, zur 
Erfassung möglicher genetischer Varianten (Einzelnukleotid-Polymorphismen 
(SNP)) innerhalb der DMD-Knockout-Tiere wurde die „Überlebensdauer“ 
verwendet. Bisher wurden somit insgesamt drei potenziell modifizierte Genloci auf 
den Chromosomen 1, 7 und 8 eruiert, welche jedoch nicht genomweit signifikant 
sind. Diese Ergebnisse könnten sich folglich, unter Einbeziehung weiterer Tiere, 
verändern. Eine Weiterführung des Projekts mit höheren Tierzahlen und 
möglicherweise ein verbessertes Kategorisierungs-System sind nötig. 
Ein weiteres Thema der vorliegenden Arbeit war die Validierung einer neuen 
somatischen Gentherapie: Im DMD-Schwein (DMDΔ52) sollte die dauerhafte 
Wiederherstellung der Expression eines verkürzten aber funktionellen Dystrophin-
Proteins durch Korrektur des DNA-Leserahmens mittels CRISPR/Cas9 bewirkt 
werden (DMDΔ51-52). Zum Transfer des CRISPR/Cas9-Systems in die Zellen 
wurden Adenoassozierte Virale Vektoren (AAV) verwendet. Die erfolgreiche 
Wiederherstellung der Dystrophin-Synthese in Skelettmuskel (u.a. Zwerchfell) und 
Herz konnte mittels verschiedener Analyseverfahren nachgewiesen werden. Zudem 
wurde eine Absinken der CK-Werte in systemisch therapierten DMD-Tieren 
beobachtet. Als weiterer wichtiger Aspekt der Validierung des Therapieerfolges 
wurde die Muskelfunktion beurteilt. Hierfür wurde Filmmaterial eines 24-Stunden 
Videoüberwachungssystems, hinsichtlich der Aktivitätsmuster der individuellen 
Tiere, ausgewertet. Ein signifikanter Anstieg der Aktivität bei systemisch 
behandelten Tieren (hohe Dosis) wurde beobachtet, vereinbar mit einem Rückgang 
der Muskelschwäche. Zusammenfassend konnten eine Verbesserung der Muskel- 
sowie Herzfunktion durch die angewandte Gentherapie im maßgeschneiderten 
DMD Schweinemodell gezeigt werden. 
Als letzter Aspekt der vorliegenden Dissertation wurde im DMD Schweinemodell 
die multispektrale optoakustische Tomographie (MSOT), ein neues nicht-invasives 
bildgebendes Diagnoseverfahren zur Erfassung von Muskeldegeneration validiert. 
Bei dem Verfahren werden Pulse eines Nahinfrarot-Lasers in das zu untersuchende 
Muskelgewebe gesandt und die dabei entstehenden optoakustischen Druckwellen, 
welche spezifisch für jeweilige körpereigene Chromophore (Farbstoffe wie z.B. 
Kollagene im Skelettmuskel) sind, visualisiert und quantifiziert. Die 
Anwendbarkeit dieser Diagnostikmethode zur Unterscheidung zwischen gesundem 
(WT) und erkranktem (DMD-Knockout) Muskel wurde in einer ersten 
Machbarkeitsstudie untersucht. In einer nachfolgenden Längsschnittstudie wurde 
auch die Fähigkeit von MSOT, das Fortschreiten der Erkrankung im Frühstadium 
quantitativ zu visualisieren, bestätigt. Im Skelettmuskel von DMD-Knockout-
Ferkeln im Vergleich zu WT-Wurfgeschwistern wurde eine hoch signifikante 
Erhöhung des MSOT-Kollagensignals festgestellt. Weiterhin konnte ein 
signifikanter Anstieg des MSOT-Kollagensignals im Laufe der Zeit bei betroffenen 
DMD-Schweinen gezeigt werden. Der erhöhte Kollagengehalt wurde durch 
Anwendung verschiedener Methoden bestätigt. So wurden zum einen auf den mit 
Masson-Trichrom- und Siriusrot-Färbung angefärbten Muskelschnitten die positiv 
gefärbter Bereiche quantifiziert. Weiterhin wurden der Gesamtkollagengehalt in 
entsprechenden Muskelproben (Nachweis von Hydroxyprolin aus Kollagen) sowie 
der Gesamtproteingehalt ermittelt. Zudem wurde eine ganzheitliche 
Proteomanalyse durchgeführt. Eine Studie an pädiatrischen DMD-Patienten 
bestätigte ebenfalls ein erhöhtes MSOT-Kollagensignal im Skelettmuskel 
betroffener Jungen. Die MSOT-Methode wurde also als praktikables, nicht-
invasives Bildgebungsverfahren zur Visualisierung und Quantifizierung von 
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Kollagen als Biomarker bei der DMD vorgestellt. 
Zusammenfassend wurde in der vorliegenden Dissertation die Anwendung des 
DMD-Schweins als adäquates Tiermodell für die Duchenne Muskeldystrophie 
demonstiert. 
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